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Abstract 
Clofazimine (CFZ), an oral FDA-approved antibiotic for over 40 years, has been used 
effectively against leprosy and multi-drug resistant tuberculosis (MDR-TB). Due to its atypical 
pharmacokinetic parameters, orally administered CFZ free base is associated with extensive 
intracellular bioaccumulation of the solid drug, primarily in tissue macrophages, in a form of 
crystal-like drug inclusions (CLDIs) that chemically and structurally resemble CFZ 
hydrochloride salt (CFZ-HCl) crystals. These biocrystals are biocompatible, stable, long-lived, 
relatively non-toxic, and have anti-inflammatory properties.  
In this dissertation, I hypothesized that CFZ-HCl is a more therapeutically efficacious 
form of CFZ compared to CFZ free base that could be potentially used in the repurposing CFZ 
for other indications. To test this hypothesis, first, I established the physicochemical parameters 
of CFZ (e.g. pHmax, apparent pKa, CFZ-HCl aqueous solubility, CFZ free base intrinsic solubility, 
Ksp, etc.) that allowed me to understand the different ionization states of CFZ and their 
relationship to the drug’s physicochemical, pharmacokinetic, and pharmacodynamic properties. 
In fact, these physicochemical parameters explained the thermodynamic mechanism of 
differential stabilization and accumulation of the HCl salt form of CFZ in macrophage 
lysosomes. Based on this mechanism, I developed a specific buffer system that mimics the 
macrophage intralysosomal microenvironment, which ultimately helped me to determine that 
CFZ free base is associated with the major side effect from CFZ treatment, drug-induced skin 
pigmentation, that results from its partitioning into subcutaneous fat layer of the skin.  
xiii 
 
Next, I developed a biomimetic formulation of CFZ drug biocrystals, micronized CFZ-
HCl salt crystals, and investigated its stability in macrophages in vitro and in vivo. As a result, I 
determined that macrophages internalize and stabilize CFZ-HCl microcrystals, just as well as 
CLDIs, without any detectable toxicological effects. Furthermore, no skin pigmentation was 
observed when an equivalent total amount of CFZ-HCl to the total oral dose that causes maximal 
skin pigmentation was administered. Thus, parenteral biomimetic formulations of CFZ-HCl 
could be instrumental in avoiding the pigmentation side effect of oral CFZ therapy.  
Finally, I explored the inflammatory status and efficacy of my formulation of CFZ-HCl 
salt microcrystals in gouty arthritis under local administration in vivo, utilizing an FDA-
recognized rat model. As a result, local injection of CFZ-HCl microcrystals led to the 
recruitment of macrophages to the site of action, a pro-inflammatory response, and did not 
facilitate the dissolution and clearance of monosodium urate (MSU) crystals from the joint, the 
main source of inflammation, by lowering the local pH of the synovium. Even though the results 
of this study suggested that my formulation is not suitable for gouty arthritis, further 
investigation is required to determine efficacy and anti-inflammatory action of my formulation in 
MDR-TB and other potential new indications. 
Overall, this dissertation augments the understanding of drug distribution and mechanism 
of action by effectively demonstrating how it is possible to distinguish the differential 
contribution of different ionization states of a drug (e.g. CFZ) to the drug’s efficacy and toxicity 
properties. Furthermore, this dissertation has advanced the rational design of formulations, in 
terms of being the first to develop a biomimetic form of a small molecule drug and 
demonstrating how the role of macrophages in determining the stability of biomimetic 
formulations can be probed.
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Chapter 1 
Introduction 
1.1 Macrophages 
Macrophages (and their precursors, monocytes) reside in every tissue of the body, 
although in different guises depending on the anatomic location (e.g. microglia, Kupffer cells, 
and osteoclasts) [1]. They are the 'big eaters' and the first line of defense of the immune system 
[1]. Through their ability to clear pathogens and instruct other immune cells, these cells have a 
central role in protecting the host [1]. Upon tissue damage or infection, monocytes are rapidly 
recruited to the tissue, where they differentiate into tissue macrophages that engulf apoptotic 
cells, pathogens, and drug molecules and produce immune effector cytokines. 
Macrophages are involved in a variety of disease states, such as inflammatory, infectious, 
cardiovascular, autoimmune diseases, and many more [2]. The role of macrophages as 
phagocytic and antigen-presenting cells is very well established. However, over or underactivity 
of these cells can result in the onset and/or progression of pathologic conditions such as growth 
and spread of malignant tumors, sepsis, chronic inflammation in rheumatoid arthritis, lysosomal 
storage disease, atherosclerosis, and major infections, including HIV/AIDS and tuberculosis [3]. 
Thus, therapies targeting macrophages appears to be a very promising strategy. Furthermore, the 
ability of the macrophages to migrate to the sites of inflammation, infection, and tissue 
degeneration makes them attractive vehicles to deliver contrast agents for diagnosis or drugs as 
therapeutic modalities [4, 5]. 
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There have been several reports showing that macrophages are also responsible for drug 
accumulation of weakly basic drugs based on ion trapping in the acidic endo-lysosomal system 
[6]. Chemicals with a propensity to accumulate in the endo-lysosomal system are commonly 
referred to as lysosomotropic agents. The trapping and accumulation of a drug within the 
lysosome, which is the subcellular organelle in macrophages that digests unwanted materials 
delivered from the cytoplasm and extracellular environment, has a variety of consequences. 
There are several studies that show that the drug entrance into the macrophage activates the 
macrophage which leads to several cellular responses. Studies by Krise et. al have demonstrated 
that drug accumulation by lysosomotropic agents results in an expanded volume of the lysosome, 
and further work by this group has demonstrated that lysosomal drug accumulation results in 
nuclear localization of the transcription factor EB (TFEB), which regulates lysosomal biogenesis 
and leads to an increase in the number of lysosomes and degradation rate of complex molecules 
[6-11]. Furthermore, lysosomal drug accumulation was also associated with macrophage 
activation and proton and chloride channel upregulation [6-9]. However, the mechanisms that 
stabilize the accumulating drug within endo-lysosomal system are not well understood yet. 
Therefore, further investigation is required.  
The trapping and accumulation of a drug within the lysosome has significant biological 
outcomes and can greatly impact the pharmacokinetics and pharmacodynamics of an 
accumulating drug. It is generally known that intracellular accumulation of the drug, especially 
of insoluble form, can lead to serious complications, including cell toxicity, blockage, and organ 
failure. However, in some cases, there are insoluble drug complexes that are not toxic and 
actually improve the parent’s drug pharmacokinetic parameters. The great example of that is 
clofazimine (CFZ). 
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1.2 Clofazimine (CFZ) 
Clofazimine is a weakly basic, very lipophilic, phenazine compound that is FDA-
approved antibiotic [12]. It has been used effectively against leprosy for over 40 years, curing 
over 14 million people worldwide, which makes it to be a part of World Health Organization’s 
list of essential medications [13]. Currently, CFZ is in clinical trials for multi-drug resistant 
tuberculosis (MDR-TB) [14].  
Due to its unique pharmacokinetic parameters, orally administered CFZ free base has a 
half-life of up to 70 days and is associated with extensive intracellular bioaccumulation of the 
solid drug, primarily in tissue macrophages, in a form of Crystal-Like Drug Inclusions (CLDIs) 
[15-17]. Even though prolonged CFZ treatment is associated with massive drug biocrystal 
accumulation within resident tissue macrophages, there are no obvious toxicological 
manifestations from these biocrystals. Instead, CLDIs are biocompatible, stable, long-lived, 
relatively non-toxic, and have anti-inflammatory properties [18]. By analyzing the isolated 
CLDIs from spleen and liver in mice, it was shown that CLDIs chemically and structurally 
resemble CFZ hydrochloride salt (CFZ-HCl) crystals (FITC(-) Cy5(+)), which is a different form 
of the drug from orally administered CFZ free base (FITC(+) Cy5(-)) [19]. These results indicate 
that a salt form of CFZ is much more stable within macrophages of the spleen and liver than a  
CFZ free base form, which is contradictive to general knowledge of pharmaceutical drug design. 
Salification usually enhances solubility of a parent drug, making it less stable or less prone to 
precipitation [20]. Therefore, it makes it very interesting to study why macrophages 
preferentially stabilize the salt form of the drug rather than free base form, which leads to 
massive drug bioaccumulation and an anti-inflammatory response, which needs further 
characterization.  
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In terms of its toxicological properties and regardless of the indication, the major side 
effect of orally administered CFZ is a strong red skin pigmentation, observed in more than 94% 
of patients [21, 22]. Patients may also experience ichthyosis or gastrointestinal symptoms, but at 
the normal dosage of 50 to 100 mg/day, no other major side effects have been reported [21, 23-
25]. It has been generally assumed that the skin pigmentation is due to the massive 
bioaccumulation of Cy5(+) CFZ-HCl within the organism, specifically within skin tissue 
macrophages; however, no one has ever determined exactly what form of the drug causes this 
major side effect from orally administered CFZ treatment.  
It is critical to understand and acknowledge the importance of off-target drug 
accumulation-related side effects from weakly basic drugs. For example, doxorubicin, 
chemotherapy medication, accumulates in the heart muscle mitochondria leading to 
cardiotoxicity [26]. By studying the drug’s physicochemical parameters, ionization states, its 
interaction with cellular membranes and ions, and ultimately, determining the thermodynamic 
mechanism that leads to its off-target accumulation, it is possible to circumvent these side effects 
through appropriate targeted formulation (e.g. liposomal doxorubicin, Doxil, avoids 
cardiotoxicity) [26].  
 Therefore, by determining the physicochemical parameters and the thermodynamic 
mechanism of differential stabilization and accumulation of the HCl salt vs free base form of 
CFZ in lysosomes of macrophages, I can properly develop solid nano/microparticulate 
formulations that target macrophages and are stabilized inside of them for more efficacious drug 
response. Furthermore, some of the methods on how to determine the physicochemical 
parameters and the thermodynamic mechanism leading to differential stability of the salt form vs 
the free base of a precipitated weak base have already been established and used for several 
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decades [27]. Overall, this will aid in the selection of superior performing formulations for future 
studies of other weakly basic drugs that are similar to CFZ for long-acting drug delivery systems 
designed to improve the dosing strategy and patient compliance. Also, since macrophages are 
distributed throughout the body in different tissues, they can be potentially utilized as drug 
delivery vehicles to prevent and treat macrophage related diseases [3].  
1.3 Microparticulate Formulation for Macrophage Targeting (Passive Targeting) 
Passive targeting refers to the accumulation of the drug or drug-carrier nano/microsystem 
by exploiting the pathophysiological condition and anatomical route [3]. For example, 
nanoparticle systems that are >100 nm are readily opsonized and removed from the circulation 
by the mononuclear phagocyte system (MPS, aka reticuloendothelial system) and degraded by 
the macrophages in the liver and spleen [3]. Thus, the tendency of unmodified nanoparticles to 
localize in the MPS has been exploited as a way to passively deliver the payload to macrophages. 
In fact, the presence of macrophages at the site of action presents an excellent opportunity to 
passively target these cells. 
Particle size reduction has been a nonspecific formulation approach for many years that is 
applicable to almost any drug [26]. Micronization means transfer of relatively coarse drug 
powder to micrometer size crystals using colloid mills or jet mills. The mean diameter of such 
micronized drug powders is in the range of approximately 1 to 5 µm, corresponding to a size 
distribution of approximately 0.1 to 20 µm [3, 26]. Owing to their particle size distribution, such 
formulations in general cannot be used for intravenous (IV) injections (unless nanonized), but 
more suitable for local administration [26]. In order to achieve a cellular delivery (i.e. 
macrophage delivery) of drug particles, the next consequent step is to go down one further 
dimension in size, which means to reduce the particle size in the nanometer range. In case of 
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drug nanocrystals, as far as they reach the site of action where macrophages are present, 
macrophages should technically engulf these drug nanocrystals via passive targeting.  
According to Thassu et al., drug nanocrystals are pure solid drug particles with a mean 
diameter below 1000 nm. A nanosuspension consists of drug nanocrystals, stabilizing agents 
(e.g. surfactants, lipids, and/or polymeric stabilizers), and a liquid dispersion medium. The 
dispersion media can be water, aqueous solutions, or non-aqueous media. The term “drug 
nanocrystals” implies a crystalline state of the discrete particles, but depending on the production 
method they can also be partially or completely amorphous. Drug nanocrystals have to be 
distinguished from polymeric nanoparticles, which consist of a polymeric matrix and an 
incorporated drug. Drug nanocrystals do not consist of any matrix material [26]. 
1.4 Central Hypothesis 
Even though clofazimine hydrochloride (CFZ-HCl) and clofazimine (CFZ) free base 
have the same active pharmaceutical ingredient (API), I hypothesize that CFZ-HCl is a more 
therapeutically efficacious form of CFZ that could be potentially used in repurposing this drug 
for other indications. 
1.5 Specific Aims 
1.5.1 Specific Aim 1 
In Specific Aim 1, I aim to establish the physicochemical parameters of CFZ that explain 
the thermodynamic mechanism of differential stabilization and accumulation of the HCl salt vs 
free base form of drug in lysosomes of macrophages. These parameters will allow us to 
determine what form of the drug causes the major side effect from clofazimine treatment – skin 
pigmentation. I hypothesize that CFZ has unique physicochemical parameters that allow it to 
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stabilize and accumulate as HCl salt form in the lysosomes of macrophages throughout the body, 
including macrophages of the skin, causing the drug-induced skin pigmentation. 
1.5.2 Specific Aim 2 
In Specific Aim 2, I aim to develop a biomimetic formulation of CFZ drug biocrystals, 
micronized CFZ-HCl salt crystals, and investigate its stability in macrophages in vitro and in 
vivo. I hypothesize that biomimetic formulation of micronized CFZ-HCl crystals will be stable 
under lysosomal conditions in vitro and in vivo. 
1.5.3 Specific Aim 3 
Explore the inflammatory status and efficacy of the biomimetic formulation of 
micronized CFZ-HCl salt crystals in gouty arthritis under local administration in vivo. I 
hypothesize that local injection of the biomimetic formulation of CFZ-HCl microcrystals in vivo 
will decrease inflammation, pain, and swelling associated with gout and facilitate the dissolution 
and clearance of monosodium urate (MSU) crystals from the joint by lowering the local pH of 
the synovium.  
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Chapter 2 
Clofazimine Biocrystal Accumulation in Macrophages Upregulates 
Interleukin 1 Receptor Antagonist Production to Induce a Systemic 
Anti-Inflammatory State 
2.1 Relevance to Thesis 
This chapter was adapted from the following publication: 
Yoon GS, Keswani RK, Sud S, Rzeczycki PM, Murashov MD, Koehn TA, Standiford TJ, Stringer 
KA, Rosania GR. 2016. Clofazimine biocrystal accumulation in macrophages upregulates 
interleukin 1 receptor antagonist production to induce a systemic anti-inflammatory state. 
Antimicrob Agents Chemother 60:3470 –3479. doi:10.1128/AAC.00265-16.\ 
 
In this study, we designed an experimental strategy to probe the site-specific 
accumulation of the Cy5(+) CFZ-HCl salt form (in the chapter referred to as “intracellular 
biocrystals”) and its downstream immunological effects to help us to distinguish between the 
potential adverse effects of CFZ-HCl from those of the soluble molecules of CFZ. We tested the 
specific hypothesis that CFZ-HCl that accumulate in resident tissue macrophages can modulate 
(or activate) these cells’ inflammatory signaling pathways in vivo that lead to systemic changes 
in the inflammatory response. My contribution in this study involved mice clofazimine treatment 
and cytokine measurements from organ homogenates via ELISA, SDS-PAGE, and Western 
Blotting. As the result, by monitoring key inflammatory cytokines in the vital organs and blood 
of CFZ-treated mice, it was demonstrated that CFZ-HCl salt form in macrophages, but not the 
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soluble form of CFZ free base, is specifically associated with an IL-1RA-mediated anti-
inflammatory response. 
The results from this study were critical because this study suggested that drug CFZ-HCl 
salt form is biocompatible, stable, long-lived, relatively non-toxic, and have anti-inflammatory 
properties compared to the soluble form of CFZ free base. In other words, CFZ-HCl, being a 
different form of the drug from the orally-administered CFZ free base, is a more therapeutically 
efficacious form of CFZ that could be potentially used in repurposing this drug for other 
indications, such as inflammatory and infectious diseases, supporting my central hypothesis. 
2.2 Abstract 
Clofazimine (CFZ) is a poorly soluble antibiotic and anti-inflammatory drug indicated for 
the treatment of leprosy. In spite of its therapeutic value, CFZ therapy is accompanied by the 
formation of drug biocrystals that accumulate within resident tissue macrophages, without 
obvious toxicological manifestations. Therefore, to specifically elucidate the off-target 
consequences of drug bioaccumulation in macrophages, we compared the level of inflammasome 
activation in CFZ-accumulating organs (spleen, liver and lung) in mice after 2 and 8 weeks of 
CFZ treatment when the drug exists in soluble and insoluble (biocrystalline) forms, respectively. 
Surprisingly, the results showed a drastic reduction in caspase 1 and interleukin-1β (IL-1β) 
cleavage in the livers of mice treated with CFZ for 8 weeks (8-week-CFZ-treated mice) 
compared to 2-week-CFZ-treated and control mice, which was accompanied by a 3-fold increase 
in hepatic IL-1 receptor antagonist (IL-1RA) production and a 21-fold increase in serum IL-1RA 
levels. In the lung and spleen, IL-1β cleavage and tumor necrosis factor alpha expression were 
unaffected by soluble or biocrystal CFZ forms. Functionally, there was a drastic reduction of 
carrageenan- and lipopolysaccharide-induced inflammation in the footpads and lungs, 
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respectively, of 8-week-CFZ-treated mice. This immunomodulatory activity of CFZ biocrystal 
accumulation was attributable to the upregulation of IL-1RA, since CFZ accumulation had 
minimal effect in IL-1RA knockout mice or 2-week-CFZ-treated mice. In conclusion, CFZ 
accumulation and biocrystal formation in resident tissue macrophages profoundly altered the 
host’s immune system and prompted an IL-1RA-dependent, systemic anti-inflammatory 
response. 
2.3 Introduction 
Clofazimine (CFZ) is an antimycobacterial agent listed in the World Health 
Organization’s List of Essential Medicines that has been in use as part of the standard treatment 
of leprosy since the 1960s [1, 2]. The number of leprosy cases has drastically dropped from 12 
million/year in 1981 to 216,000/year in 2013 [3], a testament to the effectiveness of CFZ, which 
has gained considerable attention recently as part of a treatment regimen for drug-resistant 
tuberculosis [4-6]. The efficacy of oral CFZ against leprosy is due, in part, to its well-
documented anti-inflammatory activity [2]. However, CFZ’s mechanism of anti-inflammatory 
action and atypical pharmacokinetic properties are not well understood, and its high oral 
bioavailability and poor solubility leads to significant bioaccumulation in tissues [7]. 
In previous studies, it has been shown that following prolonged oral administration of 
CFZ, the drug massively bioaccumulates as intracellular biocrystals in resident tissue 
macrophages [8-12]. Therefore, it is natural to assume that this bioaccumulation phenomenon 
contributes to the drug’s toxicity, whereas the soluble form of CFZ, which circulates and 
partitions to and from the different organs, is responsible for CFZ’s mechanism of action. 
Indeed, insoluble particles and crystals that accumulate in macrophages under various 
pathological conditions are known to activate immune signaling pathways that lead to caspase 1 
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(Casp 1) activation and increased interleukin-1β (IL-1β) secretion [13-16]. This so-called 
“inflammasome” activation pathway is often associated with many downstream pathological 
changes, as has been shown by the accumulation of cholesterol monohydrate crystals in 
atherosclerosis [13], monosodium urate crystals in gout [14], and inhaled foreign particles in the 
case of asthma and other chronic inflammatory lung diseases [15, 16]. 
In spite of its bioaccumulation, several clinical trials have established CFZ as a 
potentially useful therapeutic agent for treating a variety of chronic inflammatory diseases [17-
22]. Furthermore, in vitro studies have shown that intracellular CFZ biocrystals dampen 
proinflammatory pathways while enhancing anti-inflammatory signals [23]. 
In order to distinguish between the potential adverse effects of insoluble drug biocrystals 
from those of the soluble molecules, we designed an experimental strategy to compare how the 
accumulation of insoluble drug biocrystals might influence the immune signaling response of 
macrophages in live mice. We reasoned that macrophages exposed to the soluble form of CFZ 
(after 2 weeks of treatment) may behave differently from those that are exposed to its 
biocrystalline form (after 8 weeks of treatment). Accordingly, we tested the specific hypothesis 
that CFZ biocrystals that accumulate in resident tissue macrophages can modulate (or activate) 
these cells’ inflammatory signaling pathways in vivo that lead to systemic changes in the 
inflammatory response. By assessing tumor necrosis factor alpha (TNF-α) and IL-1 receptor 
antagonist (IL-1RA) expression, as well as Casp 1 and IL-1β maturation, in the vital organs and 
blood of CFZ-treated mice, our results demonstrate that CFZ biocrystals in macrophages, but not 
the soluble form, is specifically associated with an IL-1RA-mediated anti-inflammatory 
response. 
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2.4 Materials and Methods 
Reagents 
Anti-caspase 1 and anti-IL-1β antibodies were purchased from Thermo Pierce (Rockford, 
IL) and Novus Biologicals (Littleton, CO), respectively. Anti-F4/80 and anti-CD68 antibodies 
were purchased from Abcam (Cambridge, MA). Anti-actin antibody and lipopolysaccharide 
(LPS; from E. coli O55:B5) were purchased from Sigma (St. Louis, MO). 
Mice clofazimine treatment 
Clofazimine (CFZ; Sigma-Aldrich, catalog no. C8895) was prepared in sesame oil 
(Shirakiku, Japan, or Roland, China) and Powdered Lab Diet 5001 (PMI International, Inc., St. 
Louis, MO) and orally administered to wild-type (WT) C57BL/6 mice or IL-1RA knockout mice 
(4 to 5 weeks old; Jackson Laboratory, Bar Harbor, ME) for up to 8 weeks ad libitum as 
previously described [8, 24]. Control mice were fed with the same diet without CFZ. The animal 
protocol was approved by the University of Michigan’s Animal Care and Use Committee in 
accordance with the National Institutes of Health guidelines (UCUCA, no. PRO00005542). 
Carrageenan footpad edema test  
Footpad edema in response to carrageenan (CAR; Sigma) injection was measured in 
CFZ-treated and control mice as previously described [25]. In IL-1RA knockout (KO) mice, 
these experiments were performed at 6 weeks and not at 8 weeks because the IL-1RA KO mice 
weighed less than the WT mice and their livers were smaller (see Figure S2-4 in the Appendix 
A). In brief, the volume of each hind paw was measured before and after the intraplantar 
injection of 30 µl of 2% CAR (60 µg per paw) in phosphate-buffered saline (PBS) or an equal 
volume of PBS in the contralateral paw. Paw swelling was measured at 4 and 48 h after 
injection, after which the animals were euthanized by exsanguination while deeply anesthetized 
with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), and the skin 
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tissues of the plantar region were harvested for cytokine assay (see the Materials and Methods in 
Appendix A). 
Acute lung injury and infrared pulse oximetry 
Since C57BL/6 mice are relatively resistant toward a single dose of intratracheal (i.t.) 
LPS instillation [26], two i.t. injections of LPS (16 mg/kg; 50 µl) were administered, one on day 
0 and the second on day 3. Briefly, mice treated with CFZ for 8 weeks (8-week-CFZ-treated 
mice) and control mice were anesthetized using intraperitoneal injections of xylazine (50 mg/kg) 
and ketamine (5 mg/kg). Under direct visualization of the vocal cords using an otoscope, either 
LPS or an equivalent volume of PBS in a 1-ml syringe attached to an oral gavage needle (22G) 
was instilled into the lungs via the oral route. The mouse was then placed in a temperature-
controlled cage (37°C) for recovery from anesthesia. 
The general health status of each PBS/LPS-instilled mice was monitored by measuring 
body weight and rectal temperature (microprobe thermometer; Physitemp Instruments, Clifton, 
NJ), and cardiopulmonary function (arterial oxygen saturation, respiratory rate, heart rate, and 
pulse distention) was monitored using MouseOx with a collar clip sensor (Starr Life Sciences 
Corp., Oakmont, PA) as previously described [27, 28]. In brief, 1 day before i.t. instillations (day 
-1), the hair around the neck of each mouse was removed using Nair (Church&Dwight, 
Princeton, NJ) to enable data acquisition using the collar clip sensor. The next day (day 0), 
immediately prior to the first LPS/PBS dose, and every 24 h afterward until day 6, the body 
weight, temperature, and MouseOx readings were recorded. MouseOx data were acquired by 
very brief anesthesia of the mouse using 5% isoflurane to facilitate the placement of the collar 
clip sensor. The mouse was then placed in an enclosed chamber with ambient light and allowed 
to acclimatize for 5 min, at which point the animals had recovered normal activities and 
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physiological readings. Arterial oxygen saturation, respiratory rate, heart rate, and pulse 
distention measurements were then simultaneously recorded for 6 min (15 readings/s), and any 
errors caused by motion during recording were excluded, after which the mean value of each 
parameter was used for further data analysis. 
Terminal endpoint assessment 
To objectively assess LPS-induced mortality, we used a multiparametric scoring system 
that relied on the daily changes in vital signs associated with inflammatory injury progression 
and mortality, which included arterial oxygen saturation [27], body weight, and temperature [29, 
30]. First, the percent change from baseline (day 0) in arterial oxygen saturation, body weight, 
and temperature in each mouse caused by i.t. instillation of PBS/LPS were measured and 
calculated daily until day 6 after instillation. These data were then used in a vector equation to 
calculate the distance between each LPS-treated mouse and the mean of the PBS-treated mice to 
assess the terminal endpoint for each LPS-instilled mouse (see Materials and Methods in 
Appendix A). CFZ-treated and control mice were calculated separately, and LPS-instilled mice 
that scored a total of 18 or higher were determined as terminal, since these mice also displayed 
severe signs of sickness evidenced by impaired mobility, lack of grooming, hunched posture, and 
muscle weakness that could be felt while handling the mice. These mice were immediately 
euthanized with ketamine-xylazine (100 mg/kg, 10 mg/kg) and the bronchoalveolar lavage 
(BAL) fluid and lungs were harvested for cellular and biochemical analysis (see below). 
Remaining mice that did not reach terminal endpoint were all euthanized on day 6 after PBS/LPS 
instillation. 
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Cytokine measurements 
The harvested organs (liver, spleen, lungs, and kidneys) and footpads designated for 
cytokine assays were cut and homogenized by sonication (2-s pulses repeated five times on ice, 
level 5; Fisher model 100) in radioimmunoprecipitation assay buffer (Sigma) with added 
protease inhibitors (Halt protease and phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo 
Pierce, Rockford, IL). After centrifugation (18,000 x g, 15 min, 4°C), the supernatants were 
assayed for IL-1β, IL-1RA, and TNF-α by enzyme-linked immunosorbent assay (ELISA; 
Duoset; R&D Systems, Minneapolis, MN) in duplicate wells according to the manufacturer’s 
instructions. Cytokines in the BAL were measured after the removal of the cells. Albumin was 
assayed by ELISA (Innovative Research, Novi, MI). The cytokine concentrations were expressed 
(i) as pico-, nano-, or micrograms per milligram of protein for the organs, (ii) as pico-, nano-, or 
micrograms of paw weight, or (iii) as pico- or micrograms per milliliter of BAL fluid. 
Mouse BAL fluid harvesting, immunohistochemistry and imaging, and SDS-PAGE and 
Western blotting 
The mouse BAL fluid harvesting, immunohistochemistry and imaging, and SDS-PAGE 
and Western blotting procedures are described in the Appendix A. 
Data processing and statistics 
All data are expressed as means ± the standard deviations (SD). For multiple 
comparisons, statistical analysis was performed with one-way analysis of variance (ANOVA) 
and Tukey’s post hoc comparisons. For two-group comparisons, an unpaired Student t test was 
used. All statistical analyses employed the Sigmaplot version 13 (Systat Software, San Jose, CA) 
software and P ≤ 0.05 was considered statistically significant. 
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2.5 Results 
CFZ crystallization and bioaccumulation in the liver occurs after 2 weeks 
During the first 2 weeks of CFZ treatment, CFZ-associated diffuse red staining was 
present throughout the liver (Figure 2-1A, brightfield). However, by 4 weeks, CFZ accumulated 
in the biocrystalline form. At 8 weeks, red CFZ biocrystals were evident throughout the liver 
(Figure 2-1A, top panel). Taking advantage of solvatochromic changes in the fluorescent 
excitation and emission spectra of CFZ [31, 32], fluorescence microscopy enabled in vivo 
detection of the soluble and biocrystalline forms of CFZ. After 2 weeks of CFZ treatment, the 
drug was mostly present in the soluble form with its fluorescence mostly detectable in the FITC 
channel (Figure 2-1A, fluorescein isothiocyanate [FITC] and Cy5 panels; Figure 2-1B). At later 
time points, the fluorescence signal in the FITC channel declined, while the fluorescence signal 
in the Cy5 channel increased, indicating the relative accumulation of the biocrystalline form 
(Figure 2-1A and B). By 8 weeks, most of the fluorescence signal was detectable in the Cy5 
channel (Figure 2-1 A and B), indicating that CFZ was present almost entirely in biocrystalline 
form. Immunohistochemistry of 8-week-CFZ-treated liver sections showed that CFZ biocrystals 
are sequestered inside F4/80- positive macrophages (Figure 2-1C). Such targeted accumulation 
of CFZ biocrystals was also detected in other organs such as CD68+ alveolar macrophages (see 
Figure S2-1 in Appendix A), and F4/80+ splenic macrophages [8, 31]. 
CFZ biocrystal formation in the liver downregulates Casp 1/IL-1β processing while 
enhancing IL-1RA expression 
Intracellular crystals, such as those formed by cholesterol or uric acid, have been 
implicated in the activation of the NLRP3-Casp 1 inflammasome, which plays a major role in the 
pathogenesis of chronic inflammatory disorders [14, 33, 34]. The uptake of other nano- and 
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microparticles has also been reported to cause inflammasome activation in macrophages [35-37]. 
Therefore, to assess whether the bioaccumulation of CFZ crystals leads to activation of the 
inflammasome, we measured and compared cleaved Casp 1 and IL-1β in organs that 
bioaccumulate CFZ - i.e., the liver, spleen, and lungs - and kidneys, that do not accumulate CFZ, 
after 2 and 8 weeks of either CFZ or control treatment. Two weeks of CFZ exposure resulted in 
only moderate cleavage of hepatic Casp 1 and IL-1β (Figure 2-2A, left panel, and Figure 2-2B). 
However, by 8 weeks, Casp 1 and IL-1β cleavage was significantly reduced by CFZ treatment 
(Figure 2-2A, right panel, and Figure 2-2B); IL-1β levels in the spleen, lung, and kidneys did not 
change (see Figure S2-2 in Appendix A). The expression of the proinflammatory cytokine, TNF-
α, was unchanged by CFZ at both 2 and 8 weeks (Figure 2-2C), except in the liver, where it was 
decreased at 2 weeks compared to control livers. 
Similar to previous observations [8], we found that after 8 weeks of oral administration 
CFZ caused a major upregulation of IL-1RA expression in CFZ biocrystal-accumulating organs, 
such as the spleen, the lungs, and especially the liver, which increased by 3-fold (Figure 2-2D). 
IL-1RA levels in the kidney were unaffected (Figure 2-2D). In contrast, after 2 weeks of oral 
CFZ administration there were more modest increases in only the spleen and lungs, while the 
liver was unaffected (Figure 2-2D). Since the liver is known to be the major source of circulating 
IL-1RA [38, 39], we observed a corresponding increase in serum IL-1RA levels in CFZ-treated 
mice at 8 weeks but not at 2 weeks (Figure 2-2E). Under all conditions, neither TNF-α nor IL-1β 
was detected in the serum. In aggregate, these findings suggest that crystallized CFZ, which is 
evident after 8 weeks of CFZ administration, decreased the activation of the inflammasome in 
vivo. In parallel with this decline, crystallized CFZ induced an upregulation of endogenous IL-
1RA. 
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Systemic CFZ bioaccumulation and crystallization dampens CAR-mediated acute footpad 
inflammation 
To test the physiological impact of the CFZ-induced serum IL-1RA levels, we tested the 
acute inflammatory response of CFZ-treated mice by using a well-established footpad injury 
model [25]. The paws of 8-week-CFZ-treated mice displayed strikingly reduced swelling at 48 h 
after the injection of CAR compared to the paws of untreated CAR-injected mice (Figure 2-3A). 
Paw volume measurements showed that there was a significant reduction (57%) in footpad 
swelling as early as 4 h after the injection of CAR in 8-week-CFZ-treated mice compared to 
control mice, and the animals continued to exhibit reduced swelling over the 48-h study period 
(Figure 2-3B). CAR-induced increases in footpad IL-1β and TNF-α levels were dramatically 
reduced by 8-week-CFZ treatment (Figure 2-3C and D). In contrast to the 8-week-treated mice, 
2-week-CFZ-treated mice produced only a modest reduction in paw swelling compared to 
control mice (Figure 2-3E and F). The IL-1β and TNF-α levels in footpad homogenates from 
these animals were similar in both CFZ-treated and control mice at 48 h (Figure 2-3G and H). 
Accordingly, these results suggest that the accumulation of CFZ biocrystals modulated the 
immune response to profoundly dampen CAR-induced footpad inflammation, and this action is 
not evident for the soluble form of the drug after 2 weeks of treatment. 
CFZ biocrystals dampen the acute inflammatory response in the footpad by increasing 
blood IL-1RA 
IL-1RA is known to be an early-acting acute-phase anti-inflammatory cytokine [38], and 
circulating IL-1RA has been reported to dampen a broad spectrum of inflammatory conditions 
by inhibiting the activity of IL-1β at the site of injury [40, 41]. Therefore, we hypothesized that 
the anti-inflammatory response observed after 8 weeks of CFZ treatment may be mediated by 
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increased serum IL-1RA concentrations, which are not evident after 2 weeks of CFZ treatment 
(Figure 2-2E). Detection of serum IL-1RA in 2-week-CFZ-treated and control mice showed 
comparable IL-1RA levels before (0 h) and after (48 h) CAR injection (Figure 2-4A). However, 
serum IL-1RA levels in 8-week-CFZ-treated mice rapidly declined 4 h after CAR injection 
(Figure 2-4B). After 48 h, IL-1RA returned to similar levels in the plasma of control and 8-week-
CFZ-treated mice (Figure 2-4B). For all mice, the plasma levels of TNF-α and IL-1β were below 
the detection limit of ELISAs (15 pg/ml). These results suggest that increased circulating IL-
1RA levels associated with CFZ bioaccumulation and crystallization could be responsible for the 
anti-inflammatory activity observed in 8-week-CFZ-treated mice. 
In order to test the possibility that elevated IL-1RA expression mediates the anti-
inflammatory activity of CFZ after crystal formation, we administered oral CFZ to age-matched 
IL-1RA KO and WT mice and then subjected the animals to the CAR footpad injury model. IL-
1RA KO mouse livers also increased in weight to an extent similar to that of WT mice after 6 
weeks of CFZ treatment (see Figure S2-3B in Appendix A). Also, IL-1RA KO mice formed and 
accumulated CFZ biocrystals in the liver at a level similar to WT animals without noticeable 
differences in crystal shape or Cy5 fluorescence intensity (see Figure S2-3C and D in Appendix 
A). Remarkably, the anti-inflammatory action of CFZ bioaccumulation was greatly diminished 
in IL-1RA KO mice, since CFZ-treated and CAR-injected IL-1RA KO mice displayed similar 
swelling compared to untreated and CAR-injected IL-1RA KO mice (Figure 2-4C and D, right 
panels). In the CFZ-treated WT mice, we observed significantly reduced CAR-induced swelling 
compared to control mice at 4 and 48 h postinjury (Figure 2-4C and D, WT panels). As expected, 
the footpad IL-1β and TNF-α levels were significantly reduced in WT CFZ-treated and CAR-
injected mice compared to WT untreated and CAR-injected mice (Figure 2-4E). However, the 
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IL-1β and TNF-α levels were comparable in the CAR-injected IL-1RA KO mice with or without 
CFZ treatment (Figure 2-4F). IL-1RA KO mice with or without CFZ treatment showed higher 
cytokine levels than the control WT mice after CAR injection (Figure 2-4E versus Figure 2-4F), 
but the footpad swelling was similar (Figure 2-4D). These results are consistent with CFZ 
bioaccumulation exerting a systemic anti-inflammatory action via the elevation of blood IL-1RA 
levels. 
CFZ bioaccumulation enhances resistance to acute lung injury and improves mouse 
survival 
Given the massive bioaccumulation of CFZ observed in the lungs, we proceeded to 
determine whether the presence of CFZ biocrystals in these organs may sensitize mice to a 
sublethal proinflammatory injury. Although CFZ treatment and bioaccumulation did cause some 
physiological changes, these changes were within ranges of normal physiological readings and 
overall mouse health was normal (see Table S2-1 in Appendix A).  
To determine whether CFZ bioaccumulation induced a latent proinflammatory state in 
mouse lungs, a sublethal dose of LPS (16 mg/kg) was delivered i.t. to control and CFZ-treated 
mice. Strikingly, CFZ-treated mice were highly resistant to LPS-induced acute lung injury, with 
a 92% survival rate compared to the 42% survival rate of control mice (Figure 2-5A). The 
difference in the arterial oxygen saturation levels between control and CFZ-treated mice was 
more prominent after the second LPS injection. CFZ-treated mice displayed significantly higher 
arterial oxygen levels at days 5 and 6 than control mice because most control mice experienced 
levels of hypoxia that required euthanasia, indicating that control mice showed progressive 
deterioration in lung function compared to CFZ-treated mice (see Figure S2-4A in Appendix A). 
Paralleling the impaired lung function, LPS-injected control mice lost weight more rapidly than 
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CFZ-treated mice, such that six control mice lost >15% of their body weight compared to a 
similar weight loss in one CFZ-treated mouse (see Figure S2-4B in Appendix A). Both control 
and CFZ-treated LPS-injected mice displayed large drops in body temperature one day after LPS 
injection (days 1 and 4). However, CFZ-treated mice were more resistant to a decline in body 
temperature after the second injection compared to control mice (day 4) (see Figure S2-4C in 
Appendix A). CFZ-treated mice also displayed less reduction in heart rate, respiratory rate, and 
pulse distention after the second LPS injection (see Figure S2-4D to F in Appendix A) compared 
to control mice. Gross lung examination lungs after LPS-induced injury showed a notable 
reduction of hemorrhaging in CFZ-treated mice compared to control mice (Figure 2-5B). 
Cellular and biochemical analyses of BAL fluid to assess lung injury revealed that CFZ 
treatment reduced the LPS-induced BAL fluid cell count (Figure 2-5C) and reduced the BAL 
fluid albumin concentrations (Figure 2-5D). This CFZ-mediated reduction in lung injury was 
corroborated by CFZ-induced reductions in LPS-induced levels of BAL fluid TNF-α and IL-1β 
(Figure 2-5E and F). These results demonstrate that CFZ biocrystal accumulation in the lungs did 
not impair lung function but instead increased resistance to LPS-induced inflammatory lung 
injury. 
2.6 Discussion 
Previously, CFZ bioaccumulation has been associated with atypical pharmacokinetics, as 
well as more serious side effects, ranging from gastrointestinal problems to splenic infarcts [42]. 
Although expecting that CFZ bioaccumulation would lead to an upregulation of proinflammatory 
signaling pathways in macrophages, we were surprised to find the opposite. Instead, our 
experimental results indicate that long-term oral administration of CFZ and its sequestration as 
biocrystals within the macrophages of the lung, the spleen, and especially the liver can 
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dramatically suppress inflammation in peripheral tissues and increase mouse survival in response 
to acute lung injury. This systemic anti-inflammatory response parallels the accumulation of 
CFZ biocrystals throughout the animal and is accompanied by elevated IL-1RA levels in these 
organs and a corresponding boost in IL-1RA levels in serum. Of noteworthy significance, the 
formation and accumulation of cholesterol monohydrate and monosodium urate crystals have 
been implicated in the pathogenesis of chronic inflammatory diseases, such as atherosclerosis, 
nonalcoholic steatohepatitis (NASH) [34], and gout [43]. Moreover, other artificial nano- and 
microparticles, such as silica crystals [37], aluminum salt crystals [44], silver nanoparticles [35], 
poly(lactide-co-glycolide) (PLG), and polystyrene microparticles [36], have also been reported to 
cause inflammasome activation in macrophages. At the cellular level, the aforementioned 
particles or crystals are known to augment Toll-like receptor signaling and activate the NLRP3 
inflammasome via lysosomal destabilization, which leads to Casp 1 activation and the 
production of cleaved IL-1β [13, 14]. Therefore, the finding that inflammasome activity was 
inhibited in the CFZ biocrystal-containing liver, evidenced by the suppression of Casp 1 
activation and mature IL-1β processing, was unexpected. Moreover, the presence of CFZ 
biocrystals in the lung, spleen, or liver did not alter the TNF-α levels, a finding consistent with a 
lack of proinflammatory signaling. 
These results prompt us to question whether CFZ bioaccumulation is an inherently toxic 
phenomenon. It is well known that soluble CFZ is toxic in vitro, with a 50% inhibitory 
concentration of approximately 5 µM, whereas the insoluble crystalline form of CFZ that 
bioaccumulates in macrophages leads to very few signs of toxicity even at 100 µM [23]. Indeed, 
in spite of its massive accumulation in the liver, the hepatotoxicity of CFZ in mice and human 
patients has not been a significant concern [45-47]. Like humans, mice treated with therapeutic 
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CFZ doses (10 mg/kg/day) did not show signs of deteriorated health. In fact, the CFZ-induced 
reduction of heart rate could be linked with increased longevity in mice [48]. Also, hypothermia, 
which is most often used as an indicator of drug toxicity in mice [49], was not seen in 8-week-
CFZ-treated mice. 
Regarding the therapeutic implications of these results, CFZ has proven to be highly 
effective for treating leprosy and active against a broad range of Gram-positive bacteria strains 
(Staphylococcus, Streptococcus, Bacillus, and Listeria spp.) [50] and even against drug-resistant 
Staphylococcus aureus clinical isolates that are methicillin resistant (MRSA) and vancomycin 
intermediate resistant (VISA) [51]. Indeed, CFZ has been clinically used since the 1960s and has 
helped cure over 16 million leprosy patients. Many of these microorganisms tend to infect and 
reside within macrophages. Interestingly, chemical analysis of CFZ biocrystals has revealed that 
they are composed of protonated hydrochloride salt of CFZ (CFZ-HCl) within membrane-bound 
intracellular compartments [9]. Therefore, the bioaccumulation of CFZ biocrystals in 
macrophages could serve to maximize the therapeutic efficacy of CFZ without significant side 
effects. Accordingly, it may be possible to reformulate CFZ as injectable micro- or nanocrystals 
to specifically target macrophages at sites of infection. Targeted local delivery could maximize 
CFZ benefit as a therapeutic agent while minimizing the systemic side effects that have curtailed 
the more widespread use of CFZ. 
Considering possible signal transduction mechanisms underlying the anti-inflammatory 
activity of CFZ biocrystals, the cellular integrated stress response pathway is a candidate [52, 
53]. Although soluble CFZ can cause membrane destabilization and cell death at high 
concentrations [54], lower concentrations of CFZ lead to accumulation within intracellular 
compartments. Previously, we observed that CFZ biocrystals can also be phagocytosed by 
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macrophages, where they are stable inside low-pH [4, 5] and counterion (Cl-)-containing [9] 
membrane-bound compartments. As a weakly basic lysosomotropic drug, CFZ is prone to pH-
dependent ion trapping in lysosomes and could therefore activate transcription factor EB (TFEB 
[55]), a master transcription factor of lysosomal biogenesis and homeostasis [56-58]. In turn, this 
could attenuate inflammasome activation pathways and IL-1β processing [59]. Alternatively, like 
intracellular protein aggregates and other crystalline inclusions that form in the endoplasmic 
reticulum [60], CFZ biocrystals may activate the unfolded protein response pathway, which 
could lead to downstream effects on inflammatory signaling [61, 62]. 
Our experiments indicate that CFZ biocrystals induce a considerable upregulation of IL-
1RA production without triggering proinflammatory signaling. Since the evidence points to IL-
1RA mediating the anti-inflammatory effects downstream of CFZ bioaccumulation in 
macrophages, future experiments aimed at elucidating the signaling pathway leading from CFZ 
biocrystals to IL-1RA expression should reveal further mechanistic details about the mechanism 
of action of CFZ and perhaps serve as the starting point for the development of new kinds of 
anti-inflammatory drugs. Thus, the present study strongly warrants further investigation into the 
mechanisms and therapeutic potential of CFZ for treating inflammatory and infectious diseases 
in humans. To conclude, CFZ biocrystal accumulation in macrophages could be triggering a 
previously unknown anti-inflammatory/immunomodulatory signaling pathway(s) of potential 
therapeutic value. 
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2.8 Figures 
 
 
 
Figure 2-1. CFZ bioaccumulation and crystal formation in the liver occurs after 2 weeks. (A) Representative 
brightfield and fluorescence (FITC for soluble CFZ and Cy5 for crystalline CFZ) images of liver sections from 
control mice and mice treated with CFZ for 2, 4, and 8 weeks. Scale bar, 50 µm. (B) Fluorescence intensity values 
(FITC and Cy5 channels) of liver sections from control and CFZ-treated mice. Baseline (0 week) intensity values of 
controls were subtracted from CFZ-treated sections. The data are the means ± the SD of results from three to four 
images/time point. One-way ANOVA was used to compare fluorescence intensity between time points and P ≤ 0.05 
was considered statistically significant. *, P ≤ 0.05; **, P ≤ 0.01. (C) F4/80 (DAB) immunohistochemistry of a 
representative liver section from an 8-week-CFZ-treated mouse in which CFZ crystals (Cy5) are sequestered inside 
F4/80+ macrophages. CV, central vein. Scale bar, 100 µm. 
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Figure 2-2. CFZ bioaccumulation reduces Casp 1 and IL-1β cleavage levels in the liver but increases IL-1RA 
expression. (A) Representative Western blots of liver homogenates showing that Casp 1 and IL-1β cleavage was not 
altered by 2 weeks of CFZ treatment but that 8 weeks of treatment reduced the detection of Casp 1 and IL-1β 
cleavage. (B) Densitometry of cleaved Casp 1 and IL-1β protein in 2- and 8-week-treated liver blots, normalized to 
actin (n = 4). Hepatic Casp 1 and IL-1β cleavage were reduced by 86 and 78%, respectively, in 8-week-CFZ-treated 
mice. (C) The levels of TNF-α in the spleen, lungs, and kidneys were unchanged by CFZ treatment, but there was a 
significant decrease in liver TNF-α from 2-week-CFZ-treated mice (n = 4 to 5). (D) The organs that bioaccumulate 
CFZ crystals – liver, spleen, and lung – displayed increased IL-1RA expression, whereas the kidney, which does not 
accumulate CFZ, did not show changes in IL-1RA expression (n = 4 to 5). (E) Serum IL-1RA levels were 
unchanged after 2 weeks but were increased 21-fold after 8 weeks of CFZ treatment. The serum TNF-α and IL-1β 
levels were below the limit of detection of the assay (n = 6). *, P ≤ 0.05; **, P ≤ 0.01; #, P ≤ 0.001. Data are means 
± the SD, and an unpaired Student t test was used to compare control mice versus CFZ-treated mice. 
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Figure 2-3. Systemic CFZ bioaccumulation and crystal formation dampens CAR-induced inflammatory 
response in the mouse footpad. (A) Representative photographs of paws 48 h after CAR or PBS footpad injection 
show markedly reduced paw swelling in 8-week-CFZ-treated mice compared to control mice. Scale bar, 5 mm. (B) 
Paw swelling, as measured by foot volume, was reduced on average by 57% as early as 4 h after CAR injection in 8-
week-CFZ-treated mice compared to control mice and was sustained through 48 h. The footpad homogenate 
cytokine levels of IL-1β (C) and TNF-α (D) were reduced in 8-week-CFZ-treated mice at 48 h compared to 
untreated and injured paws. (E and F) Representative photographs of paws 48 h after CAR or PBS footpad injection 
in 2-week-CFZ-treated or control mice (E), which resulted in only a minor reduction in swelling at 4 and 48 h (F). 
Scale bar, 5 mm. (G and H) Associated footpad homogenate TNF-α (G) and IL-1β (H) levels were unchanged. 
PBS-injected paws did not show any difference in cytokine expression between CFZ-treated or control paws. Data 
are means ± the SD of n = 5 to 6/experiment. An unpaired Student t test was used to compare control versus CFZ-
treated mice. *, P ≤ 0.05; **, P ≤ 0.01. 
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Figure 2-4. The CFZ-induced dampening of the acute inflammatory response in the CAR footpad model is 
mediated by circulating IL-1RA. (A) Two-week-CFZ-treated and control wild-type (WT) mice displayed similar 
serum IL-1RA levels before (0 h) and after (48 h) CAR injection. (B) Serum IL-1RA concentrations were 
significantly increased after 8 weeks of CFZ treatment compared to controls in WT mice (0 h). CAR injection in 8-
week-CFZ-treated mice caused a sharp decline in serum IL-1RA concentrations by 4 h, whereas the levels in control 
CAR mice remained constant. At 48 h after CAR injection, the serum IL-1RA increased to similar levels in both 
control and CFZ-treated WT mice (data are means ± the SD of n = 5 to 8 animals/group/time point). (C) 
Representative images of inflamed paws of 6-week-CFZ-treated WT mice and IL-1RA KO mice at 48 h after CAR 
injection. (D) Footpad swelling, as measured by foot volume, was reduced by 27 and 38% at 4 and 48 h after CAR 
injection, respectively, in 6-week-CFZ-treated WT mice compared to control WT mice. In IL-1RA KO mice with 
CFZ treatment, paw swelling was similar at 4 h compared to untreated littermates, and at 48 h, swelling was 
marginally reduced (17%) compared to untreated IL-1RA KO mice. (E) Footpad homogenate levels of IL-1β and 
TNF-α were dampened in 6-week-CFZ-treated and CAR-injected WT mice at 48 h compared to control and CAR-
injected paws. (F) Footpad homogenate levels of IL-1β and TNF-α were unaffected in 6-week-CFZ-treated and 
CAR-injected IL-1RA KO mice at 48 h compared to control and CAR-injected paws. Data are the compilation of 
two separate experiments and are presented as means ± the SD (n = 7 to 9). A Student t test was used to compare 
untreated versus CFZ-treated mice at each time point. *, P ≤ 0.05; **, P ≤ 0.01. Scale bar, 5 mm. 
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Figure 2-5. CFZ bioaccumulation enhances resistance to LPS-induced lung injury and improves mouse 
survival. (A) Kaplan-Meier survival curve showing the 92% survival rate of 8-week-CFZ-treated mice after LPS-
induced acute lung injury compared to the 42% survival rate of control mice with LPS-induced injury. (B) A 
representative photograph shows the gross appearance of the lungs after PBS or LPS injection in control and CFZ-
treated mice. Hemorrhaged areas caused by LPS injection are outlined in black lines. (C to F) CFZ treatment 
reduced LPS-induced increases in the BAL fluid cell count (C), albumin level (D), TNF-α level (E), and IL-1β level 
(F). The data are the compilation of two separate experiments and are presented as means ± the SD (PBS, n = 4; 
LPS, n = 12). One-way ANOVA was used to compare control versus CFZ-treated mice with PBS or LPS injections, 
and P ≤ 0.05 was considered statistically significant. *, P ≤ 0.05; **, P ≤ 0.01. 
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2.9 Supporting Information 
The supplemental methods and figures are available in the Appendix A. 
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Chapter 3 
Reverse Engineering the Intracellular Self-Assembly of a Functional 
Mechanopharmaceutical Device 
3.1 Relevance to Thesis 
This chapter was adapted from the following publication: 
Woldemichael T, Keswani RK, Rzeczycki P, Murashov MD, LaLone V, Gregorka B, Swanson 
JA, Stringer KA, Rosania GR. 2018. Reverse engineering the intracellular self-assembly of a 
functional mechanopharmaceutical device. Sci Rep. 8(1):2934;doi:10.1038/s41598-018-21271-7 
 
This chapter incorporates the interdependence of lysosomal ion homeostasis and 
clofazimine drug biocrystal (Cy5(+) CFZ-HCl) accumulation. My contribution in this study 
involved studying the thermodynamic mechanism leading to differential stability of HCl salt 
form vs free base form of clofazimine by accurately measuring of the total solubility of CFZ-HCl 
as a function of pH, constructing a pH-dependent solubility profile of pure CFZ-HCl salt. By 
utilizing the data from this pH-dependent solubility profile of CFZ-HCl, the following 
physicochemical parameters were determined: pHmax, apparent pKa, CFZ-HCl aqueous solubility, 
CFZ free base intrinsic solubility, and Ksp. These key physicochemical parameters allowed us to 
discover the mechanism under which lysosomes of macrophages are able to accumulate and 
stabilize CFZ-HCl salt and not CFZ free base form of the drug. In fact, this study discusses the 
key lysosomal parameter for the physiological accumulation of biocrystal drug in a cell-type 
dependent manner by investigating the physicochemical properties of free base CFZ and CFZ-
H+Cl- salt in relation to different cellular and subcellular conditions, such as pH and ion content, 
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and modeling the effects of various cell-type dependent lysosomal features, such as membrane 
proteins and ion content on biocrystal drug accumulation.  
The results from this study enabled us to characterize the subcellular mechanism of a 
weakly basic drug (e.g. clofazimine) accumulation and stabilization in cells in a cell-type 
dependent manner, specifically in lysosomal environment of macrophages, in vitro and in vivo. 
Importantly, the findings supported our previously published results in regards to the unique 
accumulation and stabilization of CFZ self-assembled drug biocrystals, or crystal packing of 
CFZ-HCl salt in vivo, in macrophages.  
3.2 Abstract 
Weakly basic, poorly soluble chemical agents could be exploited as building blocks for 
constructing sophisticated molecular devices inside the cells of living organisms. Here, using 
experimental and computational approaches, we probed the relationship between the biological 
mechanisms mediating lysosomal ion homeostasis and the self-assembly of a weakly basic small 
molecule building block (clofazimine) into a functional, mechanopharmaceutical device 
(intracellular Crystal-Like Drug Inclusions – “CLDIs”) in macrophage lysosomes. 
Physicochemical considerations indicate that the intralysosomal stabilization of the self-
assembled mechanopharmaceutical device depends on the pHmax of the weakly basic building 
block and its affinity for chloride, both of which are consistent with the pH and chloride content 
of a physiological lysosomal microenvironment. Most importantly, in vitro and in silico studies 
revealed that high expression levels of the vacuolar ATPase (V-ATPase), irrespective of the 
expression levels of chloride channels, are necessary and sufficient to explain the cell-type 
dependent formation, stabilization, and biocompatibility of the self-assembled 
mechanopharmaceutical device within macrophages. 
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3.3 Introduction 
Clofazimine (CFZ) is a weakly basic, poorly soluble, FDA-approved small molecule 
antibiotic that self-assembles [1, 2] into insoluble, biocrystalline structures known as Crystal 
Like Drug Inclusions (CLDIs) in macrophages of both mice and humans [3-5]. In mice, CFZ 
precipitates and accumulates in tissue macrophages as a biocrystalline hydrochloride salt (CFZ-
H+Cl-). Remarkably, in Kupffer cells, splenocytes, alveolar macrophages, and peritoneal 
macrophages, the amount of intracellular CFZ-H+Cl- typically exceeds that of every other 
cellular component except water [5]. Known factors that contribute to this massive 
bioaccumulation and self-assembly phenomenon include the drug’s high oral bioavailability, 
coupled with large daily doses, prolonged treatment regimens, and long elimination half-life [6].  
The observed self-assembly, mechanical, and optical properties [7] of CFZ-H+Cl-, which 
can function as drug depots and photoacoustic contrast agents in macrophages, inspired our 
thinking about reverse engineering this weakly basic, small molecule chemical agent as a 
molecular building block for constructing other kinds of functional mechanopharmaceutical 
devices. Such devices could be used to influence the mechanical properties of cells. They could 
also be exploited as bio-responsive pharmaceutical or imaging agents by capitalizing on both 
physical and chemical interactions between cells and the self-assembled biocrystalline structures, 
in vivo [3, 5, 8]. In macrophages, CFZ-H+Cl- forms elastic structures, which bend and relax in 
response to biomechanical forces [7]. Furthermore, the presence of these 
mechanopharmaceutical devices inside macrophages is associated with augmented anti-
inflammatory activity [9, 10]: upon phagocytosis, they lead to changes in cellular function, 
which include alterations in signal transduction pathways that affect the cell’s inflammatory 
response [10]. Unlike the soluble form of CFZ, which tends to be cytotoxic, the phagocytosis of 
the self-assembled mechanopharmaceutical device does not lead to toxicity [8, 11]. 
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Thus, given that macrophages express high levels of proton pumping vacuolar ATPase 
(V-ATPase) and chloride channels on their lysosomal membranes [12-14], and that weak bases 
are prone to accumulate inside lysosomes [15], we probed whether the expression levels of these 
lysosomal membrane proteins in macrophages actively drive the accumulation of CFZ-H+Cl- and 
its self-assembly in these cells. Using a well-established and published lysosomal ion regulation 
model [16], we studied how proton pumping and chloride transport mechanisms influenced cell-
type specific stabilization of CFZ-H+Cl- inside lysosomes. In addition to verifying model 
predictions and further refining our understanding of the computational simulation results, we 
performed experiments using pharmacological inhibitors of V-ATPase [17] and chloride 
channels [18] to probe the biological mechanism underpinning the massive accumulation and 
self-assembly of the building block.  
3.4 Materials and Methods 
Solubility measurements  
Freeze-dried CFZ-H+Cl- [11] samples were weighed and 25 mg was added to each of five 
scintillation vials. Mili-Q water (15 mL) was added to each vial to ensure that CFZ-H+Cl- 
crystals were in great excess. An aliquot of 0.1 M NaOH was added to each vial to achieve the 
initial equilibration pH measurements as follows: sample vials 1-5 initially contained 0, 40, 80, 
120, and 200 µL of 0.1 M NaOH solution, respectively. After a 24-hour equilibration period, 10 
µL of 0.1 M NaOH was added each day for a period of five days resulting in pH range of 4.5 to 
8.9. The sample vials were placed on a magnetic stirrer plate in a 25 °C water bath. Each sample 
was allowed to equilibrate for at least 24 hours, after which 500 µL of sample was removed and 
filtered through a Spin-X centrifuge tube filter (0.45 µm cellulose acetate, 2 mL polypropylene 
tubes, non-sterile, Costar®, Cat # 8163) for 4 min @ 10,000 rpm. The pH of the filtered sample 
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was determined (UltraBasic pH meter, Denver Instrument, Bohemia, NY), after which the 
sample was subjected to HPLC analysis (see Supplementary Methods in Appendix B) (Waters 
Alliance, Separations Module 2695) to determine the total solubility of the drug at the measured 
pH. For each sample, solubility measurement was performed in triplicate, and the average was 
used to construct the total drug solubility-pH profile. The standard curve was generated using 
CFZ-H+Cl- crystals that were dissolved in the mobile phase at known concentrations (1-50 µM).  
Thermodynamic equilibrium model of CFZ’s solubility 
For weak electrolytes, such as weakly basic drugs, the protonation state of the drug (B) is 
dictated by the relationship between the drug’s association constant (Ka) and the acidity of its 
environment (H3O+). This is represented by the following equilibrium expression: B + H$O& ⇄ BH& +	H)O          (1) 
Where BH+ is the protonated form of the drug as a result of the interaction of the free base form 
of the drug with hydronium ion, and H2O is the byproduct of the reaction and remains constant. 
Thus, the equilibrium constant (K) is multiplied by H2O to obtain Ka. Therefore, equation (1) is 
re-written using Ka. B + H$O& ⇄ BH&           (2) 
The mass law equilibrium equation is written as the following, assuming an ideal solution where 
the activity of a given species equals the concentration of the species (represented by the 
brackets):  𝐾+ = 	 [./0][.][/230]          (3) 
By writing the logarithmic form of equation (3), we have the following relationship, which is the 
Henderson-Hasselbach equation:  pH − p𝐾+ = log [.][./0]	         (4) 
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The equation is re-written as the following to express the concentrations of both the neutral and 
ionized forms of the drug: [B] = [BH&] × 10</=<>?          (5) [BH&] = [B] × 10<>?=</	         (6) 
According to thermodynamic laws of mass action, the total amount of drug is comprised of both 
the neutral and ionized forms at any given pH of its environment [19]. Thus, the total solubility 
(ST) of the drug is written as: SA = [B] + [BH&]	          (7) 
However, depending on the pH of the solution, the total drug solubility equation must be slightly 
modified to account for the distinction of the primary species in the solid versus solution phase 
[19]. For pH < pHmax, the ionized form of the drug is the saturated species that is in equilibrium 
with the salt from of the drug in the solid phase; therefore, its solubility remains constant while 
the solubility of the neutral form of the drug varies with respect to pH. Therefore, by substituting 
equation (5) into equation (7), the total drug solubility for pH < pHmax is re-written as: SA = [BH&]B × (	1 + 10</=<>?)         (8) 
Where the solid phase is denoted by the subscript “s”. 
To the contrary, for pH > pHmax, the neutral form of the drug is in the solid phase; thus, its 
solubility remains constant whereas the solubility of the ionized form of the drug varies with 
respect to pH. Therefore, by substituting equation (6) into equation (7), the total solubility for pH 
< pHmax can be re-written as: SA = [B]B × (	1 + 10<>?=</)        (9) 
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Moreover, at pH = pHmax, both the ionized and neutral forms of the drug are the saturating 
species, where both the salt and free base precipitate forms are in the solid phase. Thus, equation 
(7) can be re-written as: SA = [B]B +	[BH&]B          (10) 
For our purpose, we substituted our model drug CFZ in the above equations (1-10). Rewriting 
equation (7) results in the following total CFZ-H+Cl- solubility equation:  SA = [CFZ]B + [CFZH&]         (11) 
Where the solid phase, which in this case is the free form of CFZ, is denoted by the subscript “s”, 
and the ionized form of the drug, [CFZH+], is in the solution phase, and similar to equation (6), is 
dictated by pKa and pH as follows: [CFZH&] = [CFZ]B × 10<>?=</        (12) 
Thus, by substituting equation (12) into equation (11), we obtain the following: SA = [CFZ]B × (1 + 10<>?=</)        (13) 
Furthermore, by using different combinations of any two solubility-pH data points from the 
experimental total solubility-pH measurements, the pKa and the intrinsic free base solubility 
values were simultaneously solved using equation (13). Then, by substituting these values into 
equation (13), the total CFZ-H+Cl- solubility was calculated for the given range of pH 4.5 to 8.9, 
and the experimentally obtained total drug solubility-pH curve was fitted. Furthermore, in order 
to generate the total solubility-pH dataset for pH below pHmax, we used the following equation: SA = [CFZ] + [CFZH&]B         (14) 
Similar to equation (8), equation (14) can be further expressed as:  SA = [CFZH&]B × (1 + 10</=<>?)        (15) 
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However, we first had to determine [CFZH+]S. Because we only used one form of the drug 
(CFZ-H+Cl- salt) as the starting material in the experimental measurements of total drug 
solubility as a function of pH, we used a mathematical proof approach to determine [CFZH+]S 
and thereby pHmax (see Supplementary Methods in Appendix B) without necessarily having to 
experimentally generate a total drug solubility-pH curve for pH below pHmax. 
Moreover, the salt solubility product (Ksp) of CFZ-H+Cl- is given by the following equation: 𝐾HI = [CFZH&]B × [Cl=]                   (16) 
However, because of the 1:1 stoichiometric relationship of CFZH+ and Cl- in CFZ-H+Cl-[7], the 
Ksp of CFZ-H+Cl- in an aqueous media can be expressed as following: 𝐾HI = ([CFZH&]B))          (17) 
Animal experiments 
Mice (4 week old, male C57BL/6J) were purchased from the Jackson Laboratory (Bar 
Harbor, ME) and acclimatized for 1 week in a specific-pathogen-free animal facility. 
Clofazimine (CFZ) (C8895; Sigma, St. Louis, MO) was dissolved in sesame oil (Shirakiku, 
Japan) to achieve a concentration of 3 mg/mL, which was mixed with Powdered Lab Diet 5001 
(PMI International, Inc., St. Louis, MO) to produce a 0.03% drug to powdered feed mix, which 
was orally administered ad libitum for up to eight weeks. A corresponding amount of sesame oil 
was mixed with chow for vehicle treatment (control). Mice were euthanized via CO2 
asphyxiation and exsanguination. Animal care was provided by the University of Michigan’s 
Unit for Laboratory Animal Medicine (ULAM), and the experimental protocol was approved by 
the Committee on Use and Care of Animals (Protocol PRO00005542). All animal experiments 
were done according to the protocol guidelines. 
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Alveolar macrophage isolation 
Following euthanasia, the trachea was surgically exposed and cannulated with a 20G 
needle, and the lungs were lavaged by instilling 1 mL DPBS (Life Technologies) containing 0.5 
mM EDTA (Sigma) six times. Approximately 90% of the instilled bronchoalveolar lavage 
(BAL) was retrieved. BAL was centrifuged (10 min at 400 x g, 4 °C), the supernatant removed, 
and the cell pellet was resuspended in RPMI 1640 media (Life Technologies) with 5% FBS (Life 
Technologies) and Penicillin/Streptomycin (Thermofisher). Cells were plated onto 4 or 8 
chamber coverglass (#1.5, Lab-Tek II, Nunc, Rochester, NY) in RPMI for imaging studies. The 
cells were allowed to attach overnight, washed, and imaged in fresh RPMI. 
Peritoneal macrophage isolation 
Following euthanasia, a small incision was made in the lower abdomen. The peritoneal 
cavity was then flushed with 10 mL of ice cold DPBS containing 5% FBS (Sigma) and collected. 
The peritoneal lavage was centrifuged for 10 min at 400 x g, 4 °C, and then re-suspended in 
DMEM media (Life Technologies) with 5% FBS and Penicillin /Streptomycin and counted. The 
cells were plated into Mat-tek dishes overnight in a serum-free growth media, and washed five 
times with phosphate-buffered saline (PBS). 
Macrophage depletion  
Mice were fed CFZ or control diet continuously for a four-week period. Following two 
weeks of feeding, mice were treated with either liposomes containing either 7 mg/mL of 
clodronate or PBS (FormuMax Scientific Inc., Sunnyvale, CA) for two weeks. Mice were 
initially treated with 200 µL of liposomes followed by 100 µL injections twice per week (or a 
matching volume of PBS) to ensure continual macrophage depletion. Liposomes were injected 
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intraperitoneally, as previously described [20]. After completing four weeks of feeding and two 
weeks of liposome treatment, mice were sacrificed and tissues were collected.  
Biochemical analysis of CFZ in tissues 
The concentration of CFZ in the organs of mice was determined spectrophotometrically. 
After four weeks of CFZ- or vehicle-diet treatment, mice were euthanized via CO2 asphyxiation, 
and organs were collected. Tissue (20-30 mg) was homogenized in 500 µL of 
radioimmunoprecipitation assay buffer (Sigma) with added protease inhibitors (Halt protease and 
phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo Pierce, Rockford, IL). Drug was 
extracted from homogenate (350 µL) with three washes with xylenes (1 mL). The drug was then 
extracted from the xylene with three 1 mL passes of 9 M sulfuric acid. The concentration of CFZ 
present in the tissue was determined using a 96-well plate reader (Biotek Synergy 2, Winooski, 
VT) (wavelength 540 nm). To account for extraction yield, untreated liver and spleen samples 
were spiked with known amounts of CFZ prior to extraction, and were analyzed in the same 
plate as the CFZ treated samples. The mass of CFZ per organ was determined using the yield-
corrected concentration of CFZ in the mass of tissue analyzed, as determined through use of a 
standard curve with known concentrations of CFZ, and is reported as mg CFZ/g tissue. 
Biochemical analysis of CFZ in plasma 
Blood was collected and centrifuged (7,000 × g for 5 minutes). The resulting supernatant 
serum was extracted with acetonitrile (90% extraction efficiency) for 10 min at 4 °C with 
vortexing. After centrifugation (15,000 rpm, 4 °C), the supernatant was injected into a Waters 
Acquity UPLC H-Class (Waters, Milford, MA) equipped with an Acquity UPLC BEH C18 
column (1.7 µm, 2.1 mm [inner diameter] by 100 mm; Waters, Milford, MA). Mobile phase A 
was 5 mM ammonium acetate, adjusted to pH 9.9 with ammonium hydroxide, and mobile phase 
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B was acetonitrile. The flow rate was 0.35 ml/min, with a linear gradient from 50 to 100% phase 
B over 1.5 min, followed by holding at 100% for 1.5 min, a return to 50% phase B, and then re-
equilibration for 2.5 min. Standards were prepared by spiking untreated plasma samples with 
known amounts of clofazimine, ranging from 0 to 30 µM. Peak area was determined using 
Empower 3 Software (Waters, Milford, MA). 
Sample preparation for microscopy 
In preparation for cryosectioning, portions of each organ were removed, immediately 
submerged in OCT (Tissue-Tek catalog no. 4583; Sakura), and frozen (-80 °C). Cryosectioning 
(5 µm) was carried out using a Leica 3050S Cryostat (Leica Biosystems Inc., Buffalo Grove, IL). 
Immunohistochemistry of F4/80 (Abcam, 1:500 dilution) was performed using Alexa-Fluor 488 
(Abcam, 1:500 dilution). 
Deep-etch, freeze-fracture electron microscopy 
At the time of euthanasia, the liver was collected and kept cold (4 °C). The organ was 
frozen against a copper block, cooled with liquid helium, and stored in liquid nitrogen. The 
sample was fractured with Balzers 400 nitrogen cooled vacuum evaporator and freeze-etched for 
two minutes (-100 °C). A rotary replica was generated with 2 nm platinum and backed with 10 
nm carbon film support. It was cleaned with chromo-sulfuric cleaning solution (Fisher Scientific, 
cat# SC88) for twelve hours and rinsed with DI water. The sample was picked up on formvar 
coated grids and viewed on a JEOL 1400 electron microscope with an AMT camera (JEOL 
USA, Inc., Peabody, MA). 
Spectral confocal microscopy 
For the preparation of slides, CFZ-H+Cl- crystals suspended in PBS (20 µl) were placed 
on a glass slide and a cover-slip was applied onto the sample prior to imaging. Spectral confocal 
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microscopy was performed on a Leica Inverted SP5X confocal microscope system with two-
photon FLIM (Leica Microsystems, Buffalo Grove, IL) using excitation wavelengths (470–670 
nm). Image analysis and quantification were performed on Leica LAS AF. Several regions of 
interest of individual crystals were used to obtain fluorescence data, which were imported into 
MS-Excel for further analysis. All fluorescence yields were normalized to the maximum 
fluorescence yield measured across the tested spectral range, and background subtracted using 
data obtained from a blank slide. 
Epifluorescence microscopy of cells incubated with CFZ and Lysotracker® Blue 
Macrophage-derived RAW264.7 cells (ATCC, Manassas, VA, ATCC Number: TIB-
71TM) at a high seeding density of 100,000 cells/well, were grown in 8-chamber multiwell plates 
(Lab-Tek® II, Nunc, Rochester, NY) in Dulbecco’s Modified Eagles Medium (DMEM) + 10% 
Fetal Bovine Serum (FBS) + 1% Penicillin/Streptomycin (P/S) (500 µl/well growth media); cells 
were pre-incubated with CFZ (20 µM) in DMSO for 24-72 hours. For lysosomal confirmation, 
RAW264.7 cells were seeded at 30,000 cells/well in an 8-chamber multiwell plate (500 µl/well 
growth media). Twenty-four hours later, the growth media was replaced with media containing 
varying concentrations (0, 1, 10, 20 µM) of Lysotracker® Blue DND-22 (Thermo Fisher 
Scientific, Waltham, MA, Catalog No. L7525, excitation/emission maxima ~ 373/422 nm) and 
CFZ (10 µM). Visualization of all samples (cells or crystals) was done on a Nikon Eclipse Ti 
(Nikon Instruments, Melville, NY). Fluorescence filters (excitation/emission) were optimized for 
4,6-diamidino-2-phenylindole dihydrochloride (DAPI) (350/405 nm, exposure - 550 ms, violet), 
fluorescein isothiocyanate (FITC) (490/510 nm, exposure - 100–500 ms, green), Texas Red 
(590/610 nm, exposure - < 500 ms, red), and Cy5 (640/670 nm, exposure - 500 ms, far-red). The 
Pearson’s Co-localization Coefficient (PCC) was computed for each individual cell as ROIs 
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using the scatterplot distribution within the Nikon Elements AR software. Brightfield color 
photographs were acquired using a Nikon DS-Fi2 camera, whereas fluorescence photographs 
were acquired using a Photometrics CoolSNAPTM MYO (Photometrics, Tucson, AZ) camera.  
Quantitative cytometric analysis 
Following macrophage staining, the population of macrophages was determined by 
taking the ratio of the total F4/80 signal to the total nuclear signal across an image. Because of 
the unique Cy5-specific fluorescence property of CLDIs [11], the prevalence of CLDIs was 
determined by taking the ratio of the total Cy5 signal to the total nuclear signal across an image. 
5 images per mouse per organ were analyzed. 
Drug stability in a lysosomal microenvironment 
CLDIs were isolated from spleen and liver of 8-week CFZ treated mice based on 
previously published protocols [10, 21]. Free base CFZ crystals were pure CFZ crystals (Sigma-
Aldrich, C8895). A speck (<< 1mg) of isolated CLDIs, CFZ-H+Cl- crystals, and free base CFZ 
crystals were placed in 2 mL of each of the stability testing medias: 1x PBS (pH 7.4), lysosomal 
buffer without sodium chloride (LB-, pH 4.5), and lysosomal buffer with sodium chloride (LB+, 
pH 4.5). Lysosomal buffers were prepared according to a previously published protocol [22]. 
Samples were stirred in media for 5-7 days; after which the stability of crystals from each sample 
was monitored using brightfield and fluorescence microscopy using a Nikon Eclipse Ti inverted 
microscope (Nikon Instruments, Melville, NY). Look-up-tables (LUTs) and exposure times were 
maintained the same throughout the samples. 
Multi-parameter microscopy 
Multi-parameter polarization, brightfield, and fluorescence microscopy was conducted 
using a Nikon Eclipse Ti inverted microscope (Nikon Instruments, Melville, NY). Polarization 
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microscopy was performed using the LC-PolScope [23], with the illuminating light narrowed to 
623 nm by an interference filter (623 ± 23 nm, Semrock Optics, Rochester, NY). Polarization 
images were captured using an Abrio imaging system (Cambridge Research & Instrumentation, 
Inc, Woburn, MA). Brightfield images were captured using the Nikon DS-3 camera (Nikon 
Instruments) and fluorescence images were taken with the Photometrics CoolSnap MYO camera 
system (Photometrics, Tuscon, AZ) under the control of Nikon NIS-Elements AR software 
(Nikon Instruments). Illumination for fluorescence imaging was provided by the X-Cite 120Q 
Widefield Fluorescence Microscope Excitation Light Source (Excelitas Technology, Waltham, 
MA). Images were acquired and analyzed as previously described [24].  
Raman sample preparation and measurements 
Isolated mouse alveolar macrophages were transferred onto pre-sterilized silicon chips 
(16008; Ted Pella, Inc., Redding, CA) and incubated for 1h (@ 37 oC and 5% CO2) to allow 
adherence to chip. The cell-containing chips were washed by brief submersion into isotonic NaCl 
(0.9%) solution followed by DI water, then allowed to air-dry. Raman measurements were 
acquired with the WiTec alpha300R confocal Raman microscope (WITec, Ulm, Germany) 
equipped with two excitation lasers: a 532 nm solid-state sapphire and a 785 nm wavelength-
stabilized diode (0-55 mW and 0-88 mW tunable intensity ranges, respectively). A 100X air 
objective (Zeiss Epiplan-NEOFLUAR, NA (numerical aperture) = 0.9) coupled to a CCD 
detector via a multi-mode fiber of 100 µm diameter serving as the confocal pinhole, produced 
0.72 µm and 1.06 µm illumination spots (for 532 nm and 785 nm lasers respectively). To 
minimize fluorescence background from pure CFZ and CFZ-H+Cl- reference crystals, samples 
were excited with 785 nm. The 532 nm laser was utilized for excitation of biological samples 
due to its elicitation of a stronger Raman signal from the microscopic inclusions/CLDIs of 
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interest. Point spectra were acquired (n ³ 40 cells/group) by focusing a laser spot on cytoplasmic 
inclusions, CLDIs, or pure reference crystals: at each point, the laser was tuned to optimum 
intensity, and acquired point spectra over an integration time of 25 seconds. Individual raw 
spectra were baseline-subtracted and normalized using a MATLAB® processing algorithm 
developed in-house. For single-cell Raman imaging, the 532 nm excitation laser was raster-
scanned across a 50 × 50 micron area with a step-size of 0.5 microns, yielding spectral datasets 
consisting of 10,000 spectra per cell. Exploiting the dramatic spectral differences arising from 
fluorescence of different CFZ forms, the un-processed Raman spectra were linearly 
deconvoluted via WiTec ProjectFOUR software’s basis component analysis using representative 
un-processed reference spectra obtained from untreated cells, pure free base CFZ crystals, pure 
CFZ-H+Cl- crystals, and the silicon substrate. Dataset acquisition, processing, and image display 
parameters were performed equivalently for each cell specimen. 
CLDI injection and stabilization assay 
To determine how macrophages stabilize CLDIs, mice were treated with either liposomal 
PBS or liposomal clodronate, as previously described [25]. 48 hours after liposome 
administration, mice were injected I.P. with 200 µg of CLDIs suspended in 1 mL of PBS (n = 3 
mice per group per time point). At time points ranging from 0 to 48 hours, the mice were 
euthanized, the peritoneal lavage was collected and pelleted, and the drug content within the 
pellet was analyzed using the previously described spectrophotometric analysis method. Using a 
simple exponential regression with recovered drug content, the half-life was estimated. 
CLDI loading within individual macrophages 
Using the total recovered mass of CLDIs within the liver and spleen, the CLDI loading 
within individual xenobiotic-sequestering macrophages was estimated using literature reported 
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values for macrophage numbers [26] within the liver and spleen, corrected for the percentage of 
cells which contained a CLDI. For the clodronate depleted organs, the reduction was accounted 
for with the quantified reduction in total F4/80 signal.  
Cell culture and pharmacological treatment 
For pharmacological inhibition experiments, macrophage-derived RAW264.7 cells 
(ATCC, Manassas, VA, ATCC Number: TIB-71TM), at a very high seeding density of 50,000 
cells/well grown in a 96 well tissue culture plate in 280 µl/well of DMEM + 10% FBS + 1% P/S 
(growth media), were pre-incubated (4h) with varying concentrations of Bafilomycin A1 
(BafA1; Sigma-Aldrich, St. Louis, MO, Cat. No. B1793) (0-10 nM) and NPPB (Sigma-Aldrich, 
St. Louis, MO, Cat. No. N4779) (0-200 µM), after which CFZ (dissolved in DMSO) was added 
to achieve a final concentration range of 0-10 µM. The effect of the treatment on cell viability 
was assessed by an XTT assay (Roche, UK). 
Drug uptake measurements 
Measurement of CFZ uptake by RAW264.7 cells was performed using a modified 
absorbance spectroscopy method using 9 M H2SO4 (pH << 0.1) to digest the entire cell 
population and extract CFZ from the cells. At two time points (2 and 4h) after CFZ exposure, 
growth media was aspirated from the culture dish and the cells were washed twice with PBS 
before adding 9 M H2SO4 (100 µl/well). The plate was incubated at room temperature for 30 min 
before spectrophotometric quantification of CFZ using a Synergy 2 plate reader (BioTek, 
Winooski, VT) at 540 nm (Abs540) and 750 nm (Abs750) (for background). Standards were 
prepared on the same plate by adding 100 µl/well pre-determined standards of CFZ. Total CFZ 
uptake is reported as total intracellular drug (in picomoles) as measured and calculated using the 
standard curve. Assuming that the doubling time of 50,000 cells/well is ~ 11h [27], and that no 
56 
 
compromise of cell viability occurs because of the optimum dose used for both CFZ and the 
pharmacological inhibitors, the total number of cells/well at the time of cellular drug uptake 
measurement is ~ 68,000.  
Experimental lysosomal pH measurements 
Lysosomal pH was measured fluorometrically in peritoneal macrophages and 
macrophage-derived RAW264.7 cells, using methods described previously [28]. In brief, 
macrophages were incubated for 40h with CFZ crystals. 20h prior to measuring pH, cells were 
incubated for 15-18h with 150 µg/ml Oregon Green-labeled dextran-10kD (OGDx; Thermo-
Fisher Scientific), and transferred to unlabeled culture medium for 3-5h to allow OGDx to traffic 
fully to lysosomes. Following transfer to Ringer's buffer, cells on Mat-tek dishes were observed 
in a Nikon TE300 microscope equipped for multichannel fluorescence microscopy with a 60X 
objective lens (N.A. 1.4). Phase contrast and three fluorescence images (excitation/emission: 440 
nm/535 nm; 485 nm/535 nm; and 580 nm/630 nm) were collected from each field. The 
580nm/630nm image was used to quantify clofazamine fluorescence. The ratio of the 
485nm/525nm to 440nm/525nm images were used to measure lysosomal pH. Calibration of 
fluorescence ratios was obtained from cells incubated in ionophores and buffers as described in 
Davis and Swanson [28]. Average lysosomal pH was determined for individual cells.   
Modeling lysosomal CFZ-H+Cl- accumulation 
A Lysosomal ion regulation model which incorporates lysosomal membrane proteins, 
such as V-ATPase, CLC7, and membrane proton permeability was utilized [16], and further 
elaborated and modified (see Supplementary Methods in Appendix B) to explore the relationship 
between lysosomal ion homeostasis and lysosomal CFZ-H+Cl- accumulation and stabilization. In 
order to incorporate the lysosomal accumulation of CFZ-H+Cl- into the model as a function of 
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lysosomal proton and chloride ions, the rate of overall drug accumulation obtained from 
experimental findings [4, 29] was used to define the rates of both lysosomal proton (Hsequestered) 
and chloride (Clsequestered) sequestrations by CFZ, in units of molecules per second. We assumed 
these rates to be equal due to the proposed equal contribution of both proton and chloride ions in 
the intracellular formation and accumulation of CFZ-H+Cl- salt precipitates:  
CFZH&Cl= = 	HJKLMKJNKOKP	 = ClJKLMKJNKOKP	       (18) 
Model parameterization 
The model incorporated 23 parameters: four were adjustable and the remaining 19 were 
fixed (Table S5-1 in Appendix B). Fixed parameters were given values obtained from the 
literature [16, 30-34], and are associated with physiological lysosomal ion homeostasis. 
Therefore, these parametric values are interchangeably referred hereon as “baseline input values” 
or “physiological baseline input values”. The adjustable parameters are those values that were 
varied from their respective baseline input values in order to investigate their individual as well 
as combined effects on the physiological lysosomal pH, Cl-, and membrane potential readout 
values, as discussed in the following subsections. These parameters include the number of active 
V-ATPase and CLC7 molecules per lysosome, as well as the cytoplasmic chloride concentration. 
In addition, the rates of proton and chloride sequestrations by CFZ are considered adjustable 
parameters as they are foreign to the lysosome. 
Simulating lysosomal CFZ-H+Cl- accumulation 
The previously mentioned rates of proton and chloride sequestrations by CFZ were 
adjusted to either 0.01 or 0.1 picomoles/cell/day [4, 29]. However, in our model simulations, we 
converted the units of these rates to picomoles/lysosome/day assuming there are ~ 100 
lysosomes in a cell. From here onwards, we interchangeably refer to these rates, 0.01 and 0.1 
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picomoles/cell/day, as 1-fold (1X) and 10-fold (10X) rates of lysosomal CFZ-H+Cl- 
accumulation, respectively.  
Simulating changes in lysosomal membrane proteins and cytoplasmic chloride amounts 
In order to study the roles of V-ATPase, CLC7, and cytoplasmic chloride concentration 
on lysosomal accumulation of CFZ-H+Cl-, we varied the total numbers of active V-ATPase and 
CLC7 molecules per lysosome, and the cytoplasmic chloride concentration, while fixing the 
values of other lysosomal parameters at their baseline physiological input values in the presence 
as well as absence of lysosomal CFZ-H+Cl- accumulation. More specifically, to simulate the 
simultaneous inhibition of V-ATPase and CLC7, the total number of CLC7 molecules per 
lysosome was varied from 0 to 5,000 (resulting in 7-16 data-generating points) while, one 
parametric simulation at a time, the total number of V-ATPase molecules per lysosome was 
manually varied from 0 to 300 (resulting in 4-7 data-generating points). Moreover, to simulate 
the simultaneous inhibition of V-ATPase and cytoplasmic chloride, the cytoplasmic chloride 
concentration was varied from 0 to 10 mM (resulting in 16 data-generating points) while, one 
parametric simulation at a time, the total number of V-ATPase molecules per lysosome was 
manually varied from 0 to 300 (resulting in 4-7 data-generating points). 
Using the aforementioned ranges of the adjustable lysosomal parameters, the 
corresponding lysosomal parameter inhibition range of 0 to 100% was calculated; where 0% 
represents no change from respective physiological baseline input value, and 100% represents 
the input value set to ~zero. The inhibition range was calculated as follows by comparing the 
corresponding input value (Adjusted Input Value) from the aforementioned given range with its 
respective physiological input value (Baseline Input Value): 
%	Inhibition = 	 .XJKYZ[K	\[<MN	]XYMK=^P_MJNKP	\[<MN	]XYMK	.XJKYZ[K	\[<MN	]XYMK × 100%    (19) 
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Calculating the effect of lysosomal CFZ-H+Cl- accumulation on lysosomal ion homeostasis 
Final lysosomal pH, chloride, and membrane potential were chosen as readout values 
because they are direct indicators of lysosomal ion homeostasis and physiology. Thus, 
parametric simulations of these variables were performed as a function of the aforementioned 
ranges of V-ATPase, CLC7, and cytoplasmic chloride in the absence and presence of lysosomal 
CFZ-H+Cl- accumulation at the rate of either 1X or 10X. Then, the readout values in the absence 
of lysosomal CFZ-H+Cl- accumulation were subtracted from those in the presence of lysosomal 
CFZ-H+Cl- accumulation in order to determine the effect of lysosomal CFZ-H+Cl- accumulation 
on lysosomal ion homeostasis.  
Calculating the effects of V-ATPase, chloride channels, and cytoplasmic chloride on the 
physiological lysosomal accumulation of CFZ-H+Cl- 
Time-plot simulations, where all of the lysosomal parameters were set to their respective 
baseline values in the absence of lysosomal CFZ-H+Cl- accumulation, were performed to obtain 
physiological final lysosomal pH, chloride accumulation, and membrane potential values, which 
from hereon we refer to as “physiological baseline readout values”. Moreover, model parametric 
simulations of final lysosomal pH, Cl-, and membrane potential as a function of simultaneous V-
ATPase-CLC7 and V-ATPase-cytoplasmic chloride inhibitions were performed in the presence 
of lysosomal CFZ-H+Cl- accumulation at the rates of 1X and 10X. These were then subtracted 
from the physiological baseline readout values in order to calculate the effects of the 
simultaneous lysosomal parameter inhibitions on the dose-dependent lysosomal CFZ-H+Cl- 
accumulation.  
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Confirmation of steady-state and mass balance 
For all of the aforementioned simulations, the final readout values were confirmed that 
they were steady-state values by performing the simulations for > 24h. We confirmed that mass 
balance was maintained in all of the simulations in the presence and absence of lysosomal CFZ-
H+Cl- accumulation as long as a physiological pH gradient of up to 4.6 pH units was maintained 
across the lysosomal membrane.  
3.5 Results 
The weakly basic building block has pH-dependent solubility properties 
CFZ is a weak base with two amines, which can be protonated depending on the pH of 
the immediate environment (Figure  3-1a). To study its pH-dependent solubility behavior, we 
used  an established approach [19] (see Supplementary Methods in Appendix B for detailed 
explanation), which allowed an accurate measurement of the total solubility of CFZ-H+Cl- as a 
function of pH. From the experimental measurements, we calculated the solubility properties of 
CFZ, in an aqueous media at 25 ºC, which include its apparent pKa,2 (pKa’ = 6.08 ± 2.43x10-3; 
95% Confidence Interval = 6.07, 6.09) and intrinsic free base solubility (S0 = 0.48 ± 4.05x10-6 
µM; 95% CI = 0.48, 0.48) (Figure 3-1b). Moreover, to determine the effect of lysosomal Cl- 
(Figure 3-1c) on the stability of the free base versus salt form of the drug, we performed drug 
stability experiments (Figure 3-1d) in the presence and absence of lysosomal buffer (pH 4.5, Cl- 
concentration = 0-100 mM). We monitored drug stability by relying on the unique fluorescence 
profile of the different forms of CFZ: CFZ free base exhibits green and red fluorescence; peak 
excitation: 540–560 nm, peak emission: 560–600 nm, whereas CFZ-H+Cl- exhibits red and far 
red fluorescence; peak excitation: 560–600 nm, peak emission: 650–690 nm [11]. Indeed, the 
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fluorescence of CLDIs resembles the fluorescence of the synthesized CFZ-H+Cl- crystals (peak 
excitation: 560–600 nm, peak emission: 650–690 nm) (Figure S3-1 in Appendix B).   
A low pH environment in the absence of Cl- (LB-) induced the destabilization of both 
CFZ-H+Cl- and free base CFZ, without affecting the stability of CLDIs. To the contrary, a low 
pH environment in the presence of a physiological lysosomal Cl- (LB+) induced the stabilization 
of CFZ-H+Cl- and CLDIs, whereas the free base CFZ precipitated out as CFZ-H+Cl- (Figure 3-
1d). Thus, these findings reveal that the precipitation of CFZ as a hydrochloride salt was highly 
sensitive to small, but physiologically relevant variations in pH and chloride concentrations 
(pHmax = 4.5 ± 7.11x10-15, 95% CI = 4.5, 4.5; and Ksp = 332.3 ± 3.71 µM2, 95% CI = 323.1, 
341.5) (Figure 3-1b, d); where the pHmax reveals the pH below which CFZ-H+Cl- salt formation 
occurs, and the Ksp elucidates the Cl- concentration, which is > (Ksp)1/2 µM, that would further 
stabilize the salt form of the drug through a common-ion effect [35]. Thus, at the 
pharmacologically-relevant CFZ concentrations that have previously been measured in serum (1 
to 20 µM), local variations in pH (~ 7.4 extracellular; ~ 7.2 cytosolic, and ~ 4.5 lysosomal) and 
chloride concentrations (~ 80 mM extracellular; ~ 10-20 mM in cytosol; and ~ 50-200 mM in 
lysosomes) can lead to a greater propensity of CFZ to precipitate as a hydrochloride salt in the 
lysosomal microenvironment (Figure 3-1c, d). 
The intracellular organization of the self-assembled mechanopharmaceutical device  
Prolonged administration of CFZ results in its accumulation in both human and animals 
as microscopic, insoluble, and membrane-bound aggregates, known as Crystal Like Drug 
Inclusions (CLDIs), which are primarily found within tissue macrophages [3-5]. CLDIs are 
primarily comprised of a protonated, hydrochloride salt of CFZ (Figure 3-2a) [7], which forms 
faceted structures possessing three orthogonal cleavage and multiple fracture planes with 
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lamellar spacing of 6 nm to 14 nm [21] (Figure 3-2b). These orthogonal cleavage and fracture 
planes correspond to the orthogonal crystallographic planes of the CFZ-H+Cl- unit cell (Figure 3-
2c). When examined under polarized light (623 nm wavelength), the orthorhombic crystal 
structure of the deep red CLDIs [11, 29, 36] exhibits dichroism (Figure 3-2d) [24]. Due to the 
biological origin of the CLDIs [7], the interaction between the cell and crystal often leads to 
significant variations in its organization, impacting the manner in which it interacts with 
polarized light (Figure 3-2d). Furthermore, reference spectra of pure CFZ and CFZ-H+Cl- 
identified characteristic Raman peaks for clear distinction between the two forms (Figure 3-2e). 
Spectra obtained from cytoplasmic regions of untreated mouse alveolar macrophages were 
typical of biological specimens with no apparent contributions from drug. However, spectra 
obtained from cytoplasmic regions of 4- and 8-week CFZ-fed mouse alveolar macrophages 
revealed the presence of CFZ-H+Cl-, which dominated any Raman signal associated with 
biological specimens, and exhibited unique peak intensities and peak widths, which attribute to 
the geometric organization of the supramolecular structures: peaks generally become narrower 
and more intense with higher degree of order in samples, which suggests that by 8 weeks, the 
macrophages have organized the accumulated drug into supramolecular crystalline packages of 
CFZ-H+Cl- salt. Moreover, Raman imaging of single-cells revealed cytoplasmic accumulation of 
both forms of the drug after just 1 week and continuing through 4 weeks; at 8 weeks CLDI 
formation was apparent and clearly distinguishable from free base CFZ, as evidenced by non-
overlapping Raman signals in the biocrystal regions of Raman image (Figure 3-2f). 
Macrophages are necessary for the self-assembly of the mechanopharmaceutical device  
To investigate whether macrophages play an active role in stabilizing CLDIs in vivo, 
macrophages were depleted by injecting mice (n = 3-4 per treatment group) intraperitoneally 
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with clodronate liposomes. This treatment depletes phagocytic cells without affecting non-
phagocytic cells [20]. Moreover, the aforementioned CFZ’s unique fluorescence characteristics 
were used to monitor the effect of macrophage depletion on the accumulation of CFZ-H+Cl- 
crystal. Following liposome therapy, the relative number of F4/80 positive macrophages within 
the liver and spleen of each treatment group was quantified using the total ratio of F4/80 to 
nuclear signal, revealing a significant reduction in the total macrophage population in the 
clodronate-CFZ fed group when compared to the PBS-CFZ treated group (p < 0.05, ANOVA, 
Tukey’s HSD) (Figure 3-3a). Consequently, using the ratio between the intrinsic far-red 
fluorescence of CFZ-H+Cl- [37] and total nuclear signal, there was a significant reduction in the 
accumulation and stabilization of CFZ-H+Cl- within the liver and spleen (p < 0.05, ANOVA, 
Tukey’s HSD) compared to the PBS-CFZ treated group (Figure 3-3b). More specifically, within 
the PBS-CFZ treated mice, the livers accumulated an average of 0.68 ± 0.27 mg CFZ/g tissue, 
while the clodronate-CFZ livers accumulated an average of 0.23 ± 0.09 mg CFZ/g tissue (p < 
0.05, two-tailed Student’s t-test); a reduction of nearly 66%. Similarly, the spleens of PBS-CFZ 
treated mice accumulated an average of 2.31 ± 0.40 mg CFZ/g tissue, compared to 0.70 ± 0.12 
mg CFZ/g tissue in the clodronate-CFZ groups (p < 0.01, two-tailed Student’s t-test); a reduction 
of 70%.  
The individual drug loading within the macrophages of the liver and spleen was 
estimated based off of literature-reported values for macrophage populations in those two organs 
[26] and the total recovered drug within each organ, and there was no difference in total drug 
loading within either population of macrophage as a result of clodronate therapy (Figure 3-3c). 
Furthermore, there was no significant difference in mean plasma concentrations of CFZ at the 
end of therapy (Figure 3-3d). Taken together, this provides evidence that, while clodronate 
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therapy was reducing the macrophage population and subsequent bioaccumulation within the 
liver and spleen, it was not impacting the general bioavailability and absorption of CFZ in the 
body. To determine how macrophages stabilized the self-assembled mechanopharmaceutical 
devices, isolated CLDIs were injected I.P. into clodronate and PBS liposome treated mice and 
collected at time points from 0 to 48 hours (n = 3 mice per group per time point). Without 
macrophages present in the peritoneal cavity to internalize the CLDI, there was a significant 
reduction in the estimated half-life of the biocrystal (p < 0.05, ANOVA) (Figure 3-3e). This was 
confirmed via microscopic analysis of the peritoneal exudate 48 hours post-injection, with 
CLDIs becoming internalized by the macrophage and retaining their far-red fluorescence in the 
PBS-treatment group, while the clodronate-treated group showed reduced CLDI content within 
the exudate (Figure 3-3f). 
Additionally, in order to confirm that clodronate did not impact drug accumulation within 
other macrophage populations, alveolar macrophages were collected and analyzed. Within the 
alveolar macrophage population, there was no significant difference in total cell number 
collected between the PBS and clodronate-treated groups (p = 0.48, two-tailed Student’s t-test), 
as well as in the ability of the cells to accumulate CFZ in the form of a CLDI; where each 
alveolar macrophage population contained approximately 20% CLDI-positive cells (p = 0.36, 
two-tailed Student’s t-test) (Figure 3-3g). Thus, the specific effect of clodronate liposomes on 
liver and spleen CLDIs and CFZ content, as well as the increased rate of CLDI destabilization 
and solubilization in the absence of peritoneal macrophages provide evidence that these cells are 
directly responsible for the in vivo accumulation, self-assembly, and stabilization of CFZ-H+Cl-. 
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The intracellular accumulation, protonation, and self-assembly of the building block in 
cytoplasmic vesicles does not interfere with lysosomal pH 
 Taking advantage of the aforementioned CFZ’s unique fluorescence properties, we 
studied the accumulation of the un-protonated free base and protonated hydrochloride salt form 
of the drug in macrophages. Incubation of macrophages with CFZ in vitro revealed vesicular 
staining pattern consistent with CFZ free base (peak excitation: 540–560 nm, peak emission: 
560–600 nm) as well as CFZ-H+Cl- (peak excitation: 560–600 nm, peak emission: 650–690 nm) 
[11]. Both fluorescent forms were visible in CFZ-treated cells and absent in untreated, control 
cells (Figure 3-4a and Figure S3-2 in Appendix B). Based on the observed little overlap of their 
orthogonal fluorescence signals, CFZ-H+Cl- did not co-localize with free base CFZ (Pearson’s 
Colocalization Coefficient - PCC between green and far-red fluorescence = 0.30 ± 0.29) (Figure 
S3-3 in Appendix B). In addition, when cells were co-incubated with both CFZ and Lysotracker 
Blue (LB), LB fluorescence signal (excitation: 373 nm, emission: 422 nm) was inhibited in the 
cytoplasm and displaced [38] to the nucleus (based on the observed nuclear staining), whereas 
the punctate green and far-red fluorescence of CFZ were clearly visible in the cytoplasm of these 
cells (Figure 3-4c, and Figures S3-2 and S3-3 in Appendix B). As a control experiment, we 
measured the lysosomal pH of macrophages following phagocytosis of CLDIs in macrophage-
derived RAW264.7 cells as well as in peritoneal macrophages of 8-week CFZ-fed mice (Figure 
3-4d). In both cases, the lysosomal pH was not physiologically affected by the presence of the 
CFZ, as reflected by < 0.1 pH unit difference between the drug-free and drug-containing 
peritoneal macrophages and RAW264.7 cells. Thus, CFZ uptake in macrophage lysosomes does 
not perturb physiological lysosomal pH homeostasis, which is required for various lysosomal 
functions, such as lysosomal trafficking and degradation of intrinsic and extrinsic materials 
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within the lysosome by various pH-dependent hydrolytic lysosomal enzymes, which are essential 
for overall cellular homeostasis and viability [39]. Moreover, because the fluorescence signals of 
Lysotracker® probes are pH-independent [40], we interpret this to mean that intralysosomal CFZ 
accumulation interferes with Lysotracker probe accumulation through a mechanism that is 
independent of changes in lysosomal pH. 
The building block’s self-assembly mechanism is biocompatible with the lysosome   
To identify the candidate mechanism driving CFZ-H+Cl- accumulation and stabilization 
in lysosomes, we used a well-established systems-based mathematical model of lysosomal ion 
regulation. We first performed a simultaneous variation of the number of active V-ATPase and 
chloride channels per lysosome (resulting in 0 to 100% inhibition of both parameters from their 
respective baseline physiological input values of 300 and 5000) in the presence and absence of 
dose-dependent lysosomal CFZ-H+Cl- accumulation (0 to 0.01 picomoles/cell/day), as measured 
in vitro [4, 29]. The simulation results indicated that CFZ-H+Cl- accumulates at the measured 
rate of 0.01 picomoles/cell/day exerting a negligible effect on lysosomal pH, Cl-, and membrane 
potential from respective physiological baseline readout values (4.53 pH units, 224.6 mM, and 
0.79 mV). Only a significant (≥ 97%) reduction in the total V-ATPase amount per lysosome led 
to changes in these values (Figure 3-5a). Consistent with this, < 97% V-ATPase inhibition per 
lysosome was required for the physiological accommodation of lysosomal CFZ-H+Cl- 
accumulating at 0.01 picomoles/cell/day (Figure 3-5b). However, unlike the number of V-
ATPase, the number of chloride channel molecules per lysosome did not show any effect on the 
physiological CFZ-H+Cl- accumulation unless this chloride current was completely absent 
(Figure 3-5b).  
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In dose-dependent simulations, CFZ-H+Cl- accumulating at a ten-fold greater (non-
physiological) rate of 0.1 picomoles/cell/day led to more pronounced changes in lysosomal pH, 
Cl-, and membrane potential (Figure 3-6a). At least < 68.3% V-ATPase inhibition per lysosome 
was required to sustain physiological ion concentrations in the presence of this 10-fold greater 
rate of CFZ-H+Cl- accumulation (Figure 3-6b). In contrast, variations in the numbers of chloride 
channels did not affect the physiological lysosomal accumulation of CFZ-H+Cl- at a rate of 0.1 
picomoles/cell/day, unless there was a complete inhibition of the chloride current (Figure 3-6b).  
V-ATPase is essential in the building block accumulation and self-assembly  
To verify our model and simulation findings, we performed experiments to detect the 
effects of V-ATPase and chloride channels on the intracellular accumulation of CFZ. All 
experiments regarding the incubation and accumulation of CFZ were performed under conditions 
in which cellular viability was maintained. In the absence of any inhibitor, 8 µM extracellular 
CFZ accumulated at a rate of 0.01 picomoles/cell/day, as previously reported [4, 29]. However, 
inhibiting the V-ATPase with BafA1 reduced cellular CFZ accumulation by 80 ± 13% (p < 0.01) 
in a 4h incubation, relative to control, uninhibited cells (Figure 3-7a). This observation is 
consistent with our simulation results, where up to 50% V-ATPase inhibition resulted in a 
lysosomal pH increment (Figure 3-5a), which associates with a reduction in cellular drug 
accumulation. In contrast, when cells were treated with the chloride channel inhibitor NPPB and 
exposed to CFZ, no significant change was measured in the accumulation of CFZ following a 4h 
incubation (Figure 3-7b). This contrasts with the effect observed with BafA1 (Figure 3-7a), and 
is consistent with our simulation results (Figure 3-5a), thereby indicating that in the presence of 
CFZ uptake, lysosomal ion homeostasis is insensitive to chloride channel inhibition.  
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3.6 Discussion 
As a weakly basic, poorly soluble small-molecule chemical that is FDA-approved, orally 
bioavailable, slowly cleared, and administered at high doses for prolonged periods of time, CFZ 
affords us the opportunity to reverse engineer the construction of a mechanopharmaceutical 
device that was found to form naturally inside cells. We report that, because of its 
physicochemical properties, CFZ is highly prone to precipitation in acidic endolysosomal 
compartments in macrophages, where it self-assembles into a highly ordered CFZ-H+Cl- 
biocrystalline, possessing many interesting optical and biomechanical features. Indeed, the 
preferential accumulation of CFZ in macrophage lysosomes is evident based on the displacement 
of Lysotracker Blue fluorescence from the cytoplasmic vesicles (Figure 3-4). Furthermore, 
fluorescence imaging revealed that CFZ was present both as a free base and hydrochloride salt 
form within intracellular vesicles (Figure 3-4). Thus, we performed computational simulations 
and experiments to probe the relationship between CFZ’s pH-dependent solubility properties, the 
formation of salt and free base crystals, and the molecular, ion transport mechanisms responsible 
for this mechanopharmaceutical phenomenon, which could be exploited for developing other 
weakly basic small molecule building blocks as cell-targeted, self-assembling 
mechanopharmaceutical devices [41, 42].   
Despite the complexities of lysosomal ion homeostasis, computational simulations and 
experimental results provide a straightforward explanation for the observed behavior of CFZ: the 
number of V-ATPase molecules that drive the lowering of macrophage lysosomal pH [43] plays 
a critical role in determining the intracellular bioaccumulation of CFZ in lysosomes without 
affecting lysosomal ion homeostasis. Our results show that very high levels of V-ATPase 
expression, that are typical of macrophages, are both necessary and sufficient to explain the 
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accumulation and stabilization of CFZ-H+Cl- salt in these cells because they allow the cells to 
maintain physiological lysosomal pH and membrane potential in spite of the accumulation of the 
drug. In addition, the intrinsic solubility properties of CFZ are such that the protonated form of 
the drug strongly interacts with chloride in a concentration range that is typically observed in 
lysosomes, which leads to the physiological accumulation of the drug in its hydrochloride salt 
form. Accordingly, V-ATPase expression establishes the ability of the cell to maintain 
physiological lysosomal pH [44], which, in relation to the drug’s pHmax and Ksp (Figure 3-1), can 
sustain the continuous accumulation of the hydrochloride salt form of the drug [19] in the 
lysosome.  
More importantly, we found that experimental results [4, 29] were highly consistent with 
model simulation results. First, the inhibition of V-ATPase activity resulted in the reduction of 
the total intracellular CFZ accumulation (Figure 3-7a), which was consistent with the model 
simulation results (Figures 3-5 and 3-6). In contrast, NPPB-mediated reduction of chloride 
channel activity did not affect the accumulation and stabilization of the salt form of the drug 
(Figure 3-7b), which was also consistent with the model simulation results (Figures 3-5 and 3-6, 
and Figures S3-5 and S3-6 in Appendix B). Furthermore, the measured Ksp of CFZ-H+Cl- and our 
CLDIs/CFZ-H+Cl- stability results (Figure 3-1) indicate that the physiological lysosomal chloride 
levels are sufficient to stabilize CFZ-H+Cl- salt formation through a common-ion “salting-out” 
mechanism [35]. Therefore, our findings collectively provide the first mechanistic framework 
that explains the accumulation of highly ordered, self-assembled CFZ-H+Cl- salt biocrystals in 
macrophages (Figures 3-2 and 3-3); which depends on the high levels of V-ATPase expression 
that is unique to this cell type16.  
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It is also noteworthy that macrophages have lysosomes which are an order of magnitude 
greater in size than that of other cell types [45]. This provides them with the capability to 
accommodate massive accumulation of weakly basic drugs [46]. Even in cases where the initial 
lysosomal size is small (< 1 µm, in radius), the macrophage lysosomes can undergo biogenesis 
[47, 48]. A master regulator of lysosomal biogenesis and V-ATPase expression is transcription 
factor EB (TFEB) [39, 46, 49]. Moreover, given the recent findings regarding the role of TFEB 
in upregulating lysosomal genes during inflammation [50], the role of TFEB in the 
bioaccumulation and stabilization of CFZ-H+Cl- salt in macrophage lysosomes, in relation to 
CFZ’s anti-inflammatory activity [9, 10], could be further investigated.  
To conclude, we have discovered how lysosomal ion transport pathways play a major 
role in the self-assembly of a biocompatible, cell-targeted supramolecular structure formed by a 
weakly basic, small molecule building block. Together with the physicochemical properties of 
the freely soluble building blocks, these transport pathways can be exploited to develop novel 
types of drug depots and cell-directed drug delivery systems [51-53]. Indeed, interest has been 
raised in macrophages as drug delivery vehicles. As our studies have shown, macrophages may 
allow drugs to be locally stabilized and undergo a sustained release in a site-specific manner, 
offering a strategy for reducing off-target side effects [54, 55]. Macrophages are also one of the 
few cell types, which are primarily involved in the phagocytosis of foreign particles of different 
sizes and shapes, including drugs [56, 57], which offer yet another opportunity for loading these 
cells with massive amounts of chemotherapeutic agents. To this end, additional investigations 
into the manner in which these cells mechanically synergize with the self-assembled weakly 
basic small molecule building blocks in order to stabilize functional mechanopharmaceutical 
devices are warranted.   
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3.8 Figures 
 
 
 
Figure 3-1. Chemical characterization of CFZ. a, Chemical structure of clofazimine (CFZ) with its two 
protonation sites and corresponding predicted (chemi-informatic) pKa values (pKa,1 = 2.31 and pKa,2 = 9.29). b, CFZ-
H+Cl- solubility-pH study revealed the solution pH dependence of the stabilization of the free base versus salt form 
of the drug with respect to its solubility parameters; which include the intrinsic free base solubility (So), apparent 
pKa,2 (pKa’), and pHmax. c, Illustration showing the cellular and subcellular accumulation of free base CFZ, its 
subsequent protonation (CFZH+ ), and ion-ion interaction of CFZH+ and cellular Cl- to form CFZ-H+Cl-. This 
phenomenon depends on the drug’s intrinsic solubility properties as well as the cellular pH and Cl- levels, which are 
primarily regulated by membrane proteins: proton-pump known as V-ATPase and Cl-/H+ antiporter known as CLC7. 
d, Stability of CLDIs, CFZ-H+Cl-, and free base CFZ in PBS (pH 7.4), lysosomal buffer without sodium chloride 
(LB-, pH 4.5), and lysosomal buffer with 100 mM sodium chloride (LB+, pH 4.5) was monitored via brightfield and 
fluorescence microscopy.  
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Figure 3-2. Intracellular self-assembled crystal organization of CFZ-H+Cl-. a, CFZ-H+Cl- chemical structure 
with color coding corresponding to the regions of the structure in the crystal arrangement. b, Freeze-fracture 
electron micrograph of CLDIs within a Kupffer cell, showing that the CLDIs are sequestered inside the cell as 
multiple layered planes with lamellar spacing of 6 nm to 14 nm, by a double membrane of biological origin (~ 20 
nm in thickness)[21]. c, Crystal packing of CFZ-H+Cl- showing the three crystallographic planes of the crystal: a 
hydrophobic face in orange (plane 1), a hydrophilic face in blue (plane 2), and an amphipathic face (plane 3)[8]. d, 
CLDIs (100-1.5X magnification) zoomed in (zoom factor of 2) in alveolar macrophages show high dichroism and an 
axis of highest transmittance, with a different profile (represented by the different signal intensity associated with 
the color bar) observed specifically around the edges of the crystal. e, Raman spectra of free base CFZ, CFZ-H+Cl-, 
untreated and treated alveolar macrophages (4 and 8wks CFZ-fed mice) show distinct Raman peaks distinguishing 
between the different forms of the drug (red in the brightfield images): free base CFZ (1341 and 1465 cm-1), CFZ-
H+Cl- (1399 cm-1). f, Reflected brightfield and Raman images of alveolar macrophages from CFZ-fed mice prepared 
on silicon chip substrates; basis spectral fitting was used to show the temporal accumulation and cytoplasmic 
packaging of CFZ into highly ordered CLDIs. 
74 
 
 
 
 
 
Figure 3-3. The role of macrophages on the intracellular accumulation of CFZ biocrystals in vivo. a, 
Clodronate depletion significantly reduces both hepatic and splenic macrophages in Clodronate-CFZ treatment 
group. b, Depletion of macrophages results in concomitant reduction in CLDI loading within the livers and spleens 
of treated animals. c, Clodronate depletion does not significantly reduce the estimated clofazimine loading per 
macrophage in the livers and spleen. d, Clodronate depletion does not significantly impact the serum concentrations 
of clofazimine following four weeks of treatment. e, Depletion of peritoneal macrophages significantly increases the 
rate of degradation of CLDIs injected intraperitoneally, leading to a significantly faster half-life. f, Peritoneal 
exudate of PBS- and clodronate-liposome treated mice 48 hours following CLDI injection showing brightfield and 
Cy5 fluorescence (red fluorescence and red in brightfield images correspond to CLDIs) (* = p < 0.05, ANOVA or 
ANOVA, Tukey’s HSD when applicable). g, Alveolar lavage from PBS- and clodronate-liposome treated mice. 
Clodronate treatment did not impact CLDI accumulation (red fluorescence and red in brightfield images correspond 
to CLDIs) within alveolar macrophages.  
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Figure 3-4. Evidence of lysosomal accumulation of CFZ via fluorescence staining patterns in RAW264.7 cells. 
a, Epifluorescence microscopy of RAW264.7 cells (40X magnification) zoomed in (zoom factor of 2.5) when 
incubated with (a) CFZ (10 µM), (b) Lysotracker Blue (LB, 1 µM), and (c) CFZ (10 µM) and LB (1 µM) together at 
t = 24 hours. Green fluorescence spots indicative of CFZ are also further annotated using white arrows for cross-
referencing with other images. Note the lack of any far-red fluorescence positive signal in the direction pointed by 
the arrows. Vesicular staining pattern of LB visible as blue punctate spots in (b) are absent in (c), while nuclear 
staining becomes visible due to LB displacement from the lysosome to the nucleus because of CFZ accumulation in 
the lysosome. Cell boundaries are shown in white in the digitally zoomed panels. d, Lysosomal pH measurements of 
RAW26.7 cells in the presence and absence of CLDIs, and peritoneal macrophages of control versus 8-week CFZ-
fed mice. Data are mean ± S.D. of 29-181 measurements; * p = 0.026; analyzed by unpaired two-tailed Student t-
test. 
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Figure 3-5. Model and simulation of the effects of V-ATPase and CLC7 on the lysosomal accumulation of  
CFZ-H+Cl-. a, V-ATPase inhibition showed a more substantial effect than CLC7 inhibition on the accumulation of 
CFZ-H+Cl- at the rate of 0.01 picomol/cell/day, as reflected by the changes in the lysosomal pH, Cl-, and membrane 
potential values of the CFZ-H+Cl- containing lysosome from that of the CFZ-H+Cl- free lysosome. b, V-ATPase 
inhibition showed a more substantial effect than CLC7 inhibition on the physiological accumulation of CFZ-H+Cl- at 
the rate of 0.01 picomol/cell/day, as reflected by the changes in the lysosomal pH, Cl-, and membrane potential 
values of the CFZ-H+Cl- containing lysosome from respective baseline physiological values. Arrow signs represent 
values outside of the axes plot range.  
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Figure 3-6. Model and simulation of the effects of V-ATPase and CLC7 on the lysosomal accumulation of 
CFZ-H+Cl- at a higher dose. a, V-ATPase inhibition showed a more substantial effect than CLC7 inhibition on the 
accumulation of CFZ-H+Cl- at the rate of 0.1 picomol/cell/day, as reflected by the changes in the lysosomal pH, Cl-, 
and membrane potential values of the CFZ-H+Cl- containing lysosome from that of the CFZ-H+Cl- free lysosome. b, 
V-ATPase inhibition showed a more substantial effect than CLC7 inhibition on the physiological accumulation of 
CFZ-H+Cl- at the rate of 0.1 picomol/cell/day, as reflected by the changes in the lysosomal pH, Cl-, and membrane 
potential values of the CFZ-H+Cl- containing lysosome from respective baseline physiological values. Arrow signs 
represent values outside of the axes plot range. 
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Figure 3-7. Intracellular CFZ accumulation. Total intracellular CFZ accumulation in picomoles (pmoles) in 
RAW264.7 cells (~ 68,000 cells/well) when pre-incubated with (a) BafA1 and (b) NPPB and initial concentration of 
CFZ = 4, 6, and 8 µM at t = 4 hours. Significant inhibition of CFZ accumulation was measured at t = 4 hours when 
cells were exposed to BafA1. To the contrary, no such inhibition was measured when cells were exposed to NPPB at 
t = 4 hours. Data are the mean ± S.D. of six experiments. * - p < 0.05, ** - p < 0.01, *** - p < 0.001. Each data point 
was compared in a pair-wise independent Student t-test. 
 
 
 
 
 
 
  
79 
 
3.9 References 
1. Zhang, Z., et al., Supersnowflakes: Stepwise Self-Assembly and Dynamic Exchange of 
Rhombus Star-Shaped Supramolecules. J Am Chem Soc, 2017. 139(24): p. 8174-8185. 
 
2. Deng, Y., et al., Multifunctional small molecule for controlled assembly of oligomeric 
nanoparticles and crosslinked polymers. Org Biomol Chem, 2011. 9(20): p. 6917-9. 
 
3. Desikan, K.V., et al., Autopsy findings in a case of lepromatous leprosy treated with 
clofazimine. Lepr Rev, 1975. 46(3): p. 181-9. 
 
4. Baik, J. and G.R. Rosania, Molecular imaging of intracellular drug-membrane aggregate 
formation. Mol Pharm, 2011. 8(5): p. 1742-9. 
 
5. Baik, J., et al., Multiscale distribution and bioaccumulation analysis of clofazimine 
reveals a massive immune system-mediated xenobiotic sequestration response. 
Antimicrob Agents Chemother, 2013. 57(3): p. 1218-30. 
 
6. O'Connor, R., J.F. O'Sullivan, and R. O'Kennedy, The pharmacology, metabolism, and 
chemistry of clofazimine. Drug Metab Rev, 1995. 27(4): p. 591-614. 
 
7. Horstman, E.M., et al., Elasticity in Macrophage-Synthesized Biocrystals. Angew Chem 
Int Ed Engl, 2017. 56(7): p. 1815-1819. 
 
8. Keswani, R.K., et al., Chemical Analysis of Drug Biocrystals: A Role for Counterion 
Transport Pathways in Intracellular Drug Disposition. Mol Pharm, 2015. 12(7): p. 2528-
36. 
 
9. Yoon, G.S., et al., Clofazimine Biocrystal Accumulation in Macrophages Upregulates IL-
1RA Production to Induce a Systemic Anti-Inflammatory State. Antimicrob Agents 
Chemother, 2016. 
 
10. Yoon, G.S., et al., Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune 
Signaling by Inhibiting TNFalpha and Boosting IL-1RA Secretion. Mol Pharm, 2015. 
12(7): p. 2517-27. 
 
11. Keswani, R.K., et al., A far-red fluorescent probe for flow cytometry and image-based 
functional studies of xenobiotic sequestering macrophages. Cytometry A, 2015. 87(9): p. 
855-67. 
 
12. Wang, S.P., et al., Regulation of enhanced vacuolar H+-ATPase expression in 
macrophages. J Biol Chem, 2002. 277(11): p. 8827-34. 
 
13. Hong, L., et al., Alteration of volume-regulated chloride channel during macrophage-
derived foam cell formation in atherosclerosis. Atherosclerosis, 2011. 216(1): p. 59-66. 
80 
 
14. Jiang, L., et al., Intracellular chloride channel protein CLIC1 regulates macrophage 
function through modulation of phagosomal acidification. J Cell Sci, 2012. 125(Pt 22): p. 
5479-88. 
 
15. Kazmi, F., et al., Lysosomal sequestration (trapping) of lipophilic amine (cationic 
amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab 
Dispos, 2013. 41(4): p. 897-905. 
 
16. Ishida, Y., et al., A model of lysosomal pH regulation. J Gen Physiol, 2013. 141(6): p. 
705-20. 
 
17. Yoshimori, T., et al., Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, 
inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol 
Chem, 1991. 266(26): p. 17707-12. 
 
18. Wangemann, P., et al., Cl−-channel blockers in the thick ascending limb of the loop of 
Henle Structure activity relationship. Pflügers Archiv, 1986. 407(2): p. S128-S141. 
 
19. Kramer, S.F. and G.L. Flynn, Solubility of organic hydrochlorides. J Pharm Sci, 1972. 
61(12): p. 1896-904. 
 
20. van Rooijen, N. and E. Hendrikx, Liposomes for specific depletion of macrophages from 
organs and tissues. Methods Mol Biol, 2010. 605: p. 189-203. 
 
21. Baik, J. and G.R. Rosania, Macrophages sequester clofazimine in an intracellular liquid 
crystal-like supramolecular organization. PLoS One, 2012. 7(10): p. e47494. 
 
22. Murashov, M.D., et al., The Physicochemical Basis of Clofazimine-Induced Skin 
Pigmentation. J Invest Dermatol, 2017. 
 
23. Oldenbourg, R., Polarized light microscopy: principles and practice. Cold Spring Harb 
Protoc, 2013. 2013(11). 
 
24. Rzeczycki, P., et al., Detecting ordered small molecule drug aggregates in live 
macrophages: a multi-parameter microscope image data acquisition and analysis 
strategy. Biomed Opt Express, 2017. 8(2): p. 860-872. 
 
25. van Rooijen, N. and E. Hendrikx, Liposomes for Specific Depletion of Macrophages from 
Organs and Tissues, in Liposomes, V. Weissig, Editor. 2010, Humana Press. p. 189-203. 
 
26. Lee, S., P. Starkey, and S. Gordon, Quantitative analysis of total macrophage content in 
adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J Exp 
Med, 1985. 161(3): p. 475-89. 
 
27. Sakagami, H., et al., Cell death induced by nutritional starvation in mouse macrophage-
like RAW264.7 cells. Anticancer Res, 2009. 29(1): p. 343-7. 
81 
 
28. Davis, M.J. and J.A. Swanson, Technical advance: Caspase-1 activation and IL-1beta 
release correlate with the degree of lysosome damage, as illustrated by a novel imaging 
method to quantify phagolysosome damage. J Leukoc Biol, 2010. 88(4): p. 813-22. 
 
29. Min, K.A., et al., Massive Bioaccumulation and Self-Assembly of Phenazine Compounds 
in Live Cells. Adv Sci (Weinh), 2015. 2(8). 
 
30. Heuser, J., Q. Zhu, and M. Clarke, Proton pumps populate the contractile vacuoles of 
Dictyostelium amoebae. J Cell Biol, 1993. 121(6): p. 1311-27. 
 
31. Van Dyke, R.W., Acidification of rat liver lysosomes: quantitation and comparison with 
endosomes. Am J Physiol, 1993. 265(4 Pt 1): p. C901-17. 
 
32. Gambale, F., et al., The Voltage-Dependent H+-Atpase of the Sugar-Beet Vacuole Is 
Reversible. European Biophysics Journal with Biophysics Letters, 1994. 22(6): p. 399-
403. 
 
33. Sonawane, N.D., J.R. Thiagarajah, and A.S. Verkman, Chloride concentration in 
endosomes measured using a ratioable fluorescent Cl- indicator - Evidence for chloride 
accumulation during acidification. Journal of Biological Chemistry, 2002. 277(7): p. 
5506-5513. 
 
34. Alberts, B.J., A.; Lewis, J.; Raff, M.; Roberts, K.;  Walter, P., Moelcular Biology of the 
Cell. Fifth edition. 2008: Garland Science, New York. 1601. 
 
35. Serajuddin, A.T., Salt formation to improve drug solubility. Adv Drug Deliv Rev, 2007. 
59(7): p. 603-16. 
 
36. Keswani, R.K., et al., Repositioning Clofazimine as a Macrophage-Targeting 
Photoacoustic Contrast Agent. Sci Rep, 2016. 6: p. 23528. 
 
37. Keswani, R., et al., A Far-Red Fluorescent Probe For Flow Cytometric Xenobiotic-
Sequestering Cell Functional Studies. Cytometry Part A, 2015(Accepted Manuscript). 
 
38. Lemieux, B., M.D. Percival, and J.P. Falgueyret, Quantitation of the lysosomotropic 
character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. 
Anal Biochem, 2004. 327(2): p. 247-51. 
 
39. Samie, M.A. and H. Xu, Lysosomal exocytosis and lipid storage disorders. J Lipid Res, 
2014. 55(6): p. 995-1009. 
 
40. Life Technologies. LysoTracker and LysoSensor Probes. 2013; Available from: 
https://tools.thermofisher.com/content/sfs/manuals/mp07525.pdf. 
 
41. Huefner, A., et al., Gold nanoparticles explore cells: cellular uptake and their use as 
intracellular probes. Methods, 2014. 68(2): p. 354-63. 
82 
 
42. Rajendran, L., H.J. Knolker, and K. Simons, Subcellular targeting strategies for drug 
design and delivery. Nat Rev Drug Discov, 2010. 9(1): p. 29-42. 
 
43. Beyenbach, K.W. and H. Wieczorek, The V-type H+ ATPase: molecular structure and 
function, physiological roles and regulation. J Exp Biol, 2006. 209(Pt 4): p. 577-89. 
44. Grabe, M., H. Wang, and G. Oster, The mechanochemistry of V-ATPase proton pumps. 
Biophys J, 2000. 78(6): p. 2798-813. 
 
45. Lüllmann-Rauch, R., History and Morphology of the Lysosome, in Lysosomes. 2005, 
Springer US: Boston, MA. p. 1-16. 
 
46. Logan, R., A.C. Kong, and J.P. Krise, Time-dependent effects of hydrophobic amine-
containing drugs on lysosome structure and biogenesis in cultured human fibroblasts. J 
Pharm Sci, 2014. 103(10): p. 3287-96. 
 
47. Emanuel, R., et al., Induction of lysosomal biogenesis in atherosclerotic macrophages 
can rescue lipid-induced lysosomal dysfunction and downstream sequelae. Arterioscler 
Thromb Vasc Biol, 2014. 34(9): p. 1942-52. 
 
48. Gao, Y., et al., Comprehensive proteome analysis of lysosomes reveals the diverse 
function of macrophages in immune responses. Oncotarget, 2017. 8(5): p. 7420-7440. 
 
49. Wang, W., et al., Up-regulation of lysosomal TRPML1 channels is essential for 
lysosomal adaptation to nutrient starvation. Proc Natl Acad Sci U S A, 2015. 112(11): p. 
E1373-81. 
 
50. Pastore, N., et al., TFEB and TFE3 cooperate in the regulation of the innate immune 
response in activated macrophages. Autophagy, 2016. 12(8): p. 1240-58. 
 
51. Brahler, M., et al., Magnetite-loaded carrier erythrocytes as contrast agents for magnetic 
resonance imaging. Nano Lett, 2006. 6(11): p. 2505-9. 
 
52. Wang, C., et al., Red Blood Cells for Glucose-Responsive Insulin Delivery. Adv Mater, 
2017. 
 
53. Paukner, S., et al., Bacterial ghosts as a novel advanced targeting system for drug and 
DNA delivery. Expert Opin Drug Deliv, 2006. 3(1): p. 11-22. 
 
54. Wang, C., et al., Multifunctional theranostic red blood cells for magnetic-field-enhanced 
in vivo combination therapy of cancer. Adv Mater, 2014. 26(28): p. 4794-802. 
 
55. Gutierrez Millan, C., et al., In vitro studies of amikacin-loaded human carrier 
erythrocytes. Transl Res, 2008. 152(2): p. 59-66. 
 
56. Rossi, L., et al., Effect of listeriolysin O-loaded erythrocytes on Mycobacterium avium 
replication within macrophages. J Antimicrob Chemother, 2004. 53(5): p. 863-6. 
83 
 
57. Mishra, P.R. and N.K. Jain, Surface modified methotrexate loaded erythrocytes for 
enhanced macrophage uptake. J Drug Target, 2000. 8(4): p. 217-24. 
 
  
84 
 
 
 
Chapter 4 
An Expandable Mechanopharmaceutical Device for Measuring the 
Cargo Capacity of Macrophages in a Living Organism 
4.1 Relevance to Thesis 
This chapter was adapted from the following publication: 
Rzeczycki P, Woldemichael T, Willmer A, Murashov MD, Baik J, Keswani RK, Yoon GS, 
Stringer KA, Rodriguez-Hornedo N, Rosania GR. 2018. An expandable mechanopharmaceutical 
device (1): measuring the cargo capacity of macrophages in a living organism. Pharm. Res. 
36:12; doi: 10.1007/s11095-018-2539-6 
 
In this study, we asked whether specific accumulation of CFZ hydrochloride crystals in 
lysosomes could be explained as a passive, thermodynamic equilibrium phenomenon. To answer 
this, we further investigated the mechanism of CFZ-HCl salt formation and accumulation in 
lysosomes of macrophages (in the chapter referred to as CLDIs or mechanopharmaceutical 
device). In fact, we modeled the subcellular transport and precipitation properties of CFZ using a 
physiologically based pharmacokinetics approach to assess whether thermodynamics alone could 
explain the selective accumulation and stabilization of the drug in macrophage lysosomes. My 
contribution in this study involved experimentally determining the physicochemical properties 
(Chapter 3) and octanol solubility measurements of HCl salt form and free base form of CFZ that 
were used in the cellular pharmacokinetic model. The simulation results supported the notion 
that the proton and chloride ion concentrations of macrophage lysosomes are sufficient to drive 
the massive, cell type-selective accumulation and growth of CFZ hydrochloride biocrystals. It 
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was also determined that the solubility of CFZ-HCl in lysosomes was 3 nM, which is far lower 
than the free base solubility of CFZ free base due its Ksp and pHmax. Importantly, the CFZ-HCl 
salt form of the drug was used as a physical probe in this study, hence mechanopharmaceutical 
device, to measure the cargo loading capacity of different macrophage subpopulations in vivo. 
4.2 Abstract 
Clofazimine (CFZ) is an FDA-approved, poorly soluble small molecule drug that 
precipitates as crystal-like drug inclusions (CLDIs) which accumulate in acidic cytoplasmic 
organelles of macrophages. In this study, we considered CLDIs as an expandable 
mechanopharmaceutical device, to study how macrophages respond to an increasingly massive 
load of endophagolysosomal cargo.  
First, we experimentally tested how the accumulation of CFZ in CLDIs impacted 
different immune cell subpopulations of different organs. Second, to further investigate the 
mechanism of CLDI formation, we asked whether specific accumulation of CFZ hydrochloride 
crystals in lysosomes could be explained as a passive, thermodynamic equilibrium phenomenon. 
A cellular pharmacokinetic model was constructed, simulating CFZ accumulation driven by pH-
dependent ion trapping of the protonated drug in the acidic lysosomes, followed by the 
precipitation of CFZ hydrochloride salt via a common ion effect caused by high chloride 
concentrations.  
While lower loads of CFZ were mostly accommodated in lung macrophages, increased 
CFZ loading was accompanied by organ-specific changes in macrophage numbers, size and 
intracellular membrane architecture, maximizing the cargo storage capabilities. With increasing 
loads, the total cargo mass and concentrations of CFZ in different organs diverged, while that of 
individual macrophages converged. The simulation results support the notion that the proton and 
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chloride ion concentrations of macrophage lysosomes are sufficient to drive the massive, cell 
type-selective accumulation and growth of CFZ hydrochloride biocrystals. 
CLDIs effectively function as an expandable mechanopharmaceutical device, revealing 
the coordinated response of the macrophage population to an increasingly massive, whole-
organism endophagolysosomal cargo load. 
4.3 Introduction 
In multicellular organisms, macrophages are well equipped to internalize extracellular 
solutes and particles through pinocytosis and phagocytosis, respectively.  These processes allow 
them to execute a number of critical, immune surveillance functions, ranging from destruction of 
pathogens to removal and recycling of dead cells and aged tissue components [1-3]. In addition 
to being highly phagocytic, the endolysosomal system of the macrophage is especially adapted 
for accommodating and degrading foreign material due to higher expression levels of lysosomal 
acidification mechanisms [4], particularly the vacuolar-type proton ATP-ase (V-ATPase) [5]. 
However, there is no information about the extent of loading or the cargo storage capacity of 
macrophage populations in vivo, since the majority of measurements have been performed in 
vitro and in very short treatment periods by ‘feeding’ the cells with fluorescent tracer molecules 
[6] or inert beads of varying sizes [7,8] under artificial conditions.  
Even though macrophages are found everywhere in the organism, their ability to 
influence the transport and disposition of small molecule drugs is mostly unknown. Due to their 
ubiquitous presence and high rates of endocytosis, pinocytosis, and phagocytosis, they are 
recognized to play a major role in the clearance of drug nano- or microparticles from the 
circulation [9,10]. Potentially, this action could be exploited for the delivery of small molecule 
drugs [11-14] , particularly those that are poorly soluble because they are prone to form insoluble 
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aggregates that may ultimately accumulate in macrophages [15,16]. Furthermore, cationic, 
amphiphilic molecules, particularly weakly basic molecules, can become trapped within 
lysosomes following protonation in the acidic lysosomal microenvironment [17-19]. The 
sequestration of weakly basic, hydrophobic drug molecules within acidic subcellular (ion-
trapping) compartments of macrophages is a well-documented phenomenon [17].  
To study the in vivo, cargo storage capacity of macrophages in an intact, living organism, 
we have co-opted an FDA-approved and biocompatible antibiotic, clofazimine (CFZ) [15,16]. 
CFZ is a weakly basic anti-mycobacterial agent that is clinically used to treat leprosy and multi-
drug resistant tuberculosis [20-22]. It exhibits extensive bioaccumulation following oral 
administration, in both humans and animal models [23-25]. Because CFZ is both highly 
lipophilic (LogP = 7.66) [26,27] and contains an ionizable amine group (pKa = 6.08) [28], it is 
poised to accumulates in adipose tissue, intracellular membranes, and acidic organelles such as 
lysosomes. In both human and animal models it has been shown that, following prolonged oral 
dosing, CFZ forms insoluble Crystal-Like Drug Inclusions (CLDIs) within macrophage 
lysosomes [15].   
Here, by exploiting CFZ’s self-assembly into CLDIs, we decided to further probe the 
macrophage’s response to an increasing load of drug cargo. Experimentally, CLDIs were 
microscopically monitored to determine the numbers of drug-sequestering macrophages in 
different organs. From these same organs, CLDIs were then biochemically isolated and the drug 
content chemically analyzed to determine the average amount of drug per CLDI-containing cell 
[15,16]. Additionally, we modeled the subcellular transport and precipitation properties of CFZ 
using a physiologically based pharmacokinetics approach to assess whether thermodynamics 
alone could explain the selective accumulation and stabilization of the drug in macrophage 
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lysosomes.  Based on the results, we propose that CLDIs function as an expandable 
mechanopharmaceutical device, which impacts the structural and functional properties of 
macrophages in different organs, and accounts for a drug loading-dependent increase in the 
volume of distribution (VD) of the drug. 
4.4 Materials and Methods 
Animal Studies and Treatment Protocols  
Animal care was provided by the University of Michigan’s Unit for Laboratory Animal 
Medicine (ULAM), and the experimental protocol was approved by the Committee on Use and 
Care of Animals (Protocol PRO00005542). Mice (4 weeks old, male C57Bl6) were purchased 
from the Jackson Laboratory (Bar Harbor, ME) and acclimatized for 1 week in a specific-
pathogen-free animal facility. Clofazimine (CFZ) (C8895; Sigma, St. Louis, MO) was dissolved 
in sesame oil (Shirakiku, Japan) to achieve a concentration of 3 mg/ml, which was mixed with 
Powdered Lab Diet 5001 (PMI International, Inc., St. Louis, MO) to produce a 0.03% drug to 
powdered feed mix, and orally administered ad libitum. Mice were fed for 2, 3, 4, and 8 weeks, 
which yielded estimated whole body cargo loads of 3.5mg, 5.25mg, 7mg, and 14mg, 
respectively. A corresponding amount of sesame oil was mixed with chow for vehicle treatment 
(control). For washout experiments, mice were fed with drug free, vehicle-containing diet for 
eight weeks, after an eight week loading period with the CFZ-containing diet. At the end of 
experimentation, mice were euthanized via carbon dioxide asphyxiation followed by 
exsanguination.   
Macrophage Isolation  
Following euthanasia, four different macrophage populations were isolated to study CFZ 
accumulation. Alveolar [16,29] and peritoneal macrophages [15], and bone marrow monocytes 
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[30] were all isolated using previously described techniques. To isolate Kupffer cells, the portal 
vein was injected with 10 mL of 1 mg/mL Collagenase D (Worthington  Biochemical 
Corporation, Lakewood, NJ) in DMEM-low glucose (Life Technologies) with 15 mM HEPES 
(Life Technologies). The tissue was then removed, placed in a sterile petri dish, and minced into 
small (2-4 mm) pieces using a sterile scalpel blade. Collagenase solution (15 mL) was added, 
and the tissue was incubated (40 min, 37°C), with occasional pipetting to dissociate tissue. The 
suspension was then filtered through a 100 µm cell strainer (Fisher Scientific, Waltham, MA) 
and centrifuged (200 x g, 5 min). The supernatant was discarded, and the cells were resuspended 
in 15 mL DMEM-low glucose with 15 mM HEPES, and centrifuged (200 x g, 5 min). This was 
repeated for two additional washes. After the final wash, the cells were suspended in 
DMEM:F/12 (1:1) (Life Technologies) with 10% FBS and penicillin/streptomycin and 
macrophages were counted. For all cell groups, an aliquot was plated onto 4 or 8 chamber 
coverglass (#1.5, Lab-Tek II, Nunc, Rochester, NY), and for Kupffer cells, the plates were 
coated with Collagen 1 (Corning, Corning, New York) for imaging.  The cells were allowed to 
attach overnight, washed with media, and imaged using a multi-parameter microscope imaging 
system (vide infra). 
Multi-parameter Microscope Imaging and Analysis of Macrophage Sub-Populations  
Multi-parameter polarization, brightfield, and fluorescence imaging and analyses of 
different macrophage subpopulations were performed using a custom-built imaging system, as 
previously described [16]. Brightfield, fluorescence, and polarization images were acquired on 
adherent cells. Images were analyzed using ImageJ software [31,32]. Values for dichroism and 
optical density are reported as an average signal per cell, from 0-1. At least 150 cells of each type 
were analyzed at each time point.  Following loading with 7 and 14 mg of cargo, macrophages 
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were classified as xenobiotic sequestering based on whether or not they contained a detectable 
Cy5 signal from CFZ-HCl [15] using a K-means clustering analysis, with the clusters set to 2 
based on of the Log10(Intracellular Cy5 fluorescence).  
Biochemical Analysis of Cellular Drug Cargo  
The drug concentration in cells was calculated after measuring drug content in isolated 
macrophage populations and organ homogenates using established methods [15,24,33,34]. For 
isolated macrophage populations, cells were counted within each cell sample using a 
hemocytometer to determine the total recovered macrophage population. The cells were then 
centrifuged, and the media was removed. The cell pellet was suspended in 1 mL of DI water, and 
the drug was extracted and measured using a previously described spectrophotometric method 
[34-36]. Drug accumulation is reported as fmol CFZ/xenobiotic sequestering cell. 
Sample Preparation for Microscopy  
In preparation for microscopy, portions of the organ were removed, immediately 
submerged in OCT (Tissue-Tek catalog no. 4583; Sakura), and frozen (-80°C). For transmission 
electron microscopy, organs were prepared using previously described methods [23]. 
Immunohistochemistry of F4/80 (Abcam, 1:500 dilution) stained sections (5µm) was performed 
using Alexa-Fluor 488 (Abcam, 1:500 dilution). 
Determination of Cargo Volume Occupancy  
The volume occupied by biocrystalline drug molecules within a macrophage was 
estimated by using the reported crystal-packing density of 1.36 g/mL [34] for CFZ-HCl, which 
was then converted to a molar volume of 0.377 µm3/ fmol. Cellular volume occupancy was then 
estimated using the measured drug content per cell and the calculated molar volume. 
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Determination of Vesicle Size and Shape  
The size and shape of cargo loaded vesicles was microscopically measured within loaded 
macrophages obtained from CFZ-treated animals, using the Cy5 fluorescence channel to 
specifically monitor the vesicles containing CFZ-HCl. Using ImageJ [31,32], the radius of each 
vesicle was determined. Vesicles which showed Cy5 fluorescence were counted as CFZ 
sequestering. The vesicle volume was estimated assuming spherical shape, while CLDI volume 
was estimated assuming a cylindrical shape. 
Analysis of Organ Macrophage Counts  
To determine the macrophage population numbers in lung, liver, and spleen from animals 
treated with CFZ, cryosections were obtained (5µm). The change in the number of macrophages 
in a volume of tissue was determined by dividing the total F4/80 signal staining intensity 
between an 8 week CFZ-treated sample by the total F4/80 signal staining intensity of a vehicle-
treated sample (the area and thickness of the sections analyzed were kept the same). The total 
macrophage population was then determined by multiplying literature reported (baseline) 
macrophage population values for each organ [37] by the relative expansion factor determined 
via increased intensity of the macrophage marker’s fluorescence signal, via immunofluorescence.  
To determine the fraction of macrophages that contained CLDIs, the fraction of cells which were 
positive for Cy5 fluorescence and F4/80 staining were determined by visual inspection, using a 
mask of the F4/80 staining. Five images per organ per animal were analyzed for each 
measurement.    
Measurement of Drug Accumulation based on Whole Organ Homogenates  
For chemical analysis protocol development, organs were obtained from euthanized, 
untreated mice. Samples from the different organs (20-30 mg) were homogenized in 
radioimmunoprecipitation assay buffer (500 µL; Sigma) with added protease inhibitors (Halt 
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protease and phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo Pierce, Rockford, IL). In 
order to determine the recovery yield, the organ homogenates were spiked with a known amount 
of drug. For analysis, homogenate (350 µL) was removed, and drug was extracted as described 
under “Biochemical Analysis of Cellular Drug Concentrations.”  
Determining the Fraction of Drug Sequestered by Macrophages of Different Organs  
The total drug content of lung, liver, and spleen tissues at eight weeks of treatment was 
determined as described above, using established protocols [33]. Because CLDIs form and 
become stabilized exclusively within macrophages [23,28,34], we sought to determine the 
fraction of drug sequestered within macrophages of each organ. To accomplish this, tissues (n=3) 
were removed, weighed, and placed in a sterile petri dish, where they were manually minced and 
homogenized using a scalpel and syringe plunger. The resulting homogenate was filtered through 
a cell strainer (40 µm) to remove larger cellular clusters and debris. The filtrate was then 
centrifuged (300 x g, 10 min) to pellet the CLDIs. The supernatant was removed, and the CLDI 
pellet was resuspended in 10% sucrose in DPBS (Life Technologies, Carlsbad, CA) without 
calcium chloride or magnesium chloride, pH=7.4. CLDIs were further purified using a 3-layer 
sucrose gradient (50%, 30%, and 10% sucrose in DPBS) centrifugation method (3200 x g, 60 
min). The pelleted CLDIs were then dissolved in 9 M H2SO4, and the mass of drug was 
determined using a plate reader (Biotek Synergy 2, Winooksi, VT) at wavelength 450 nm, and 
background corrected at wavelength 750 nm, which was determined using a standard curve with 
solutions of known concentration. 
Determination of the Cargo Volume Occupied per Macrophage  
Using the total recovered mass of drug associated with CLDIs isolated from the liver, 
lung, and spleen, the volume occupied by drug within individual xenobiotic-sequestering 
macrophages was estimated based on the number of CLDI containing cells, using the total 
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expanded macrophage population present in the measured tissue sample, multiplied by the 
fraction of cells which contained a CLDI (determined microscopically). Using literature reported 
values for cellular volume of the macrophage [38], the percentage of cellular volume occupied 
by drug was estimated by dividing the total recovered mass of drug associated within the isolated 
CLDIs, by the total (calculated) number of CLDI containing cells in the sample of tissue from 
which the CLDIs were isolated. The fraction of the phagocytic capacity occupied by cargo was 
calculated by dividing the measured cargo volume by the maximum phagocytic capacity of 
macrophages [8].  
Biochemical Analysis of Drug Concentrations  
The concentration of CFZ in plasma or organ homogenates was determined using a 
previously described method [24]. In brief, blood was collected in microtainer serum separator 
tubes (catalog no. 3659656; Becton Dickinson, Franklin lakes, NJ) and allowed to clot at room 
temperature and centrifuged (5,000 x g, 5 min). Samples (20 µl) were extracted with acetonitrile 
(60 µl, 90% extraction efficiency) for 10 min at 4°C with vortexing. After centrifugation (5,000 x 
g, 4°C), the supernatant was injected into Agilent 1200 RRLC coupled to 6410 Triple Quad LC-
MS equipped with a Waters Xbridge C18 column (2.5 µm x, 2.1 mm x 100 mm). A standard 
curve was generated by extracting spiked drug samples using serum (or the organ homogenates) 
from a vehicle-only treated mouse mixed with CFZ stock solution from dimethyl sulfoxide, 
resulting in 10 different CFZ concentrations between 0 and 30 µM. The peak area was quantified 
using MassHunter Quantitative Analysis software, vB.04.00.  This standard curve was then used 
to establish the concentration of drugs in experimental samples from blood of drug-treated mice 
(or from organ homogenates of these mice). 
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Determination of the Volume of Distribution of the Drug in Different Organs (VOD)  
Following treatment with 5.25 or 14 mg of CFZ, mice (n=3 per time point) were 
euthanized and the liver, spleen, small intestine, fat, kidney, and lung were removed, weighed, 
and the mass of CFZ within each tissue and the concentration within plasma were determined as 
previously described [24]. The VOD of the drug within macrophages, tissue, and the whole body 
at the different loading amounts was determined using the ratio between the total drug within 
tissues or individual cells and the measured plasma concentration. 
Experimental Measurement of CFZ’s Physicochemical Properties  
Using Flynn and Kramer’s methodology [39], the pHmax, apparent pKa, intrinsic 
solubility, salt solubility, and solubility product constant (Ksp) of CFZ were experimentally 
determined as previously reported [28]. Briefly, an excess of CFZ-HCl (25 mg) was placed in 15 
mL of Milli-Q water, and 0, 40, 80, 120, or 200 µL of 0.1 M NaOH were added to the vials to 
achieve an initial equilibration pH measurement. Following a 24 h equilibration period,	10 µL of 
0.1 M NaOH was added daily over a five day period, leading to a pH range from 4.5 to 8.9. The 
samples were then stirred using a magnetic stirrer plate in a 25°C water bath to allow them to 
equilibrate for 24 h. A 500 µL sample was removed from each vial and filtered through a Spin-X 
centrifuge tube filter (0.45 µM cellulose acetate, 2 mL polypropylene tubes, non-sterile, Costar®, 
Cat #8163) for 4 min at 10,000 RPM. The pH of the filtrate was measured (UltraBasic pH meter, 
Denver Instrument, Bohemia, NY) both before and after the completion of the assay, prior to 
measurement of solubilized CFZ. The concentration of CFZ was then determined using HPLC 
analysis (Waters Alliance, Separations Module 2695). Each measurement was performed in 
triplicate and the average used to construct the pH-dependent solubility profile. Through 
mathematical manipulation of the Henderson-Hasselbalch equation and inputting different 
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combinations of the experimental, pH-dependent solubility measurements, the apparent pKa, 
intrinsic free base solubility, pHmax, and Ksp were calculated, as previously described [28]. 
Solubility Measurements for CFZ and CFZ-HCl in Octanol 
In order to determine the solubility values for CFZ and CFZ-HCl in 1-octanol (293245; 
Sigma-Aldrich), both forms of the drug were introduced in great excess to 1-octanol in glass 
scintillation vials. A small magnetic stir bar was added to each sample, and the samples were 
placed on the magnetic stirrer inside the incubator (37°C). After a 24-hour equilibration period, 
samples were removed from the incubator and immediately filtered using Spin-X centrifuge tube 
filters (0.45 µm cellulose acetate, 2 mL polypropylene tubes, Costar®) for 4 min at 5,000 x g. 
The concentration of the soluble drug in 1-octanol was spectrophotometrically determined (285 
nm, 37°C; Synergy-2 plate reader; Biotek Instruments, Winooski, VT). For each sample, 
solubility measurement was performed in triplicate, and the average was reported. The standard 
curve was generated using CFZ crystals that were dissolved in 1-octanol at known 
concentrations (1-200 µM). Pure 1-octanol was used as a baseline absorbance. 
Statistical Analysis of Experimental Data  
All data are expressed as mean ± standard deviation (SD). For multiple comparisons, 
statistical analysis was performed with one-way analysis of variance (ANOVA) and Tukey's post 
hoc comparisons. All statistical analyses were performed using IBM SPSS Statistics version 24.0 
(IBM Software, Armonk, New York). p values less than or equal to 0.05 were considered 
statistically significant. 
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Physiologically-based Drug Transport Modeling and Simulation of Intracellular Drug 
Supersaturation   
We used an established, physiologically-based cellular pharmacokinetic modeling 
framework [39-41] to calculate the time-dependent changes in the concentration of a monovalent 
weakly basic small molecule drug inside each compartment within a cell following exposure of 
the cell to a constant extracellular drug concentration.  For the present study, we used the open-
source modeling software Virtual Cell®. All of the following models can be freely accessed at 
http://vcell.org.  The model used here (awillmer: Macrophage Cargo Capacity) was built from 
the established Virtual Cell model: jsbaik: 1-Cell PK acid/base/neut total. For boundary 
conditions, we used the previously published, standard eukaryotic cell parameter values as input 
(Table S4-1).  
Modeling the Passive Transport Properties of a Weakly Basic Drug that Stably 
Accumulates and Self-Assembles in Macrophage Lysosomes 
We used CFZ as a weakly basic model drug to predict its subcellular phase-transition 
dependent accumulation. Even though it has two ionizable groups, it can be modeled as a 
monobasic compound because at physiological pH, the ionization of the amine with the lower 
pKa of ~2 will not influence the transmembrane fluxes to any significant extent.  In lysosomes, 
CFZ accumulates as CLDIs, which mostly contain hydrochloride salts of the weak base (CFZ-
HCl). Thus, using predetermined physicochemical properties of the free base as well as the salt 
form of the drug (apparent pKa = 6.08 [28], and octanol/water partition coefficient logP (logKow 
= 7.66 [26,27])) as input in the Virtual Cell model, we calculated the time-dependent subcellular 
distribution of both neutral and ionized molecular species as a function of an extracellular total 
drug concentration of 10 µM (concentrations in all subcellular compartments are linearly related 
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to the extracellular concentration). We set the extracellular volume to a high value (Table S4-1), 
so that the extracellular drug concentrations would remain nearly constant, without being 
affected by cellular drug uptake. In turn, the degree of supersaturation of the drug molecules in 
the different cellular compartments was calculated by dividing the concentrations of the 
protonated and unprotonated species of the drug in those compartments by the calculated 
solubility of the corresponding charged or neutral species in said compartments. Detailed 
theoretical calculations and equations used to determine the concentration of the ionized and 
unionized form of the weakly basic drug within subcellular compartments, and degree of 
supersaturation of the drug within various subcellular compartments can be found in the 
Supporting Information. 
4.5 Results 
Testing the in vivo adaptive response of different macrophage populations to a massive, 
whole organism cargo load 
To determine how CFZ bioaccumulation as an expandable mechanopharmaceutical 
device affects macrophage function, we measured the response of different macrophage 
subpopulations to an increasingly massive CFZ load. Experimentally, at the smallest whole body 
cargo load measured (3.5 mg), the drug was mostly present in alveolar macrophages (Figure 4-
1a). This cargo was associated with red, optically dense, cytoplasmic vesicles which exhibited 
little dichroism signal, corresponding to a disordered, amorphous, supramolecular organization 
[42,43] (Figure 4-1b). A 7 mg whole body cargo load resulted in a modest increase in 
accumulation in the alveolar macrophages (Figure 4-1c), and a small percentage of the drug was 
apparent in the peritoneal and liver macrophages (Figure 4-1a). However, the structure of the 
intracellular cargo became more organized with increasing amounts of drug as reflected in the 
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elevated optical density (Figure 4-1c) and dichroism (Figure 4-1d) of alveolar, peritoneal, and 
liver macrophages. At 14 mg, cargo loads redistributed into large, highly ordered CLDIs 
exhibiting strong dichroism signals in all macrophages (Figure 4-1b). Under all loading 
conditions, the less mature bone marrow monocytes were free of cargo. At a population level, 
these trends were confirmed by multi-parameter image-based cytometric analyses [16] (Figure 4-
1c, d).  
The results of chemical analyses paralleled the observed changes in loading dynamics 
and the redistribution of cargo among the different macrophage populations. At low (3.5 mg) 
cargo loading, alveolar macrophages sequestered 29.9 ± 12.4 fmol of CFZ/cell, while the other 
populations showed minimal loading (Figure 4-1e). After a whole body load of 3.5 mg, less than 
0.3% of the maximal phagocytic capacity of the alveolar macrophages was reached (Figure 4-
1f). At a larger (7 mgs) whole body cargo load, alveolar macrophages accumulated 34.0 ± 20.3 
fmol CFZ/cell, which primarily remained in a disordered form as reflected in the low dichroism 
signal (Figure 4-1b, d). Peritoneal and liver macrophage populations, due to their differential 
accumulation pattern (Figure 4-1b), increased their cargo loading per cell to 105.7 ± 10.0 and 
63.5 ± 16.2 fmol/cell, respectively. It is noteworthy that at the highest loads of cargo (14 mg), all 
tissue macrophage subpopulations exhibited similar levels of cargo loading (Figure 4-1e), except 
for monocytes. Thus, the formation of CLDIs facilitated intracellular cargo loading coincided 
with a systemic redistribution of cargo among all macrophage sub-populations, such that the load 
became more evenly distributed in the cell. In these isolated macrophages, the highest cargo 
volume corresponded to ~1% of the maximal phagocytic capacity of cell (Figure 4-1f) [8]. As 
such, only a small fraction of the potential intracellular cargo space was occupied even at the 
highest whole body loads that were measured in vivo.  
99 
 
To achieve an even distribution of cargo (which was observed in the most massively 
loaded condition), macrophages visibly adjusted their intracellular, cytoplasmic membrane 
organization. For example, with a relatively low amount of loading (3.5 mg), the alveolar 
macrophage population accumulated an average of 21.6 ± 5.0 vesicles per cell, with each vesicle 
occupying a mean volume of 0.43 ± 0.29 µm3 (Table 4-1). Transmission electron micrographs of 
alveolar macrophages revealed numerous dark, lipid bound inclusions within the cytoplasm 
(Figure 4-2a). A larger (7 mg) whole body cargo load increased the number of cytoplasmic 
vesicles by >50% per cell (n=30 cells, p<0.05, ANOVA, Tukey’s HSD), with the mean vesicular 
volume increasing by ~125% (Table 4-1). At the largest whole body cargo load tested (14 mg), 
an expansion of membrane-bound cytoplasmic vesicles was clearly visible (Figure 4-2b). At this 
point, the number of loaded vesicles per cell decreased by >40%. The expanded, membrane 
bound vesicles remained stable within the macrophages as long as eight-weeks following the 
discontinuation of drug administration (Figure 4-2c). 
Of noteworthy significance, the amount of cargo in the isolated macrophage populations 
effectively accounted for most of the total cargo load measured in whole organ homogenates 
(Table 4-2). Based on the amount of cargo within each organ, the volume of blood that was 
cleared by the macrophages in the different organs was estimated (the organ-specific Volume of 
Distribution, VOD; Table 4-3). In pharmacokinetic terms, the whole body VD  of a molecule is the 
ratio between the amount of drug in the organism and the plasma concentration of the drug [44]. 
VD represents the extent of tissue distribution [45] as reflected in the theoretical volume required 
to contain an administered amount of drug at the same concentration found in plasma. With an 
increasing cargo load, each macrophage population significantly contributed to VOD and 
consequently, to VD (Table 4-3). Given that the volume of a single macrophage is ~1 pL, they 
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contribute to VD via the solute-to-solid phase transition that accompanies CLDI formation. At the 
whole organ level, there was a nearly ~100-fold increase in the VOD within the liver and small 
intestine, a ~60-fold increase within the spleen and ~10-fold increase within the lung, paralleling 
an increasing whole body cargo loading from 5.25 to 14 mg (Table 4-4). Adipose tissue and 
kidneys, neither of which contain large populations of tissue macrophages compared to other 
organs, had modest increases in the VOD that were much lower than those observed in liver, 
spleen, lung, and intestine (Table 4-4). 
 The most important finding in the VOD analysis pertains to the role of organ-specific 
macrophage subpopulations in the redistribution of cargo loads and its ultimate impact on the 
measured differences in the VOD of the different organs. The difference in organ-specific VOD 
(Table 4-4) between animals exposed to a moderate (5.25 mg) or a large (14 mg) cargo load, 
seemed to result in an increasingly divergent loading pattern. With a 14 mg load, for example, 
the spleen VOD was >50 times greater than that of the kidney, while at a 5.25 mg load, the spleen 
VOD was only ~3 times greater than kidney. However, when looking at the specific accumulation 
of drug in macrophages (Table 4-2 and 4-3; and Figure 4-1e, f), it was apparent that the 
divergence in the whole organ distribution was due to differences in the number of macrophages 
per organ mass, since the cargo became more evenly distributed among the resident macrophages 
of the respective organs.    
Passive transport acting in concert with a pH and chloride-dependent phase transition is 
sufficient to explain the function of CFZ as an expandable mechanopharmaceutical device 
In order to determine whether passive transport can explain the selective precipitation and 
growth of CFZ hydrochloride crystals in lysosomes, we proceeded to dissect the subcellular 
transport and self-assembly properties of CFZ using a physiologically based, cellular 
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pharmacokinetics modeling and simulation approach (Figure 4-3). Previous analyses have 
identified the hydrochloride salt form of CFZ as the major fraction of the bioaccumulated drug 
[28,34]. This hydrochloride salt form was specifically present in CLDIs, which are stabilized 
within acidic intracellular vesicles (as revealed by inhibiting the proton-pumping, V-ATPase 
which decreases CLDI formation and CFZ accumulation) [28]. Without macrophages, CLDIs 
also failed to form and CFZ accumulated in tissues to a much lesser extent [28].  
Consistent with these previous experimental observations [28,34], our simulation results 
revealed how the unprotonated, neutral molecular species of CFZ accumulated intracellularly in 
the presence of a constant extracellular drug concentration (Fig. 4a). As expected, because of the 
higher pH (relative to the drug’s pKa) of the cytoplasm and mitochondria, the unprotonated free 
base concentration was highest in the cytoplasm (Fig. 4b) and mitochondria (Fig. 4c), relative to 
lysosomes (Fig. 4d). Simulating the distribution of the ionized (protonated) molecular species of 
the drug over time, we observed that the protonated form remained nearly constant in the 
extracellular medium (Fig. 4e). The concentration of protonated drug was lowest in cytoplasm 
(Fig. 4f) and mitochondria (Fig. 4g), but increased dramatically in the lysosomes (Fig. 4h) due to 
ion trapping [46]. In fact, lysosomes possessed the highest drug concentration of all cellular 
compartments (Fig. 4h). Because of the linearity of the model, the neutral and protonated, 
charged molecular species in all of the compartments proportionally decreased when the total 
initial extracellular CFZ concentration was reduced (for example, changing the units of 
micromolar to nanomolar). 
 In order to determine the propensity of the free base and ionized forms of the drug to 
precipitate in the different cellular compartments, we calculated the degree of supersaturation of 
both forms of the drug using their solubility properties obtained from experimental 
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measurements (Table 4-5). Degrees of supersaturation were calculated by determining the ratio 
of simulated steady state CFZ concentration to CFZ solubility (Equations 3 and 4 in the 
Appendix C). The greatest degree of supersaturation for the ionized form of the drug was 
observed in the lysosomal compartment (Table 4-5). Within the lysosomal lumen, the 
supersaturation of CFZ-HCl exceeded all other compartments by more than two orders of 
magnitude (Table 4-5). The primary reasons for the high supersaturation in the lysosomal lumen 
were the high chloride concentrations and a lysosomal pH lower than the pHmax of CFZ-HCl. 
Moreover, the degree of supersaturation of CFZ-HCl in the lysosome was exceeded by 3 to 6 
orders of magnitude over that of CFZ free base (Table 4-5). This indicates that the conditions for 
salt precipitation would be most favorable in the lysosomal lumen, and as a result, would be the 
first location within the cell that precipitation would be expected to occur, as concentrations in 
all compartments increase following drug administration. Note that the intracellular 
concentrations predicted by the transport model were linearly dependent on the starting drug 
concentrations in the extracellular medium, so the model effectively predicted the most likely 
site of intracellular drug precipitation based on the lowest extracellular concentration necessary 
to achieve supersaturation in any intracellular compartment. 
4.6 Discussion 
In this study, we propose that CFZ accumulation in macrophages leads to physical 
alterations in cell structure and function that result from CFZ’s self-assembly into an expandable 
mechanopharmaceutical device. This expandable mechanopharmaceutical device specifically 
accumulates in macrophage lysosomes following prolonged oral drug administration, and its 
effects are posited to result from a physical space occupied by the drug, independent of the 
drug’s pharmacological activity. As an expandable mechanopharmaceutical device, we 
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considered CLDIs as a physical probe that can be used to measure the cargo loading capacity of 
different macrophage subpopulations in vivo, and used it to directly determine the VD of the drug 
in different organs. While prior studies have determined that CLDI formation is compatible with 
the maintenance of normal ion homeostasis in lysosomes of macrophages [28], this is the first 
study to show that the mass and volume occupied by drug is specifically accumulating in 
lysosomes within these cells, while assessing its impact on the drug’s volume of distribution 
(VD) [16,34]. While it is often assumed that the VD of a therapeutic agent is a constant, our 
measurements indicate that this is not necessarily the case.  Furthermore, based on our 
mathematical modeling and simulation analysis, lysosomal pH and chloride content were found 
to be sufficient to account for the selective accumulation of CFZ in macrophage lysosomes 
accounting for the cell type selectivity of this phenomenon.  
When studying the impact of macrophages on transport phenomena, fluid tracers or 
nanoparticles that are readily ingested by macrophages have been previously used as functional 
markers of macrophage-mediated clearance. To assess whole organism cargo capacity of 
macrophages in vivo, our results show how an expandable mechanopharmaceutical device that 
self-assembles from a small molecule building block could potentially be used to stretch the 
cell’s cargo carrying capacity with the largest possible cargo load that can be accommodated by 
a living organism. This led us to consider the following question: how exactly does the organism 
respond to the massive build-up of a whole-body macrophage cargo load? In the experiments 
reported herein, the null hypothesis was that all macrophages would accumulate the drug to the 
same extent in all organs, and that at some point a toxicological effect may become manifested. 
However, our experimental results led us to reject this, in favor of an alternative hypothesis: 
different macrophage subpopulations initially vary in their ability to bioaccumulate drug, but 
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gradually respond to an increasingly massive amount of cargo so that the load does not exceed 
the cargo capacity of the individual cells and becomes more evenly distributed across all of the 
macrophage populations throughout the different organs of the body. Based on theoretical 
considerations, a physiologically-based cellular pharmacokinetic model indicated that this 
phenomenon may be entirely determined by an energetically-favorable, thermodynamically-
driven loading state that decreases the total free energy of the drug while maximizing the 
volume-to-surface area ratio of intracellular drug inclusions. The significantly different rates at 
which this occurs in macrophage subpopulations do not simply reflect the extent of perfusion of 
the different organs, nor do they reflect the partitioning of soluble drug or trapping of circulating 
drug particles in these organs since it varied as the whole organism drug load increased.  Since 
undifferentiated, bone marrow monocytes did not accumulate drug to any significant extent, we 
infer that differences in drug accumulation kinetics reflect organ-specific variations in the 
differentiation of macrophages into specialized, xenobiotic sequestering cells.   
In terms of how these findings impact pharmacokinetics, CFZ induced changes in VD 
which counters the underlying assumptions about the mechanistic underpinning of this 
pharmacokinetic parameter. VD is usually considered the apparent volume that a systemically 
administered drug distributes in to reach a measureable concentration in the blood. For many 
poorly soluble, weakly basic drugs, the VD can be in the order of thousands of liters, which 
greatly exceeds the volume of body water (60-100 liters). Large VD is generally thought to be 
due to the preferential partitioning of hydrophobic drug molecules into adipose tissue or cellular 
membranes and lipids. For poorly soluble drugs that are administered at high doses for prolonged 
periods of time, if the drug molecules are metabolically stable and eliminated very slowly, 
bioaccumulation could eventually lead to a phase transition, with insoluble aggregates forming 
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throughout the organism, expanding the VD. Accordingly, the experimental and theoretical 
analysis presented in this study suggests that the simple, thermodynamic partitioning 
mechanisms underlying the general concept of VD may need to be revisited, especially for poorly 
soluble weakly basic drugs like CFZ which massively bioaccumulate in the organism. 
 Indeed, the experimental results presented in this study add support to the role of 
macrophage lysosomal pH and chloride ion regulation in contributing to, and accounting for, 
most of the accumulation and distribution of CFZ in vivo [28,34]. The results of our 
physiologically based model was consistent with CFZ precipitation occurring selectively in 
macrophage lysosomes, because the stability of CFZ hydrochloride precipitates in this organelle 
surpassed that of all other sites in the cell, as well as in the extracellular environment, by more 
than three orders of magnitude. Macrophages possess highly acidic lysosomes, which can expand 
to accommodate large cargo loads, and the macrophage population itself is able to undergo 
changes in structure and function to adapt to the cargo. In the future, the mathematical model 
could be used to predict the intracellular concentration and precipitation of ionized vs. neutral 
molecular species of other weakly basic small molecule drugs and to identify other small 
molecule chemical agents that have similar subcellular disposition characteristics as CFZ. 
 Regarding our use of the word “device”, it may sound unusual if one only considers the 
formation of a precipitate as a side-effect or as a toxic phenomenon arising from poor 
pharmacokinetics or inadequate dosing. In this particular case, the precipitation behavior of the 
drug is being purposefully co-opted as a volumetric instrument. It is being introduced as a tool to 
expand the macrophage cargo capacity and to probe how the organism responds to an increasing 
endophagolysosomal cargo load. In the scientific literature, one can find many references in 
which drugs are referred to as pharmacological “probes” or “tools” when used as inhibitors or 
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stimulators of endogenous molecular targets or pathways, with the goal of obtaining information 
about how these targets or pathways mediate biochemical signaling or physiological responses in 
living organisms [47–50]. The word “device” was purposefully chosen to highlight how CFZ 
was used as a self-assembling building block to construct a physical object to study the “cargo 
capacity” of macrophages. To use CLDIs as measurement “devices”, we have developed 
methods to isolate and stabilize CLDIs [33] as well as microscopy instruments to monitor their 
optical [16], photoacoustic [51] and biomechanical properties [52]. Instead of engineering a new 
chemical compound to measure the cargo capacity in a living organism, CFZ was repurposed 
and administered to the animals to operate in this very physical manner, independently of the 
antimicrobial, redox, and other pharmacological interactions of freely soluble CFZ molecules.  
4.7 Conclusion 
To conclude, the results presented herein suggest a physical stimulus-dependent, 
macrophage-mediated biological response mechanism that is activated by the function of CFZ as 
a building block of an expandable mechanopharmaceutical device that accumulates within these 
cells. Macrophages actively stabilize intracellular CFZ as insoluble complexes that are trapped 
within their endophagolysosomal compartment. To accommodate increasingly massive loads of 
cargo, macrophages increased in numbers and adapted their intracellular membrane organization 
to expand the intracellular cargo space; this resulted in a gradual but dramatic increase in VD. 
While resident macrophages of different organs demonstrate significant variations in their 
response to increasing loads of cargo, all differentiated macrophage populations were capable of 
sequestering very large loads. Of noteworthy significance, to our knowledge this is the first time 
that changes in the VD of a small molecule drug has been directly linked to an adaptive, immune 
system-mediated, xenobiotic sequestration response.  
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4.10 Figures and Tables 
 
 
 
 
Figure 4-1: Microscopic imaging cytometry and quantitative chemical analysis indicate variations in cargo 
loading dynamics of different macrophage sub-populations. (a) Brightfield images of isolated macrophage and 
monocytes with increasing whole-body cargo loading. (b) Linear diattenuation images of isolated macrophage and 
monocytes with increasing whole-body cargo loading. Optical density (c), linear diattenuation (d), cargo loading per 
xenobiotic-sequestering cell (e), and percent of maximal cargo loading (f) of alveolar macrophages (black), 
peritoneal macrophages (red), bone marrow monocytes (green), and Kupffer cells (blue) with increasing cargo 
loading. Data are the mean (SD) of 150 cells per cell type and condition, for imaging studies, n=3 mice per cargo 
treatment for drug accumulation, (*=p<0.05, ANOVA, Tukey’s HSD) (Scale bar = 10 µm). 
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Table 4-1: Vesicle number, size, and volume occupancy in alveolar macrophages following cargo loading. 
Cargo 
Loading 
Mean number of 
vesicles per cell ± SD 
(n=30 cells) 
Mean vesicle 
volume ± SD (n=50 
vesicles) 
Mean total volume occupied 
by vesicles ±SD (n=50 
vesicles) 
3.5 mg 21.6 ± 5.0 0.43 ± 0.29 µm3 9.2 ± 6.7 µm3 
7.0 mg 32.6 ± 6.8* 0.97 ± 0.96 µm3 31.7 ± 32.1 µm3 
14.0 mg 18.4 ± 11.1 13.8 ± 10.4 µm3* 253.8 ± 244.5 µm3 
* = p < 0.05, ANOVA, Tukey’s HSD 
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Figure 4-2: Macrophage cargo accumulation induces reorganization of internal membrane architecture. (a) 
Following whole-body cargo loading of 3.5 mg, small vesicles that fill the cytoplasm are apparent in alveolar 
macrophages. (b) A higher cargo load (14mg) results in accumulation of crystal-like drug inclusions (CLDIs) 
throughout the cytoplasm. (c) CLDIs remain stable even following an eight week washout period. Black arrows 
denote cargo-laden vesicles and red arrows denote cavities left from CLDIs removed during sample preparation. 
Scale bar is 2000 nm. 
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Table 4-2. Estimated cargo loads of liver, spleen, and lung macrophages, at a 14 mg whole body load. 
Data represent the mean ± S.D., n = 3 mice. 
  
Macropha
ge 
Population 
Cargo 
mass 
(mg) 
Percent 
Xenobiotic 
Sequesterin
g 
 
Total 
Xenobiotic 
Sequestering 
Cells ( x 106 )  
Fmol 
Cargo/Xenobiot
ic Sequestering 
Cell 
% Cell 
Volume 
Occupied by 
Cargo 
Liver 4.57 ± 
0.78 
88.5 ± 3.3% 80 ± 19 120.9 ± 35.3 2.11 ± 0.62%  
Spleen 3.23 ± 
0.27 
83.9 ± 
12.5% 
22 ± 5.9  310.5 ± 86.9 5.42 ± 1.52% 
Lung 0.32 ± 
0.06 
81.1 ± 3.2% 3.7 ± 1.7  183.2 ± 91.5 3.20 ± 1.60% 
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Table 4-3. Volume of distribution in liver, lung, and spleen macrophage, at a 5.25 and 14 mg whole-body 
loads. 
Macrophage Population 5.25 mg cargo VOD 
(nL/macrophage) 
14 mg cargo VOD 
(nL/macrophage) 
Liver 0.66 ± 0.08 33.51 ± 16.43* 
Spleen 0.49 ± 0.03 64.25 ± 32.48* 
Lung 5.51 ± 0.16 42.73 ± 31.58* 
* = p < 0.05, Two-tailed Student’s t-test 
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Table 4-4. Volume of distribution within specific organs, at a 5.25 and 14 mg whole-body load. 
Tissue (n=3 per treatment) 5.25 mg cargo VOD (L/kg 
tissue) 
14 mg cargo VOD (L/kg 
tissue) 
Liver 33.9 ± 13.1 2232.5 ± 958.2* 
Spleen 118.8 ± 85.4 6139.3 ± 2637.0* 
Lung 91.2 ± 12.0 902.3 ± 524.1 
Fat 91.8 ± 15.2 129.1 ± 61.1 
Jejunum and Ileum 11.1 ± 6.3 1085.2 ± 606.2* 
Kidney 31.1 ± 7.3 125.6 ± 55.5 
* = p < 0.05, Two-tailed Student’s t-test 
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Figure 4-3: Diagrammatic representation of the integrated, transport and precipitation modeling approach 
used to determine the most likely cite of intracellular CFZ precipitation. The definition of each parameter value 
is given in Table S1 in the Supporting Information.  
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Figure 4-4: Time-plot simulations of intracellular concentrations of neutral and protonated species of 
clofazimine (CFZ) in different subcellular compartments. (a) Extracellular drug accumulation of neutral CFZ 
remains constant during the time course of the simulation; (b) neutral drug molecules enter and reach steady state in 
cytoplasm; (c) the mitochondrial compartment has the highest free base drug concentration due to a pH higher than 
the cytosol and significant lipid content; (d) lysosomes have low concentrations of the neutral species due to their 
low pH; (e) extracellular concentrations of ionized CFZ (CFZH+) are much lower than neutral CFZ species, and 
remains constant; (f) due to the physiological pH of the cytoplasmic compartment, there is very little protonated 
drug, as well; (g) the high pH of the mitochondria leads to a low concentration of protonated free base, although the 
concentration is higher than in the extracellular medium due to the mitochondrial membrane potential-dependent 
uptake; (h) the lysosomal compartment has the highest ionized drug concentration due to ion trapping. 
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Table 4-5. Steady-state degree of supersaturation of free base CFZ and CFZ-HCl based on a simulated, initial 
extracellular concentration of 10 µM 
Compartments 
Estimated degree of 
supersaturation of free base 
CFZ at steady state 
Estimated degree of 
supersaturation of  CFZ-HCl at 
steady state 
Extracellular (b)1.98x101 0(a) 
Cytosol (b)4.95x104 0(a) 
Mitochondrial 
lumen 
(b)5.36x104 0(a) 
Lysosomal lumen (b)2.25x103 (c)1.36x107 
(a)Because the local pH is higher than the pHmax, only the free base form is predicted to 
accumulate as the most stable precipitate.  
(b)The simulated, steady state concentration of CFZ free base in the given aqueous compartment 
was divided by the experimentally measured, intrinsic aqueous solubility of CFZ (0.48 µM) [28].  
(c)Based on this degree of supersaturation calculated with Equation 4 in the Appendix C, the 
solubility of CFZ-HCl in lysosomes, in the presence of 110 mM chloride at pH = 4.5, was 3 nM. 
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Chapter 5 
The Physicochemical Basis of Clofazimine-Induced Skin 
Pigmentation 
5.1 Relevance to Thesis 
 This chapter was adapted from the following publication: 
Murashov MD, LaLone V, Rzeczycki PM, Keswani RK, Yoon GS, Sud S, Rajeswaran W, Larsen 
S, Stringer KA, Rosania GR. 2018. The physicochemical basis of clofazimine-induced skin 
pigmentation. J Invest Dermatol 138:697-703; doi: 10.1016/j.jid.2017.09.031 
 
This study allowed me to conclude Specific Aim 1 of this thesis. To test whether CFZ-
induced skin pigmentation is due to CLDI formation, I identified a closely related clofazimine 
analog that does not precipitate under physiological pH and chloride conditions that are required 
for CLDI formation (Chapter 3). As a result, I developed methods to isolate, quantify, and 
analyze CFZ in mice skin tissues and determined that the major side effect from orally 
administered CFZ is associated with the CFZ free base, and not the accumulated drug biocrystals 
(e.g. CLDIs).  
These results further validated the central hypothesis that even though CFZ-HCl and CFZ 
free base have the same API, the CFZ-HCl is a more therapeutically efficacious form of CFZ 
that could be potentially used in repurposing this drug for other indications. In fact, to 
reformulate and repurpose this drug for other indication and potentially circumvent the CFZ-
induced skin pigmentation, I developed biomimetic formulation of CLDIs (synthetic, micronized 
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CFZ-HCl crystals) for parenteral administration (Chapter 6) and tested its efficacy in a different 
indication, gouty arthritis (Chapter 7). 
5.2 Abstract 
Clofazimine is a weakly basic, Food and Drug Administration-approved antibiotic 
recommended by the World Health Organization to treat leprosy and multi-drug-resistant 
tuberculosis. Upon prolonged treatment, clofazimine extensively bioaccumulates and precipitates 
throughout the organism, forming crystal-like drug inclusions (CLDIs). Due to the drug’s red 
color, it is widely believed that clofazimine bioaccumulation results in skin pigmentation, its 
most common side effect. To test whether clofazimine-induced skin pigmentation is due to CLDI 
formation, we synthesized a closely related clofazimine analog that does not precipitate under 
physiological pH and chloride conditions that are required for CLDI formation. Despite the 
absence of detectable CLDIs in mice, administration of this analog still led to significant skin 
pigmentation. In clofazimine treated mice, skin cryosections revealed no evidence of CLDIs 
when analyzed with a microscopic imaging system specifically designed for detecting 
clofazimine aggregates. Rather, the reflectance spectra of the skin revealed a signal 
corresponding to the soluble, free base form of the drug. Consistent with the low concentrations 
of clofazimine in the skin, these results suggest that clofazimine-induced skin pigmentation is not 
due to clofazimine precipitation and CLDI formation, but rather to the partitioning of the 
circulating, free base form of the drug into subcutaneous fat. 
5.3 Introduction 
Drug-induced skin pigmentation corresponds to approximately 10-20% of all cases of 
hyperpigmentation [1]. It can be induced by a wide variety of drugs (i.e., nonsteroidal anti-
inflammatory drugs, weakly basic drugs, heavy metals, psychotropic drugs, etc.) through several 
mechanisms that can involve an accumulation of melanin as a nonspecific postinflammatory 
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change in predisposed individuals, often worsened by sun exposure; an accumulation of the 
triggering drug itself and/or reacting with other substances in the skin; and due to deposits of 
certain heavy metals (i.e., iron) that can cause damage to the dermal vessels [1]. 
Hyperpigmentation caused by weakly basic drugs (i.e., chloroquine, amiodarone, and 
clofazimine) is of particular interest and importance because approximately 75% of drugs on the 
market are classified as weak bases [1-5]. One of the most extreme examples of weakly basic 
drugs that causes severe hyperpigmentation is clofazimine, and yet, the basis of clofazimine 
drug-induced skin pigmentation has never been investigated. 
Clofazimine (CFZ) is a weakly basic, very lipophilic, phenazine antibiotic [6] that has 
been effectively used to treat leprosy for over 40 years. Curing more than 14 million people 
worldwide, this drug is on the World Health Organization’s list of essential medications [7]. 
Furthermore, because of its potent activity against Mycobacterium tuberculosis, CFZ is now 
recommended by World Health Organization as a second line agent against multi-drugresistant 
tuberculosis, which is supported by in vitro animal and human studies [8, 9], including a 
randomized, prospective clinical trial [5]. 
Regardless of the indication, whether it is for leprosy or multi-drug-resistant tuberculosis, 
studies that have evaluated the clinical efficacy and tolerability of CFZ have reported that skin 
pigmentation is the most common and dominating side effect that is observed in more than 94% 
of the patients [3, 5]. Patients may also experience ichthyosis or gastrointestinal symptoms, but 
at the normal dosage of 50 to 100 mg/d, no other major side effects have been reported [3, 10-
12].  
In mice, long-term exposure (≥8 weeks) to orally administered CFZ has also been 
associated with extensive pigmentation of skin and internal organs (Figure 5-1) [13]. Solid drug 
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precipitates accumulate in tissue macrophages, forming crystal-like drug inclusions (CLDIs) that 
are most abundant in the liver and spleen [13-15]. CLDIs have also been reported in humans 
treated with the drug [16, 17]. Once inside the cell, these biocrystals display robust stability and 
remain in the body long after the discontinuation of treatment [13]. 
Microscopically, CLDIs show strong fluorescence in the Cy5 channel (650 nm 
excitation/670 nm emission) [18]. Furthermore, CLDIs are also detected via diattenuation 
because of the interaction of these supramolecular ordered structures with polarized light [19]. 
The analysis of isolated CLDIs revealed chemical and structural properties that are consistent 
with that of a specific CFZ hydrochloride salt (CFZ-HCl) polymorph [20]. 
Because orally administered CFZ has been associated with massive intracellular 
accumulation of CLDIs and strong red pigmentation of macrophage-containing organs [13], we 
hypothesized that skin pigmentation is associated with CLDI bioaccumulation in macrophages. 
To test this hypothesis, we identified a closely related CFZ analog that does not form CLDIs and 
determined its ability to cause skin pigmentation. In addition, we characterized the spectral 
properties of CFZ-induced skin pigmentation and conducted detailed microscopic analysis to 
identify the optical signature of CLDIs or precipitated CFZ hydrochloride salt in the skin of 
drug-treated mice. 
5.4 Materials and Methods 
Animal experiments 
 All animal care was provided by the University of Michigan’s Unit for Laboratory 
Animal Medicine (ULAM), and the experimental protocol was approved by the Committee on 
Use and Care of Animals. As per previously established dosage regimen [13, 18, 21], 4- to 5-
week-old Balb/c and C57BL/6 mice from Jackson Laboratory (Bar Harbor, ME) were given an 
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ad libitum drug powder feed diet, designed to target oral dose equivalent of 10 mg/kg/d CFZ 
(C8895, Sigma-Aldrich, St. Louis, MO) or CFZ analog 568. Compound 568 was synthesized in 
bulk using a previously established protocol [22]. After 3 to 4 weeks of dosing, photographs of 
mice were taken using an iPhone SE camera, the mice were euthanized via CO2 asphyxiation, 
and a blood sample was acquired via cardiac puncture. The liver, spleen, and ears were harvested 
and washed in cold phosphate buffered saline. For microscopy analysis, a portion of each tissue 
was excised, submerged in an optimal cutting temperature compound (Sakura Finetek USA, 
Torrance, CA) before freezing (-80°C). Cryosectioning was carried out using a Leica 3050S 
Cryostat (Leica Biosystems, Buffalo Grove, IL) with a section thickness of 5 µm. 
Physicochemical Parameters of CFZ and Analog 568 
LogP and LogD determination 
To predict pKa values and draw structures of CFZ and 568, ChemAxon MarvinSketch 
Software (Version 5.12.0) was used. LogP and LogD at pH 7.4 were determined experimentally 
for CFZ and 568 based on the established protocols from Quigley et al. (1990) for CFZ with 
minor modifications [23]. Briefly, the partition behavior of CFZ and the 568 analog was 
determined by mixing phosphate buffer at pH 3 and 1-octanol (293245; Sigma-Aldrich) 1:1 (v/v) 
system at 25°C. The partitioning process was carried out in a thermostatically controlled water 
bath with a magnetic stir bar. The stirring time of 24 hours was considered to be sufficient to 
produce equilibration. Each compound was introduced in organic solvent at its maximum 
solubility, and the concentration of drug in organic and aqueous layers was 
spectrophotometrically determined (285 nm; Synergy-2 plate reader; Biotek Instruments, 
Winooski, VT). CFZ and 568 concentrations were calculated from a standard curve. After 
concentrations were calculated and the apparent partition coefficient was determined, LogP and 
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LogD at pH 7.4 were determined using equations previously described by Quigley et al. (1990) 
[23]. 
CFZ and analog 568 hydrochloride salt synthesis 
To synthesize the hydrochloride salt crystals for CFZ and 568, 7 mM drug solution in 
DMSO (67-68-5, Fisher Scientific, Fair Lawn, NJ) was added to 1 M NH4Cl in 1:1 (v/v) ratio 
and left for 24 to 48 hours at room temperature in the dark. After 24 to 48 hours, the solution 
with crystals was washed three times with diminishing concentrations of aqueous NH4Cl (100 
mM, 10 mM, 1 mM) to reduce the amount of chloride in the solution. In between washing steps, 
samples were centrifuged (2,000g for 10 minutes at 4°C). After the last wash, crystals were 
resuspended in MilliQ water and immediately snap frozen in liquid nitrogen and then freeze-
dried. 
Absorbance profiles of CFZ and analog 568 
To compare absorbance profiles among CFZ free base, 568 free base, CFZ-HCl salt, and 
568-HCl salt, samples were dissolved in DMSO at the same concentrations (70 µM) and 
determined spectrophotometrically (200-550 nm with 5 nm steps; Synergy-2 plate reader; Biotek 
Instruments) in a UV 96-well plate (8404; Thermo Scientific, Rockford, IL). Blank DMSO was 
used to obtain the baseline absorbance profile. 
Assay for HCl salt precipitation 
To understand precipitation behaviors and the ability of CFZ and analog 568 to form 
hydrochloride salts, an in vitro assay was developed to mimic lysosomal conditions. Two buffer 
solutions were made: 10 mM sodium acetate buffer (pH 4.5) with 10 mM CTAB (solution A) 
and 10 mM sodium acetate buffer (pH 4.5) with 10 mM CTAB and 100 mM NaCl (solution B). 
In a UV 96-well plate (8404; Thermo Scientific) 1 µL of 7 mM CFZ / 568 in DMSO was added 
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to 99 µL of each buffer solution, and the precipitation was observed and quantified. The 
quantification of hydrochloride salt formation was done spectrophotometrically (2.5 hours of 
shake cycle – varying speeds, 285 nm, Synergy-2 plate reader; Biotek Instruments). Buffer 
solution with DMSO was used for baseline absorbance, and brightfield images of the 
hydrochloride salt precipitation were obtained based on the protocol described in the 
“Multiparameter microscopic imaging” section. 
Imaging and quantification of pigmentation using various optical filters  
Based on the absorbance profiles of CFZ and 568, three available single-band bandpass 
optical filters were used: 480 nm (D480/30x; Chroma, Bellows Falls, VT), 535 nm (D535/40m; 
Chroma), and 623 nm (FF01-623/24-25; Semrock, Brightline, Rochester, NY). These filters were 
attached to an iPhone SE camera for image acquisition. The flash and high dynamic range 
options on the camera were disabled, and the camera editing filters were not applied. 
Quantification analysis of pigmentation was performed using ImageJ image processing software 
[24]. 
Quantification of CFZ in tissues 
Harvested tissues were thawed, weighed, cut, and homogenized by sonication (liver and 
spleen) and mechanical homogenizer (ear) (Pro200; Pro Scientific, Oxford, CT) in 
radioimmunoprecipitation assay buffer (89900; Thermo Scientific) containing protease inhibitor 
cocktail (78410; Thermo Scientific). Homogenates were centrifuged (15,000 rpm at 4°C for 5 
minutes), and the supernatants were collected. The lipophilic tissue fraction was extracted with 
xylenes (CAS 1330-20-7/100-41-4; Fisher Chemical, Fair Lawn, NJ) in triplicates, followed by 
the second extraction in triplicates with 9 M H2SO4 of diprotonated CFZ from the xylenes 
extract. Samples were centrifuged (2,000g at 4°C for 10 minutes) to facilitate layer separation 
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during extractions. After acid fractions were collected, the volumes were recorded, and CFZ 
concentrations were determined spectrophotometrically. The absorbance of the supernatants was 
measured at λ = 540 nm (A540) and 750 nm (A750) using a Synergy-2 plate reader (Biotek 
Instruments). Corrected absorbance (A540 - A750) was used to determine CFZ content via a 
standard curve of standards in 9 M H2SO4, and the concentration values were corrected for organ 
weight [25, 26]. To correct for extraction yield, known amounts of CFZ were added to tissue 
samples (untreated liver, spleen, and ear tissues) before extractions; these samples were 
processed and analyzed concurrently with the test samples. For liver and spleen tissues, the 
extraction yield averaged 90%; for skin tissues, the extraction yield averaged 62%. 
Multiparameter microscopic imaging 
Multiparameter polarization, brightfield, and fluorescence microscopy was carried out 
using a Nikon Eclipse Ti inverted microscope (Nikon Instruments, Melville, NY). Polarization 
microscopy was performed using the LC-PolScope [27], with the illuminating light narrowed to 
623 nm by an interference filter (623 ± 23 nm, FF01-623/24-25; Semrock, Brightline). 
Polarization images were captured using an Abrio imaging system (Cambridge Research & 
Instrumentation, Woburn, MA). Brightfield images were captured using the Nikon DS-3 camera 
(Nikon Instruments), and fluorescence imaging was performed with the Photometrics CoolSnap 
MYO camera system (Photometrics, Tuscon, AZ) under the control of Nikon NIS-Elements AR 
software (Nikon Instruments). Illumination for fluorescence imaging was provided by the X-Cite 
120Q Widefield Fluorescence Microscope Excitation Light Source (Excelitas Technology, 
Waltham, MA). An in-depth discussion of this multiparameter microscopic imaging method was 
recently described [19]. 
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Statistics 
Statistical analysis was performed using SPSS Statistics Software (Version 24; Armonk, 
New York). Data are expressed as the mean ± SD. A one-way analysis of variance single factor 
followed by a Tukey’s honest significant difference or Games-Howell post hoc tests were used to 
determine significant differences when applicable. 
5.5 Results and Discussion 
In our previous study, we synthesized a focused library of phenazine derivatives of CFZ 
and assayed their bioaccumulation and self-assembly properties in RAW264.7 macrophages and 
Madin-Darby canine kidney epithelial cells [22]. As a result, three derivatives yielded cellular 
staining patterns comparable in morphology and intensity to those of CFZ; one of them was CFZ 
analog 568 [22], which was chosen to be used as an experimental control for this study. A 
comparison of key physicochemical parameters between CFZ and this analog revealed minor 
differences in molecular weights, physiologically relevant pKa values, and partition coefficients 
(logP and logD at pH 7.4) (Table 5-1). 
Based on spectrophotometric comparison, absorbance profiles of CFZ and the 568 analog 
were nearly identical for both free base and salt forms (Figure 5-2b). Both compounds exhibited 
strong absorbance in the UV region at 285 nm due to their phenazine backbones; free base forms 
showed maximum visible absorbance at 450 nm, whereas the salt forms shifted the visible 
absorbance peak to 495 nm, which is consistent with our previous study [22]. 
Next, an in vitro precipitation assay that mimics the in vivo conditions that lead to CLDI 
formation was developed to screen for CFZ derivatives that do not form CLDIs. The rationale 
behind the assay is that CLDIs form by the precipitation of CFZ in the acidic lysosomal 
microenvironment (pH 4.5) and the formation of a hydrochloride salt in the presence of 
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physiological sodium chloride concentrations. Thus, a pH of 4.5 and chloride concentration of 
100 mM were chosen to mimic the lysosomal environment [28]. Furthermore, to recapitulate 
lipophilic drug partitioning within lysosome membranes, cetrimonium bromide (CTAB) was 
used as a biorelevant surfactant because it does not interfere with absorbance at 285 nm – the UV 
wavelength of detection for phenazine derivatives (Figure 5-2b). The optimal concentration of 
CTAB was determined based on the calculated molar solubilization ratio between CFZ and 
CTAB at pH 4.5 (data not shown) [29]. Finally, this novel assay was calibrated so the presence 
of chloride would act as the driving force for the formation of hydrochloride salt. For this, two 
conditions were employed: solution A (no chloride) and solution B (100 mM chloride). The 
precipitation was measured as the decrease in absorbance in 285 nm wavelength that correlated 
with the drug concentration in the solution resulting from precipitation. 
By screening the CFZ derivatives using the aforementioned assay, we identified the 568 
analog as the most closely related CFZ derivative that did not precipitate out in the lysosomal 
microenvironment. CFZ and 568 share similar chemical structures (Figure 5-2a), spectral 
properties (Figure 5-2b), physicochemical characteristics (Table 5-1), and both can be 
solubilized by detergent in the absence of chloride due to the fact that CFZ and 568 remained 
soluble in solution A (no chloride) to a similar extent as in dimethyl sulfoxide (DMSO) (Figure 
5-2c). Nevertheless, the 568 analog remains in solution in the presence of physiological chloride 
concentrations (solution B: 100 mM chloride), whereas CFZ precipitates out as hydrochloride 
salt, which was indicated by a 4-fold decrease in absorbance (Figure 5-2c) and by employing 
microscopy techniques (Figure 5-2d). Brightfield and positive Cy5 fluorescence confirmed CFZ 
precipitates as an HCl salt form of the drug; no precipitates were observed for analog 568 (Figure 
5-2d). 
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On the basis of the differences in the behavior of CFZ and the 568 analog in the in vitro 
lysosomal microenvironment precipitation assay, we designed experiments to test the behavior of 
these compounds in vivo. After 3-4 weeks of treatment with a drug powder feed diet containing 
either a dose equivalent of 10 mg/kg/d CFZ or analog 568, skin pigmentation was visually 
evident, which was consistent with observations from previous CFZ studies [13]. Skin 
pigmentation in animals was quantitatively determined using 480 nm, 535 nm, and 623 nm 
optical filters. The reflectance spectra of the skin were compared with that of pure free base and 
hydrochloride salt solids of CFZ and analog 568 (Figure 5-3a). Images of CFZ and analog 568 
free base and HCl salt forms of the drug powders revealed visual similarities in color and the 
extent of reflectance at different optical filters (Figure 5-3a). Both forms of each drug appeared 
similarly dark in 480 nm and 535 nm filter images (Figure 5-3a), supported by high optical 
density (OD) values (OD values > 0.5) at those wavelengths (Figure 5-3c) – making 480 nm and 
535 nm filters ideal for detecting drug-induced skin pigmentation regardless of the drug form. In 
contrast, 623 nm optical filter distinguished free base from hydrochloride forms of both 
compounds, with high OD values (OD values > 0.5) indicative of the hydrochloride salt forms 
and low OD values (OD values < 0.2) indicative of the free base forms (Figure 5-3c). In this 
manner, we found that 568 analog-treated mice achieved an identical level of pigmentation as 
CFZ-treated mice (no significant difference in OD values; Figure 5-3b and c), and both were 
significantly higher than the untreated group (P < 0.01, analysis of variance single factor, Tukey 
honest significant difference, n = 3). Interestingly, the use of the 623 nm optical filter was unable 
to detect the skin pigmentation in CFZ- and 568 analog-treated mice, consistent with the spectra 
of the free base form of the compounds.  
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To further elucidate the distribution behaviors of these compounds, the tissues of interest 
from CFZ- and 568 analog-treated mice were harvested and cryosectioned for multiparameter 
microscopic imaging [19] (Figure 5-4). As previously reported, CLDIs were observed in the liver 
and spleen of CFZ-treated mice based on brightfield images and positive fluorescence and 
diattenuation signals [19]; however, CFZ skin sections did not contain CLDIs (Figure 5-4). A 
few dark spots present in both untreated animals and in drug-treated animals were attributed to 
melanosomes, which give mice skin its natural pigmentation [30, 31]. In contrast to CFZ, all 
tissues from 568 analog-treated animals had no evidence of CLDI accumulation due to the lack 
of fluorescence and dichroism signal in the liver and spleen, which are the main bioaccumulating 
organs (Figure 5-4). Because treatment with the 568 analog resulted in significant skin 
pigmentation, to the same extent as in CFZ treatment, we concluded that the skin pigmentation 
caused by both CFZ and 568 analog is not associated with CLDI bioaccumulation. 
Lastly, the extent of drug bioaccumulation in the liver, spleen, and skin of CFZ-treated 
mice was compared. Tissue concentrations of the drug in the liver, spleen, and skin were 
determined to be 2.37 ± 0.62 mg/g, 4.34 ± 0.41 mg/g, and 0.16 ± 0.04 mg/g, respectively. The 
skin showed significantly lower concentrations compared with the liver and spleen (P < 0.001, 
analysis of variance single factor, Tukey honest significant difference, n = 3 [skin], n = 4 [liver 
and spleen]). Interestingly, because the skin is the biggest organ, representing 9.8% of total 
bodyweight [32], it accommodated a similar total CFZ mass as the spleen but at a 20-fold lower 
concentration. This much lower concentration of CFZ in the skin suggests that skin pigmentation 
is not associated with extensive bioaccumulation of the hydrochloride salt of CFZ and its 
precipitation into CLDIs, as is observed in the liver and spleen. Instead, the lower concentration 
of CFZ in skin is attributed to the soluble free base form of the drug that is expected to partition 
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into the subcutaneous fat [13]. In fact, the amount of clofazimine in skin (0.16 mgCFZ/gTissue) 
is consistent with an approximately 20% lipid content in skin, assuming that CFZ partitions into 
skin lipids similar to the measured concentration that is found in adipose tissue (0.74 
mgCFZ/gFat) [13]. 
Overall, in case of oral or systemic administration of CFZ, our results suggest that skin 
hyperpigmentation should be expected because after absorption, the drug will naturally 
accumulate in the skin by partitioning from the systemic circulation. Therefore, the most viable 
alternative approach to reduce CFZ-induced skin hyperpigmentation would be to minimize the 
concentrations of drug in the circulation. This can be achieved through local administration and 
controlled release formulations. In this regard, an inhalable CFZ formulation has already been 
shown to be efficacious against M. tuberculosis in human monocyte-derived macrophage 
cultures and in a relevant animal model [33]. On the basis of our own findings, we are currently 
working toward reformulating CFZ, both as a locally injectable suspension of micronized, 
biomimetic crystals of CFZ hydrochloride and as an inhalable dry micronized powder. By 
advancing solid, micro- or nanoparticles of CFZ that mimic the solid form of the drug that 
naturally bioaccumulates in CLDIs on prolonged oral dosing [13, 14, 20], it may be possible to 
achieve prolonged, therapeutic drug concentrations at the site of action while avoiding CFZ-
induced skin pigmentation that would result from high drug concentrations circulating 
throughout the body. Indeed, although the clinically used, oral formulation of CFZ is specifically 
indicated to treat leprosy, which primarily affects the skin, more targeted formulations and local 
delivery routes could be useful to repurpose the drug for other indications. 
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5.7 Figures and Tables 
 
 
 
Figure 5-1. Extent of skin pigmentation in CFZ-treated mice compared to untreated mice (control). CFZ, 
clofazimine. 
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Table 5-1. Physicochemical parameters of CFZ and 568. 
 
 CFZ 568 
M.W. 473.4 g/mol 475.4 g/mol 
pKa pKa1 = 9.291 
pKa2 = 2.311 
pKa1 = 8.651 
pKa2 = 2.311 
LogP 7.662 6.692 
LogD @ pH 7.4 5.763 5.423 
1Values were predicted by ChemAxon MarvinSketch Software (Version 5.12.0) 
 
2CFZ mean ± 0.00 (n=3); 568 mean ± 0.04 (n=3) 
 
3CFZ mean ± 0.00 (n=3); 568 mean ± 0.04 (n=3) 
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Figure 5-2. Comparison of CFZ and CFZ analog 568: structures, precipitation assay, and absorbance 
profiles. (a) The structural difference between CFZ and analog 568 at the tertiary amine is a specific substitution of 
the isopropyl group with a 2-hydroxyethyl. (b) The absorbance profiles (270 - 550 nm) show the similarity of CFZ 
and analog 568 free base and hydrochloride salt forms, respectively. (c) The ability of both CFZ and analog 568 to 
precipitate as hydrochloride salt in simulated lysosomal conditions (pH 4.5). This was determined by measuring the 
absorbance (285 nm) in different conditions: Soln A (no chloride), Soln B (100 mM chloride), and DMSO (red = 
CFZ, blue = 568). (d) Hydrochloride salt precipitation in the presence of chloride (Soln B) was verified by 
brightfield (BF) and fluorescence microscopy (Fcy5). Scale bar = 50 µm. CFZ, clofazimine; DMSO, dimethyl 
sulfoxide. 
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Figure 5-3. Optical properties of CFZ and CFZ analog 568 and quantitative analysis of skin pigmentation 
using various optical filters. (a) Images of CFZ and analog 568 free base and HCl salt powders and the extent of 
their reflectance using 480 nm, 535 nm, and 623 nm optical filters. (b) Images of mouse ears after 3-4 weeks of CFZ 
or analog 568 treatment and the extent of their reflectance using 480 nm, 535 nm, and 623 nm optical filters. (c) 
Quantitative analysis of the drug powder images (n = 7) and images of mouse ears after 3-4 weeks of CFZ or 568 
treatment compared with untreated mice (n = 3) (blue = 480 nm filter; green = 535 nm filter; red = 623 nm filter; *P 
< 0.01, analysis of variance single factor, Tukey’s HSD). CFZ, clofazimine; HSD, honest significant difference. 
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Figure 5-4. Multiparameter imaging of CFZ and CFZ analog 568 treated and untreated tissues. Images of 
liver, spleen, and skin sections were taken using brightfield, Cy5 fluorescence (Fcy5), and dichroism at 623 nm 
(D623nm) to identify and compare for CFZ-HCl/CLDI signatures with corresponding untreated samples. Scale bar = 
25 µm. CFZ, clofazimine; CLDI, crystal-like drug inclusion. 
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Chapter 6 
Synthesis and Characterization of a Biomimetic Formulation of 
Clofazimine Hydrochloride Microcrystals for Parenteral 
Administration  
6.1 Relevance to Thesis 
This chapter was adapted from the following publication: 
Murashov MD, Diaz-Espinosa J, LaLone V, Tan JWY, Wang X, Stringer KA, Rosania GR. 2018. 
Synthesis and  characterization of a biomimetic formulation of clofazimine hydrochloride 
microcrystals for parenteral administration.  Pharmaceutics 10(4), 238; doi: 
10.3390/pharmaceutics10040238 
 
This chapter investigated and concluded the Specific Aim 2 of this thesis. As a result, I 
developed a biomimetic formulation of CLDIs, micronized CFZ-HCl salt crystals for parenteral 
administration, and determined that RAW 264.7 macrophages internalized and stabilized CFZ-
HCl microcrystals, just as well as isolated CLDIs, without any cytotoxicity in vitro.  
Furthermore, these results led me to conclude that these drug microcrystals would also be 
prone to phagocytosis and stabilization by resident tissue macrophages in mouse model in vivo. 
As a result, all mice that were injected with the CFZ-HCl microcrystal formulation survived the 
injection (100% survival) and did not show any signs of toxicity. Importantly, injected CFZ-HCl 
microcrystals displayed the same distribution patterns as CLDIs (from orally administered CFZ 
treatment) and did not result in detectable skin pigmentation. 
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These findings further validated the central hypothesis and suggested that parenteral 
(injected or inhaled) biomimetic formulations of CFZ-HCl could be instrumental to avoid the 
pigmentation side effect of oral CFZ therapy. 
6.2 Abstract 
Clofazimine (CFZ) is a broad spectrum antimycobacterial agent recommended by the 
World Health Organization as a first line treatment for leprosy and second line treatment for 
multidrug resistant tuberculosis. Oral administration of CFZ leads to a red skin pigmentation side 
effect. Since CFZ is a weakly basic, red phenazine dye, the skin pigmentation side effect results 
from lipophilic partitioning of the circulating, free base (neutral) form of CFZ into the skin. 
Here, we developed a stable and biocompatible formulation of CFZ-HCl microcrystals that 
mimics the predominant form of the drug that bioaccumulates in macrophages, following long 
term oral CFZ administration. In mice, intravenous injection of these biomimetic CFZ-HCl 
microcrystals led to visible drug accumulation in macrophages of the reticuloendothelial system 
with minimal skin accumulation or pigmentation. In fact, no skin pigmentation was observed 
when the total amount of CFZ-HCl administered was equivalent to the total oral dose leading to 
maximal skin pigmentation. Thus, parenteral (injected or inhaled) biomimetic formulations of 
CFZ-HCl could be instrumental to avoid the pigmentation side effect of oral CFZ therapy. 
6.3 Introduction 
Clofazimine (CFZ) is a weakly basic, red-pigmented, FDA-approved, phenazine 
antibiotic that is included in the World Health Organization’s (WHO) List of Essential 
Medications as part of the antibiotic cocktail used for the standard treatment for leprosy [1–5]. It 
has been in clinical use since the 1960s and has contributed to the cure of more than 16 million 
people worldwide [1–5]. Due to its potent activity against Mycobacterium tuberculosis, the 
WHO now recommends CFZ as a second line agent against multi-drug resistant tuberculosis 
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(MDR-TB) [3,6–10]. In humans, CFZ exhibits atypical pharmacokinetic properties [11,12]. In 
mice, following long-term (i.e., weeks) oral administration, solid drug precipitates accumulate in 
tissue macrophages, forming red crystal-like drug inclusions (CLDIs) that are most abundant in 
the liver and spleen [13–15]. This phenomenon has also been reported in humans treated with 
CFZ [11,12]. Interestingly, these biocrystals display robust stability inside macrophages and 
remain in the body long after discontinuation of treatment (>8 weeks) [13]. The preliminary 
analysis of isolated CLDIs from spleen and liver of CFZ treated mice revealed that CLDIs 
contained a hydrochloride salt form of the drug, which is stabilized by the acidic and high 
chloride concentrations present in macrophage lysosomes, while the orally-administered form of 
the drug is the free base [16]. 
In terms of its toxicological properties, the major side effect of orally administered CFZ 
is a strong red skin pigmentation, observed in more than 94% of patients [17,18]. CFZ-induced 
skin pigmentation is attributed to the circulating, soluble free base form of CFZ that partitions 
into the subcutaneous fat layer of the skin rather than CLDI formation and accumulation [19]. 
Even though prolonged CFZ treatment is associated with massive drug biocrystal accumulation 
within resident tissue macrophages, there are no obvious toxicological manifestations from these 
biocrystals. Instead, CLDIs are biocompatible, stable, long-lived, and relatively non-toxic [3,20]. 
Phagocytosed CLDIs modulate innate immune signaling by dampening pro-inflammatory and 
enhancing anti-inflammatory pathways via inhibition of tumor necrosis factor alpha (TNFα) and 
enhancement of interleukin 1 receptor antagonist (IL-1RA) secretion [3,20]. Specifically, CFZ 
inhibited carrageenan- and lipopolysaccharide-induced inflammation in the footpads and lungs, 
respectively, in 8-week-CFZ-treated mice, in an IL-1RA-dependent manner [3]. 
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Since the skin pigmentation side effect is likely due to the free base form of the drug that 
partitions from the blood to the skin following oral administration, we decided to test whether 
parenteral administration of CFZ-HCl microcrystals could be used to avoid the drug’s skin 
pigmentation side effect. We hypothesized that the injected, micronized CFZ-HCl particles 
would be ingested by macrophages and stabilized by the phagolysosomal microenvironment. In 
order to test this hypothesis, we developed and tested CFZ-HCl particles side-by-side with 
CLDIs and other solid forms of CFZ, in terms of their physicochemical characteristics. 
Furthermore, biological experiments were conducted to test the performance of biomimetic CFZ-
HCl formulations following phagocytosis by macrophages in vitro, and in vivo after 
administering the drug via intravenous (IV) tail-vein bolus injection. The results indicate that a 
biomimetic formulation of CFZ-HCl can be effectively synthesized and delivered parenterally to 
circumvent the CFZ-induced skin pigmentation side effect. 
6.4 Materials and Methods 
Synthesis of different Clofazimine (CFZ) solids 
Different CFZ salt crystals were synthesized by adding 1 M of ammonium salts in MiliQ 
water to 2 mM CFZ (C8895, Sigma-Aldrich, St. Louis, MO, USA) in methanol in a 1:1 ratio 
(v/v). Ammonium bromide, carbonate, citrate dibasic, nitrate, phosphate dibasic, and sulfate were 
all purchased from Sigma-Aldrich (213349; 207861; 25102; 221244; 215996; A4418 
(respectively); Sigma-Aldrich, St. Louis, MO, USA). Ammonium acetate and chloride were 
purchased from Fisher Scientific (A639; A661 (respectively); Fisher Scientific, Fair Lawn, NJ, 
USA). Ammonium iodide was purchased from Acros Organics (448071000, Acros Organics, 
Morris Plains, NJ, USA). 
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Isolation of Crystal-Like Drug Inclusions (CLDIs) 
 CLDI purification and isolation were performed as previously described with minor 
modifications [13,14,21]. In brief, liver and spleen from mice that were fed CFZ for 8 weeks 
from previous experiments were homogenized by cutting the organs into smaller pieces and 
utilizing mechanical homogenizer (Pro200; Pro Scientific, Oxford, CT, USA). Liver and spleen 
homogenates were filtered through a 100 µm strainer, and the filtrate was collected in a 50 mL 
centrifuge tube and diluted up to 50 mL with 1× Phosphate Buffered Saline (PBS) (10010023, 
Gibco, Life Technologies, Carlsbad, CA, USA). The filtrate was then centrifuged at 250× g for 6 
min. The supernatant was discarded, and fresh PBS was added up to 50 mL. This step was 
repeated twice, and after the final washing step, the red-CLDI containing pellet was resuspended 
in 2–5 mL of 10% sucrose. From the pellet, CLDIs were further purified using a three-layer 
discontinuous gradient (50%, 30%, and 10% sucrose in PBS) centrifugation method (3200× g, 
60 min). After centrifugation, the top layers were discarded, and the CLDIs pellet was 
resuspended in PBS and snap frozen in liquid nitrogen in preparation for future analysis. 
Bulk Synthesis of CFZ-HCl Salt Crystals 
CFZ free base (10 g; Sigma-Aldrich, St. Louis, MO, USA) was placed in 2 L of 1 M HCl 
in an Erlenmeyer flask with a magnetic stir bar. After the addition of CFZ, the reaction was 
sealed with parafilm and stirred in the dark for 72 h. After 72 h, the stirring was turned off and 
CFZ salt crystals were allowed to precipitate. Following crystal precipitation, the HCl reactant 
was decanted and discarded. The residual acid containing the CFZ salt crystals was centrifuged 
(2000× g, 10 min, 4 °C), the supernatant was discarded, and the pellet was washed thrice with 
declining concentrations of HCl (100 mM, 10 mM, and 1 mM) to reduce the amount of chloride 
present in the solution. In between washing steps, samples were centrifuged (2000× g, 10 min, 4 
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°C). After the last wash, crystals were resuspended in MiliQ water and immediately snap frozen 
in liquid nitrogen and then freeze-dried. 
Micronization (Jet Milling) and Sterilization 
A SepSol, Sturtevant Inc. (Separation Solutions; SepSol Process Solutions, Kalamazoo, 
MI, USA) air jet mill was used to micronize the bulk synthesized CFZ-HCl crystals and CFZ 
free base crystals (control) to a particle size distribution within the desired range (0.5–5 µm). 
Following the company’s specifications, the air jet mill was set at 50 psi grind pressure and 100 
psi feed pressure. Filtered, dried, compressed air was used as the air source for the mill. 
Altogether, four batches of CFZ-HCl microcrystals (net weight ~40 g) and three batches of CFZ 
free base microcrystals (net weight ~20 g) were produced with ~80–90% yield from milling. 
Both types of micronized CFZ crystals were stored at −20 °C until the time of experimentation. 
Before each experiment, CFZ microcrystals were sterilized by dry heat at 170 °C for 1.5 h, using 
a bench top vacuum oven at 5 psi (Model 5831; National Appliance Co., Portland, OR, USA). 
Particle Size Determination 
The CFZ microcrystals particle size after synthesis and after micronization were analyzed 
using Zeta-Sizer (Malvern Instruments, Nano-ZS90, Malvern, UK) and brightfield microscopy 
using Nikon Eclipse Ti inverted microscope (Nikon Instruments, Melville, NY, USA). 
Proton Nuclear Magnetic Resonance Spectroscopy Analysis 
Proton (1H) nuclear magnetic resonance (NMR) spectroscopy was performed as 
previously described [16]. Briefly, one-dimensional 1H-NMR spectra of micronized CFZ-HCl 
crystals at different stages of manufacturing were acquired using an 11.74 T (500 MHz) NMR 
spectrometer with a VNMRS console and a 7510-AS autosampler system operated by host 
software VNMRJ 3.2 and equipped with a 5 mm Agilent One NMR probe with Z-axis gradients. 
The samples were dissolved in dimethyl sulfoxide-D6 (D, 99.9%) (DMSO-d6; Cambridge 
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Isotope Laboratories, Inc., Andover, MA, USA). The NMR data were acquired at room 
temperature and processed using MestreNova 9.0 software (MestreLab, Santiago de Compostela, 
Spain). 
Powder X-Ray diffraction Analysis 
Powder X-ray diffraction (pXRD) spectra of micronized CFZ-HCl crystals at different 
stages of manufacturing were taken by Rigaku Miniflex X-ray diffractometer (Rigaku-USA Inc., 
Danvers, MA, USA) using Cu−Kα radiation, a tube voltage of 30 kV, and a tube current of 15 
mA. Measurements were taken from 5° to 40° at a continuous scan rate of 2.5°/min. 
Raman Microscopy 
Raman spectra were acquired with a WiTec alpha300R confocal Raman microscope 
(WiTec, Ulm, Germany) equipped with a 532 nm solid-state sapphire excitation laser and charge 
coupled device (CCD) detector. For single point spectra, the laser was focused on the sample 
acquiring each Raman spectrum with an integration time of 75 s, using Zeiss EC EPIPLAN 50X 
objective (N.A. = 0.75). Alternatively, for large area scans, the laser rastered across a 100 µm by 
100 µm area of the sample with a step size of 10 µm and an integration time of 2 s per pixel, 
using Zeiss 10 X objective. To measure quality and stability of individual CFZ microcrystals, 
single point spectra were taken from individual particles for micronized CFZ-HCl, micronized 
CFZ-HCl in diluent, and micronized CFZ free base that were dispersed on mica chips. Cosmic 
rays were removed from all spectra using the WiTec Project FOUR software. A MATLAB® 
processing algorithm developed in-house [22] was used to baseline-subtract, normalize, and 
overlay spectra to qualitatively identify the collected micronized sample spectra by comparing 
them to both CFZ-HCl and CFZ free base reference spectra. 
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Brightfield and Fluorescence Microscopy 
Microscopy was performed using a Nikon Eclipse Ti inverted microscope (Nikon 
Instruments, Melville, NY, USA) as previously described [19,23]. Briefly, brightfield images 
were captured using the Nikon DS-3 camera (Nikon Instruments, Melville, NY, USA), and 
fluorescence imaging in FITC channel (490/510 nm, green) and Cy5 channel (640/670 nm, far-
red) was performed with the Photometrics CoolSnap MYO camera system (Photometrics, 
Tuscon, AZ, USA) under the control of Nikon NIS-Elements AR software (Nikon Instruments, 
Melville, NY, USA). Illumination for fluorescence imaging was provided by the X-Cite 120Q 
Widefield Fluorescence Microscope Excitation Light Source (Excelitas Technology, Waltham, 
MA, USA). 
Assaying Stability of CFZ-HCl in Aqueous Buffers 
The stability of CFZ-HCl microcrystals was evaluated in IV diluent, synthetic lysosomal 
buffer [19], and PBS. A small amount of CFZ-HCl crystals (<1 mg) was placed in a large 
volume of test media (~20 mL) and gently stirred for 24 h to make sure that the equilibrium 
between the microcrystals and the test medium was reached. After 24 h, the small drop of test 
media with microcrystals was placed on the glass microscope slide, and the stability of CFZ-HCl 
microscrystals was evaluated using brightfield and fluorescence microscopy (see “Brightfield 
and Fluorescence Microscopy” section). 
The diluent for the IV injectable formulation was made using polysorbate 80 (59924 
Sigma-Aldrich, St. Louis, MO, USA), sodium chloride (BP358, Fisher Scientific, Fair Lawn, NJ, 
USA), and Milli-Q water. To coat, disperse, and adjust the size of the lipophilic CFZ-HCl 
microcrystals, the varying concentrations of polysorbate 80 (0–0.5%) was used [24]. Sodium 
chloride was added to maintain isotonicity. The pH was adjusted to pH 5 using 0.01 M HCl or 
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0.01 M NaOH to ensure the stability of CFZ-HCl microcrystals in the formulation. For 
experiments, the diluent was sterilized by sterile filtration with a syringe filter (09-719A; 0.22 
µm, MCE, Sterile; Fisher Scientific, Fair Lawn, NJ, USA). 
The synthetic lysosomal buffer was prepared as previously reported [19]. In brief, 
synthetic lysosomal buffer was made by preparing 10 mM sodium acetate buffer (pH 4.5) with 
10 mM cetrimonium bromide (CTAB) and 100 mM NaCl to mimic lysosomal conditions [19]. 
Cell-based stability assays 
The stability of CFZ-HCl microcrystals was evaluated following phagocytosis, using the 
RAW 264.7 murine macrophage cell line. The cell line was purchased from ATCC (Manassas, 
VA, USA) and maintained in Dulbecco’s modified Eagle medium (DMEM) (11995-065, Gibco, 
Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) 
(16000-044, Gibco, Life Technologies, Carlsbad, CA, USA) and 0.1% penicillin/streptomycin 
(15140-122, Gibco, Life Technologies, Carlsbad, CA, USA). Cells were maintained at 5% CO2 
at 37 °C and passaged at 80% confluency. For the assay, the cells were seeded at 5 × 104 
cells/well in 6-well plates and were allowed to grow for 24 h, at which point, isolated CLDIs, 
CFZ-HCl microcrystals, and CFZ free base microcrystals were added at 20 µg/mL in DMEM 
with 5% FBS to designated drug treatment plates. The same volume of DMEM with 5% FBS 
without drug treatment was added to wells of negative control plates. The cells were treated for 1 
h, at which point, the media was removed, and the cells were thoroughly washed twice. DMEM 
with 10% FBS and 0.1% penicillin/streptomycin was then added back into the wells (t0). Over 
the next 48 h (t8h, t24h, t48h), total cell viability was assessed using trypan blue (0.4%) exclusion 
(15250-061, Gibco, Life Technologies, Carlsbad, CA, USA). At every time point, brightfield and 
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fluorescence images were taken, and the viability measurements were calculated in triplicate (# 
cells >100 per measurement). 
Animal studies 
Animal care was provided by the University of Michigan’s Unit for Laboratory Animal 
Medicine (ULAM), and the experimental protocol was submitted to and approved by the 
University of Michigan’s Institutional Committee on Use and Care of Animals (PRO00007593; 
5 May 2017). 
In order to assess of the skin pigmentation induced by micronized CFZ-HCl crystals 
following injection into the systemic circulation, 14 male mice (10–19 weeks old, C57BL6, 
Jackson Laboratory, Bar Harbor, ME, USA) were assigned to one of 3 groups: CFZ orally fed 
(OF) group (n = 5), CFZ-HCl IV injected group (n = 5), and the control group (n = 4). The CFZ 
orally fed group and control group mice were fed CFZ or vehicle chow for 9 weeks, respectively, 
as previously reported [13,14,20]. The CFZ-HCl IV injected group received a single IV bolus 
tail-vein injection with the formulation of CFZ-HCl microcrystals (200 mg/kg), using a 300 uL 
injection volume, which translates to an approximate total dose of 6 mg of drug microcrystals or 
3 weeks of orally administered CFZ (assuming 100% bioavailability). Animals were sacrificed 
24 h post injection. At the time of sacrifice, mice were euthanized with CO2 inhalation and 
exsanguination. 
Toxicological evaluation  
The mice were monitored for behavioral changes and survival (e.g., lethargy, scruffy fur, 
squinted eyes, etc.) 24 h post-injection to evaluate the toxicity of the CFZ-HCl injections. In 
addition, plasma samples from the in vivo experiments were assayed for IL-1RA, IL-1β, and 
TNFα by enzyme linked immunosorbent assay (ELISA; Quantikine; R&D Systems, 
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Minneapolis, MN, USA) in duplicate according to the manufacturer’s instructions. The cytokine 
concentrations were expressed as picograms per milliliter of plasma. 
Immunohistochemistry 
Immunohistochemistry was performed using a previously published protocol with some 
modifications [25]. In brief, following euthanasia, the liver and spleen were removed en bloc and 
embedded in Tissue-Plus Optimal Cutting Temperature (OCT) compound (4585, Fisher 
HealthCare, Houston, TX, USA). Frozen tissue blocks were sectioned (6 µm thick) using Leica 
3050S cryostat, fixed in 4% paraformaldehyde (15710, Electron Microscopy Sciences, Hatfield, 
PA, USA) for 10 min, and blocked with 1% bovine serum albumin (BSA) (810033, MP 
Biomedicals, Solon, OH, USA), 5% goat serum (Sigma-Aldrich, St. Louis, MO, USA), and 0.3 
M glycine (G8898, Sigma-Aldrich, St. Louis, MO, USA) in PBS for 2 h. The samples were then 
incubated with primary antibodies, anti-CD68 antibody (ab53444; 1 mg/mL stock; 1:200 dilution 
in 1% BSA; Abcam, Cambridge, UK) or purified rat IgG2a κ isotype control antibody (400502; 
0.5 mg/mL stock; 1:100 dilution in 1% BSA; Biolegend, San Diego, CA, USA), overnight at 4 
°C, followed by incubation with anti-rat IgG (H + L) Alexa Fluor® 488 conjugate secondary 
antibody (4416; 5 mg/mL stock; 1:500 dilution in 1% BSA; Cell Signaling Technology, 
Danvers, MA, USA) for 1 h at room temperature. Finally, the samples were incubated with 
Hoechst 33,342 solution (H3570; 1 µM stock; 1:10,000 dilution in PBS; Life Technologies, 
Carlsbad, CA, USA) for 10 min at room temperature for nuclear detection. After staining was 
complete, sections were mounted with a drop of ProLong® Gold antifade reagent (P36930, Life 
Technologies, Carlsbad, CA, USA) and sealed with a cover slip. Brightfield and fluorescence 
images were acquired as previously described in “Brightfield and Fluorescence Microscopy” 
section. 
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Imaging and Quantification of Skin Pigmentation 
Imaging and quantification of mouse skin samples were performed using the previously 
published protocol [19]. Briefly, two single-band bandpass optical filters were used: 480 nm 
(D480/30x; Chroma, Bellows Falls, VT, USA) and 623 nm (FF01-623/24–25; Semrock, 
Brightline, Rochester, NY, USA). These filters were attached to an iPhone SE camera for image 
acquisition. The flash and high dynamic range options on the camera were disabled, and the 
camera editing filters were not applied. Quantification analysis of pigmentation was performed 
using ImageJ image processing software [26]. 
Statistics 
Statistical analyses were performed using SPSS Statistics Software (Version 24; IBM 
Corp, Armonk, NY, USA). Data are expressed as the mean ± SD. A one-way analysis of 
variance single factor followed by either a Tukey’s honest significant difference or Games-
Howell post hoc test were used to determine significant differences when applicable. 
6.5 Results and Discussion 
First, we synthesized a focused library of CFZ salts (hydrochloride, hydrobromide, 
hydrogen sulfate, nitrate, citrate, hydroiodide, hydrogen phosphate, acetate, and carbonate salts) 
and compared their fluorescence and Raman spectral properties. For fluorescence analysis, 
image data were acquired with the standard FITC and Cy5 excitation/emission channels of an 
epifluorescence microscope; for Raman spectral data, single crystals were analyzed and 
compared to spectra of isolated CLDIs (Figure 6-1). By visual inspection, CLDIs and CFZ-HCl 
exhibited almost identical fluorescence and Raman spectra, sharing the CLDIs signature peak at 
1400 cm−1 (red line). CFZ-hydrobromide, CFZ-hydrogen sulfate, and CFZ-nitrate had similar 
Raman spectra when compared to CLDIs and CFZ-HCl; however, the Cy5 signal was much less 
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prominent. Furthermore, based on CLDIs signature peak, the most prominent spectral peak of 
CFZ-hydrobromide, CFZ-hydrogen sulfate, and CFZ-nitrate showed a small shift in wavelength. 
All other CFZ salt crystals displayed a completely different Raman spectrum or possessed 
different visual/fluorescent profile compared to CLDIs. Thus, CFZ-HCl salt crystals most closely 
mimicked the optical properties of CLDIs. 
To scale the synthesis of CFZ-HCl to multigram and larger quantities for manufacturing 
of a pharmaceutical-grade formulation for clinical trials, a new synthesis scheme was developed 
using hydrochloric acid for transforming clofazimine free base to hydrochloride salt crystals 
directly, without dissolving the free base in organic solvents. For free base particles of ~100 µm 
diameter or less, direct conversion hydrochloride crystals were complete by 72 h, as determined 
using microscopy, 1H-NMR, and Raman (Figure 6-2). 
The protonation state of the CFZ molecule in the different CFZ crystal forms was 
examined via solution 1H-NMR studies, conducted in DMSO-d6. 1H-NMR data of newly 
synthesized CFZ-HCl crystals (CFZ-HCl*) depicts: 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 
1H), 8.94 (s, 1H), 8.26–8.17 (m, 1H), 8.04–7.95 (m, 2H), 7.79 (m, 4H), 7.60–7.53 (m, 2H), 7.49–
7.41 (m, 2H), 7.37 (s, 1H), 7.15–7.07 (m, 1H), 5.82 (s, 1H), 3.68 (dq, J = 6.5 Hz, 1H), 1.23 (d, J 
= 6.3 Hz, 6H). 1H-NMR data of control CFZ-HCl crystals depicts: 1H NMR (500 MHz, DMSO-
d6) δ 9.18 (s, 1H), 8.86 (s, 1H), 8.25–8.18 (m, 1H), 8.05–7.95 (m, 2H), 7.79 (m, 4H), 7.62–7.54 
(m, 2H), 7.49–7.42 (m, 2H), 7.37 (s, 1H), 7.16–7.08 (m, 1H), 5.82 (s, 1H), 3.68 (dq, J = 6.5 Hz, 
1H), 1.23 (d, J = 6.4 Hz, 6H). Using our scalable synthesis method, the resulting CFZ-HCl* 
NMR spectra matched CFZ-HCl control spectra and was consistent with published spectra [16]. 
Both CFZ-HCl* and control CFZ-HCl crystals revealed the expected protonation of the tertiary 
amine (Figure 6-2A) by having an extra singlet peak at 9.29 and 9.18 ppm, respectively (minor 
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difference in chemical shift is attributed to the difference in the pH of the samples from different 
synthesis schemes). Furthermore, this protonation of the tertiary amine caused the chemical shift 
(+δ = 0.05–0.60 ppm) for all other protons in CFZ-HCl* to the same extent as in the control 
CFZ-HCl spectrum with respect to the CFZ free base spectrum, which confirmed the 
monoprotonated characteristic of the molecule (Figure 6-2C) [16]. Overall, the 1H-NMR 
spectrum of CFZ-HCl* and control CFZ-HCl crystals reflected identical protonation states of the 
molecule. 
The chemical “fingerprint” of CFZ-HCl* was further confirmed by Raman micro-
spectroscopy due to the almost identical match of all of the peaks to CFZ-HCl control spectra, 
including the signature peak at 1400 cm−1. Furthermore, the aqueous solubility of CFZ-HCl* 
matched the aqueous solubility of CFZ-HCl control crystals of approximately 18 µM at 25 °C 
(data not shown) [22]. In conclusion, the final product was verified to have the same optical and 
fluorescence properties (Figure 6-2B), as well as the same chemical characteristics, according to 
1H-NMR and Raman micro-spectroscopy, as the reference, pure CFZ-HCl salt crystals, 
synthesized using the established method [16,19] (Figure 6-2C,D). 
To formulate micronized CFZ-HCl salt crystals and characterize the extent to which they 
mimicked CLDIs, 1H-NMR, single crystal Raman micro-spectroscopy, and pXRD were used for 
comparative analysis. Following micronization and sterilization of bulk CFZ-HCl, chemical and 
structural characteristics of CFZ-HCl salt crystals remained relatively unchanged (Figure 6-3A–
C). 1H-NMR spectral (Figure 6-3A) and single crystal Raman micro-spectroscopy peaks (Figure 
6-3B) were preserved with almost identical match, indicating that the chemical structure of CFZ-
HCl crystals was not altered by micronization or sterilization. Furthermore, pXRD spectra 
revealed that the majority of diffraction peaks were preserved as well, including the CFZ-HCl 
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signature peak at 2θ = 7.2° that is absent in CFZ free base, indicating the preservation of the 
crystal structure (Figure 6-3C) [16]. 
Following dispersion of individual drug crystals in IV diluent buffer, Raman spectral 
analysis quantitatively confirmed that the CFZ-HCl particles from the micronized, sterilized 
powder, had the same properties (Table 6-1). 
In IV diluent buffer, the micronized, sterilized microparticles were completely dispersed. 
Ultimately, the size and the dispersion of the particles can be adjusted by varying the 
concentration of the detergent present in the diluent (e.g., polysorbate 80); the higher the 
concentration, the smaller and more dispersed the particles are (data not shown). In this case, the 
IV injection, the maximum concentration of polysorbate 80 was used (0.5%) to make the 
particles as small and as dispersed as possible [24]. As a result, the microcrystals exhibited the 
expected Cy5 and FITC fluorescence of CFZ-HCl and were homogeneous in size distribution 
(Figure 6-3D). By utilizing dynamic light scattering analysis (Figure 6-3E), there was one 
narrow particle distribution of 547 ± 160 nm, an ideal size for parenteral formulations. In 
contrast, prior to micronization, the starting material exhibited 2 major wide particle size 
distributions of 621 ± 300 nm and 5035 ± 592 nm, respectively (Figure 6-3E). Thus, air jet 
milling produced a stable micronized product that could be readily sterilized, preserving a 
desirable size distribution. 
Following physical characterization, the sterilized CFZ-HCl microcrystals were tested for 
stability properties, by comparing fluorescence in the IV diluent, synthetic lysosomal buffer [19], 
and physiological saline media (PBS) (Figure 6-4). The micronized particles were stable in 
diluent (pH 5) and synthetic lysosomal buffer (pH 4.5) as evidenced by the preservation of a 
strong fluorescence signal in the Cy5 channel (indicative of CFZ-HCl salt) and absence of 
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fluorescence in the FITC channel (indicative of CFZ free base) (Figure 6-4). In PBS (pH 7.6), 
the CFZ-HCl microcrystals were unstable as evidenced by the increased fluorescence in the 
FITC channel and decreased fluorescence in the Cy5 channel, consistent with the conversion of 
CFZ-HCl to CFZ free base (Figure 6-4). Based on these results, we inferred that the diluent 
would be appropriate for in vivo injection and that the particles may be stabilized by 
macrophages following phagocytosis. 
To confirm this, RAW 264.7 macrophages were incubated with isolated CLDIs and 
micronized CFZ-HCl. The stability of the phagocytosed drug particles in live cells was 
microscopically evaluated following ingestion, by visual inspection (Figure 6-5A). RAW 
macrophages internalized and stabilized CLDIs as well as CFZ-HCl microcrystals, based on the 
strong Cy5 fluorescence signal and the absence of a FITC fluorescence signal observed in 
macrophages during the course of a 48-h incubation period (Figure 6-5A). As a control for these 
experiments, macrophages were incubated with CFZ free base microcrystals which fluoresce in 
the FITC channel, but not in the Cy5 channel. Interestingly, brightfield and fluorescent images 
showed that the CFZ free base gradually lost their FITC fluorescence and gained the Cy5 
fluorescence, suggesting that the macrophages can transform the free base to the protonated salt 
form of the drug (Figure 6-5A). 
Most importantly, incubation with CFZ-HCl was not cytotoxic. In fact, cell viability was 
constant (~90–100%) throughout the 48 h incubation regardless of the treatment (Figure 6-5B). 
These results were further validated by the fact that the biomimetic formulation of CFZ-HCl 
microcrystals were phagocytosed and stabilized by macrophages, mimicking CLDIs, which led 
us to conclude that these drug microcrystals would also be prone to phagocytosis and 
stabilization by resident tissue macrophages in vivo. 
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In vivo studies were performed to assess the effect of injected CFZ-HCl on the spectral 
reflectance properties of the skin and also to determine whether the particles accumulate in 
macrophages of the different organs as reported in mice fed with oral CFZ (i.e., spleen and liver) 
[13–15,19]. Since this analysis was primarily focused on assessing the extent of skin 
pigmentation, the IV dose (200 mg/kg), which translates to an approximate total dose of 6 mg of 
CFZ-HCl microcrystals (assuming 100% bioavailability) was specifically chosen to be 
equivalent to the amount of orally administered CFZ (total of ~6 mg, based on a bioavailability 
of 10mg/kg/d) [3,13,19,21] under which the maximum CFZ-induced skin pigmentation occurs 
when CFZ is administered orally (~3 weeks of oral administration) [19]. 
All mice (n = 5 out of 5) that were injected with the CFZ-HCl microcrystal formulation 
survived the injection (100% survival) and did not show any signs of toxicity. Analyzing the 
distribution patterns of CFZ-HCl microcrystals in these animals, Cy5 fluorescence was observed 
in liver and spleen, form naturally in CFZ-fed mice (Figure 6-6). 
In regards to the major side effect of oral CFZ therapy, the impact of the injected 
microparticles on skin pigmentation was quantitatively determined using a spectral reflectance 
assay as previously established [19]. Based on the skin reflectance signal acquired at the 480 nm 
and 623 nm optical filters, IV CFZ-HCl injected mice did not result in detected skin 
pigmentation (480 nm, no significant difference versus untreated mice, analysis of variance 
single factor, n = 4). Both untreated and IV injected mice exhibited significantly lower 
pigmentation than 9 week orally fed CFZ mice, with the 480 nm wavelength filter (p < 0.05, 
analysis of variance single factor, Games-Howell, n = 4) (Figure 6-7A,B). Importantly, the skin 
pigmentation of orally-fed mice is maximal at 3 weeks and then declines with continued feeding 
[19]; therefore, we can infer that IV injected mice are also less pigmented than mice fed with 
160 
 
CFZ for 3 weeks. Additionally, the 623 nm optical filter (indicative of the presence of CFZ-HCl) 
was also unable to detect any significant skin pigmentation that may have arisen from 
partitioning of circulating CFZ-HCl particles from blood to skin [19]. Of noteworthy 
significance, the lack of skin pigmentation observed in the CFZ-HCl injected mice cannot be 
explained by an overt toxicological effect of the drug leading to decreased mice viability, as all 
mice survived the injection without obvious toxicological consequences. As a caveat, it is 
important to note that the extent of skin pigmentation is not necessarily a direct reflection of CFZ 
accumulation in the skin, since the spectral reflectance properties of the skin can also be 
impacted by the amount of CFZ that circulates through the skin capillaries, as well as the optical 
(absorbance) properties of the CFZ molecules which can change depending on the molecules’ 
ionization, aggregation, and redox states. Ultimately, the advantages of parenteral versus oral 
CFZ remain to be conclusively established under conditions leading to therapeutic efficacy, 
which will depend on the treatment regimen and clinical indication. 
To further probe for the presence of toxic side effects resulting from the injected 
microparticles, TNFα, IL-1RA, and interleukin-1 beta (IL-1β) were measured. TNFα and IL-1β 
are pro-inflammatory cytokines that are released by cells, primarily macrophages, in response to 
inflammatory stimuli. IL-1RA is an early-acting acute-phase anti-inflammatory cytokine that 
dampens a broad spectrum of inflammatory conditions by inhibiting the activity of IL-1β, an 
important mediator of the inflammatory response [3,20]. However, none of these cytokines were 
significantly altered by an IV injection of CFZ-HCl (Figure 6-7C). In fact, IL-1RA levels were 
similar between treated and untreated groups (p < 0.05, analysis of variance single factor, 
Games-Howell, n = 5 (both CFZ groups), n = 4 (Control group); Figure 6-7C), while the plasma 
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IL-1β and TNFα concentrations were below the limit of detection (IL-1β LOD = 12.5 pg/mL; 
TNFα LOD = 10.9 pg/mL). 
6.6 Conclusions 
In conclusion, a biocompatible, biomimetic formulation of CFZ-HCl microcrystals 
proved suitable for parenteral, systemic administration, while avoiding the skin pigmentation and 
immunological response that accompanies oral CFZ administration. Based on our in vitro and in 
vivo data, micronized CFZ-HCl crystals were ingested by tissue macrophages and accumulated 
in liver and spleen, similar to CLDIs; yet, no skin pigmentation was evident, unlike oral 
administration of CFZ. IV administration did not result in overt toxicity and did not induce 
measurable changes in acute inflammatory response biomarkers. The anti-inflammatory 
cytokine, IL-1RA, which we have previously shown to be elevated following oral administration 
of CFZ [3,20], was not changed by the injected CFZ-HCl microparticles. Our findings support 
additional studies into the possible use of parenteral CFZ-HCl as a means to circumvent the skin 
pigmentation side effect of the oral drug. For example, an inhalable, aerosolized formulation of 
CFZ-HCl may be a good strategy for treating MDR-TB. Previously, Brunaugh et al. [27] and 
Verma et al. [28] investigated the feasibility of inhalable micronized CFZ free base 
microparticles against MDR-TB. Nevertheless, based on a more straightforward synthesis route, 
scalable manufacturing, and other practical considerations, an inhalable formulation of CFZ-HCl 
microcrystals could offer a more viable approach for pharmaceutical product development. As a 
wise man once said: “the most fruitful basis for the discovery of a new drug is to start with an old 
drug [29–31]”.
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6.8 Figures and Tables 
 
 
 
Figure 6-1. CFZ-HCl salt best resemble CLDIs. Single crystal Raman micro-spectroscopy spectra and brightfield 
(BF)/fluorescent (FITC, Cy5) microscopy images of various synthesized clofazimine (CFZ) salts compared to 
crystal-like drug inclusions (CLDIs) and CFZ free base. The red line represents the signature peak of CLDIs at 1400 
cm−1. Scale bar = 20 µm. 
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Figure 6-2. Validation of multigram synthesis of CFZ-HCl salt. Chemical structures of CFZ free base and CFZ-
HCl (A). Brightfield (BF)/fluorescent (FITC, Cy5) microscopy images (B); 1H-NMR (C), and Raman micro-
spectroscopy spectra (D) of synthesized CFZ-HCl salt crystals via new synthesis scheme (*) compared to the 
established CFZ-HCl salt crystals and CFZ free base. Scale bar = 50 µm. 
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Figure 6-3. Characterization of CFZ-HCl salt crystals throughout the manufacturing process. The integrity of 
the salt crystals was maintained throughout the manufacturing process (synthesis, micronization, and sterilization) of 
a biomimetic formulation of micronized CFZ-HCl salt crystals. This is evidenced by the spectra from 1H-NMR (A); 
single crystal Raman micro-spectroscopy (B); and powder X-ray diffraction (pXRD) (C). The red arrows in pXRD 
spectrum (C) indicate the peaks that are preserved after micronization and sterilization. The efficacy of 
micronization is depicted in brightfield and fluorescent images (D) and particle size distribution (E). Scale bar = 5 
µm. 
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Table 6-1. Quality and stability of single CFZ-HCl and CFZ free base micronized drug crystals measured by 
single crystal Raman micro-spectroscopy. 
Sample (n = 3) 
# Drug Crystals 
Scanned 
# CFZ-HCl 
Crystals 
# CFZ Free Base 
Crystals 
# Other 
Particles 
Micronized CFZ-HCl 100 98 ± 1 0 2 ± 1 
Micronized CFZ-HCl in Diluent * 100 98 ± 1 0 2 ± 1 
Micronized CFZ Free Base 100 0 97 ± 1 3 ± 1 
* Diluent in IV injectable formulation for in vivo studies 
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Figure 6-4. In vitro stability of the biomimetic formulation of micronized CFZ-HCl salt crystals in IV diluent, 
synthetic lysosomal buffer, and PBS after 24 h utilizing brightfield and fluorescent (FITC, Cy5) microscopy. 
Scale bar = 5 µm. 
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Figure 6-5. In vitro stability of the micronized CFZ-HCl salt and CFZ free base drug crystals in RAW 264.7 
murine macrophages over 48 hours compared to CLDIs. The stability is depicted via brightfield and fluorescent 
images (FITC, Cy5) (A). Cell viability was not altered by 8, 24, and 48 hours of treatment with CLDIs, CFZ-HCl, or 
CFZ free base (B). 
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Figure 6-6. In vivo stability and phagocytosis of the biomimetic formulation of micronized CFZ-HCl salt 
crystals following IV injection to mice compared to orally fed (OF) CFZ mice. Images represent CD68 
immunohistochemistry of cryo-sections of spleen and liver from OF CFZ and untreated (negative control) mice. 
Blue (DAPI) – nucleus; green (FITC) – CD68(+) macrophages; red (Cy5) – CLDIs / CFZ-HCl microcrystals. Scale 
bar = 20 µm. 
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Figure 6-7. Quantitative analysis of skin pigmentation and plasma IL-1RA concentrations following IV 
administration of CFZ-HCl (IV CFZ-HCl) and oral administration of CFZ (OF CFZ) compared to untreated 
mice (control). Images of mouse ears from treatment groups and the extent of their reflectance using 480 nm and 
623 nm optical filters (A). Quantitative analysis of the pigmentation of mouse ears from CFZ treated mice compared 
to untreated mice (n = 4) via reflectance spectroscopy (blue = 480 nm; red = 623 nm filter; * p < 0.05, analysis of 
variance (ANOVA) single factor, Games-Howell) (B). Plasma concentrations of IL-1RA in CFZ treated mice 
compared to untreated mice (n = 5 (CFZ groups); n = 4 (untreated group)) (* p < 0.05, analysis of variance 
(ANOVA) single factor, Games-Howell) (C). 
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Chapter 7 
Inhibition of Macrophage Recruitment Decreases the Stability of 
Injected Microcrystalline Particles in the Joint and Reduces the 
Associated Inflammatory Response 
7.1 Relevance to Thesis 
This chapter was adapted from the following manuscript: 
Murashov MD, Stringer KA, Rosania GR. 2018. Inhibition of Macrophage Recruitment 
Decreases the Stability of Injected Microcrystalline Particles in the Joint and Reduces the 
Associated Inflammatory Response. Manuscript has not been submitted. 
 
This chapter investigated and completed the Specific Aim 3 in this thesis. In one of new 
potential indications (e.g. gouty arthritis) for CFZ treatment, I explored the inflammatory status 
of the biomimetic formulation of micronized CFZ-HCl salt crystals (Chapter 2) under local 
administration in rat model, in vivo, and determined that the local injection of CFZ-HCl 
microcrystals leads to the recruitment of macrophages to the site of action, a pro-inflammatory 
response. Furthermore, micronized CFZ-HCl particles did not facilitate the dissolution and 
clearance of MSU crystals from the joint, main source of inflammation, by lowering the local pH 
of the synovium (Chapter 3).  
7.2 Abstract 
In macrophages, phagocytosis of monosodium urate crystals promotes the production of 
pro-inflammatory cytokines leading to pain, swelling and furthering monocyte recruitment. Here, 
we studied whether the inflammatory response induced by MSU crystals directly injected into 
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joints may be related to their alkalinizing effect on the local microenvironment or to their impact 
on macrophage recruitment. For this purpose, clofazimine hydrochloride (CFZ-HCl) 
microcrystals were injected into the rat knee, alone or in combination with MSU crystals. As a 
hypothesis, the micronized CFZ-HCl particles should lower the pH of the synovium upon 
dissolution, facilitating the dissolution and clearance of MSU crystals from the joint and 
reducing their alkalinizing effects. Contrary to expectations, the results indicated that CFZ-HCl 
injections significantly increased the severity of the inflammatory response induced by co-
injecting MSU microcrystals. Furthermore, treatment with methylprednisolone, reduced both 
CFZ- and MSU-induced inflammation, while destabilizing the CFZ-HCl microcrystals through 
increased alkalinization. Because methylprednisolone is known to inhibit macrophage migration, 
we infer that macrophages exacerbate joint inflammation by stabilizing injected microcrystals; 
by reducing macrophage recruitment, methylprednisolone decreased injected microcrystal 
stability and lessened the inflammatory response.  
7.3 Introduction 
Gout is the most common inflammatory, crystal-induced arthropathy, characterized by 
severe pain, red, and swollen joint [1-3]. It is caused by hyperuricemia, which leads to the 
accumulation of monosodium urate (MSU) crystals in a joint, tendons, and surrounding tissues, 
resulting in an attack of gout [1]. Hyperuricemia is typically defined as a serum urate 
concentration that exceeds 6.8 mg/dL, which is above the saturation point of MSU [1]. Soluble 
urate is one of the final products of the metabolic breakdown of purine nucleotides [1, 4], and the 
body normally clears it via the enzyme uricase, which degrades urate to the more soluble 
molecule allontoin [1, 5-7]. However, several factors (i.e., genetic mutational inactivation of the 
gene for the uricase; renal underexcretion of urate; conditions of excessive cell and purine 
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turnover (e.g., leukemias, etc.) [4]; high purine dietary intake [8]; and/or genetic factors that 
result in primary urate overproduction [9]) can lead to hyperuricemia [1]. Even though gout may 
attack any single joint in the body (acute gout) or many joints at once with repeated episodes 
(chronic), in extreme cases, it may also result in tophi, kidney stones, and/or urate nephropathy 
[10]. 
Gout afflicts approximately 8 million patients every year, which is a prevalence of more 
than 10% in certain populations [11]. More than 10 pharmaceutical companies in world (e.g., 
AstraZeneca PLC, Novartis AG, Polaris Group, BioCryst Pharmaceuticals Inc., Teijin Pharma 
Limited, etc.) are currently working on treatments for gout that include: non-steroidal anti-
inflammatory drugs (NSAIDs), colchicines, and corticosteroids that help with pain and 
inflammation; enzyme and protein inhibitors that ultimately reduce serum urate levels; and 
modified urate oxidase that metabolizes urate into highly soluble allantoin [12]. However, none 
of these treatments target the source of inflammation, the MSU crystals within the joint. 
Therefore, a treatment that facilitates the clearance of accumulated urate out of the joint by 
contributing to the dissolution of accumulated MSU crystals could lead to new and novel 
approaches to treating gout. 
Under physiological conditions (pH 7.4), uric acid predominantly exists as a charged, 
urate anionic form. Urate has a pKa of 5.75, below which it turns into uric acid crystals (enol 
form, square-like crystals) [1]. In the most common form of gout, however, due to hyperuricemia 
and low affinity for sodium cation (Ksp), urate ions precipitate as monosodium urate salt crystals 
(needle-like crystals). Importantly, MSU salt crystals are more stable in joints of the extremities 
because they tend to be colder than the rest of the body; in these physiological conditions once 
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MSU salt crystals form, the only way to destabilize them is by lowering the pH and shifting the 
equilibrium to the enol form of urate.  
Thus, as a means to lower and sustain the pH below the pKa of 5.75, we considered 
injecting micronized hydrochloride salt crystals of a weakly basic drug.  Looking for the most 
biocompatible and stable weakly basic drug crystals that could function as a proton-donor to 
facilitate the dissolution of monosodium urate crystals, we selected clofazimine (CFZ).  CFZ is a 
weakly basic, broad spectrum, orally administered, antimycobacterial agent recommended by the 
World Health Organization as a treatment for leprosy and multidrug resistant tuberculosis [13-
21]. In patients, CFZ exhibits atypical pharmacokinetic properties, forming solid drug 
precipitates in tissue macrophages that display robust stability inside macrophages and remain in 
the body long after discontinuation of treatment [22-26]. The preliminary analysis of these 
biocrystals revealed that they contained a hydrochloride salt form of the drug, which is stabilized 
by the acidic and high chloride concentrations present in macrophage lysosomes, while the orally 
administered form of the drug is the free base [27]. Even though prolonged CFZ treatment is 
associated with massive drug biocrystal accumulation, there are no obvious toxicological 
manifestations from them. Instead, they were determined to be biocompatible, stable, long-lived, 
relatively non-toxic, and anti-inflammatory [28, 29].  
Previously, we reported on the synthesis and characterization of a biomimetic 
formulation of CFZ hydrochloride microcrystals that proved suitable for parenteral, systemic 
administration without major toxicological consequences (Chapter 6). Thus, we proceeded to 
determine whether intra-articular (IA) injection of CFZ-HCl microcrystals could facilitate the 
dissolution of co-injected monosodium urate (MSU) crystals, by reducing the alkalinizing effects 
of MSU crystals and by destabilizing them by donating protons to the synovial fluid. As a 
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hypothesis, micronized CFZ-HCl particles should decrease inflammation, pain, and swelling 
associated with IA injections of MSU crystals, facilitating the dissolution and clearance of MSU 
crystals from the joint by lowering the local pH of the synovium. The schematic that depicts this 
hypothesis is shown in Figure 7-1. 
7.4 Materials and Methods 
Animals 
All animal care conformed to the guidelines cited in the Guide for the Care and Use of 
Laboratory Animals (NIH Guide, 2011), the applicable standard operating procedures of Bolder 
BioPATH, Inc. Male Lewis rats were obtained from Charles River (Wilmington, MA). Rats 
weighed 245–310 grams (mean = 287 g) at enrollment Days (-12) and (-4) (Table 7-1). Animals 
were identified by a distinct mark at the base of the tail delineating group and animal number. 
After randomization, all cages were labeled with protocol number, group numbers, and animal 
numbers with appropriate color-coding. 
Upon arrival, animals were housed 3–5/cage in shoe-box polycarbonate cages with wire 
tops, wood chip bedding, and suspended food and water bottles. An attending veterinarian was 
on site or on call during the live phase of the study. No concurrent medications were given. 
During the acclimation and study periods, animals were housed in a laboratory environment with 
temperatures ranging 67–76°F and relative humidity of 30%–70%. Automatic timers provided 
12 hours of light and 12 hours of dark. Animals were allowed access ad libitum to Harlan Teklad 
Rodent Chow and fresh municipal tap water. 
Upon completion of the study, the animals were euthanized for necropsy. Specifically, the 
rats were exsanguinated under deep anesthesia followed by bilateral pneumo-thoracotomy.  
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Test Article Identification and Preparation 
Micronized CFZ Hydrochloride 
Micronized CFZ-HCl crystals were synthesized as previously described (Chapter 6). To 
prepare a CFZ-HCl formulation for injection, the CFZ-HCl microcrystals were suspended in 
formulation diluent at different concentrations based on the treatment scheme (Table 7-2). The 
formulation diluent was made using polysorbate 80 (59924 Sigma-Aldrich, St. Louis, MO); 
polyethylene glycol 3350 (PEG; P146-3, Lot #174436, Fisher Scientific, Fair Lawn, NJ); sodium 
chloride (BP358, Fisher Scientific, Fair Lawn, NJ), and Milli-Q water. To coat and disperse the 
lipophilic CFZ-HCl microcrystals, the maximum concentrations of 0.2% polysorbate 80 and 3% 
PEG 3350 were used [30]. Sodium chloride was added to maintain isotonicity. The pH was 
adjusted to pH 4 using 0.01 M HCl or 0.01 M NaOH to ensure the stability of CFZ-HCl 
microcrystals in the formulation. Before suspending the CFZ-HCl microcrystals, the diluent was 
sterilized by sterile filtration with a syringe filter (09-719A; 0.22 µm, MCE, Sterile; Fisher 
Scientific, Fair Lawn, NJ). Micronized CFZ-HCl crystals were carefully mixed prior to injection 
via sonication and vortexing. 
Methylprednisolone (DepoMedrol) 
Methylprednisolone (DepoMedrol®, 40 mg/mL, 1 mL single-dose vial, Lot #T81737, 
Pfizer, NY) was purchased from the University of Michigan hospital pharmacy. DepoMedrol 
injections were carefully mixed prior to use via sonication and vortexing at the concentrations 
according to the treatment scheme (Table 7-2). 
Monosodium Urate (MSU) 
Bolder BioPATH supplied the MSU crystals (Invivogen, Cat #Tlrl-msu-25, Lot #MSU-39-
04). MSU crystals were prepared at a concentration of 40 mg/ml in sterile endotoxin free 
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phosphate buffered saline (PBS, Lot #24317003). The MSU injections were carefully mixed 
prior to use via sonication and vortexing at the concentrations according to the treatment scheme 
(Table 7-2).  
Experimental Study Design 
The study was divided into two phases: 
Phase 1: On Study Day (-12) (Table 7-1), Groups 1–2 received intra-articular (IA) 
injections of MSU vehicle and CFZ vehicle or CFZ injection into the right knee according to the 
treatment information (Table 7-2). Knee caliper measurement were taken at 0, 4, 8, and 24 h 
post-injection as described in Section 4a. Inflammatory activation was observed in animals 
treated with CFZ; therefore, a second injection was administered into the other (left) knee on 
Day (-8) to optimize formulation/dosing. Knees were calipered at 0, 4, 8, and 24h post-injection. 
After the final caliper measurements, animals in Groups 1–2 were necropsied as described in 
Section 4e. 
Phase 2: On Study Day (-4) (Table 7-1), animals in Groups 3–6 were randomized by 
body weight into treatment groups, and baseline knee caliper, Von Frey, gait, and incapacitance 
(IC) measurements were taken. On Day (0), the animals were anesthetized with isoflurane and 
given IA injections of test article or vehicle and MSU crystals into the right knee joint as 
indicated in Table 7-2. Knee caliper, Von Frey, IC, and gait measurements were taken again on 
Day (0) and Day (1) (Table 7-1) as described in Sections 4a-d. The animals were euthanized for 
necropsy at 24 hours post-injection on Day (1) as described in Section 4e (neutrophil infiltration 
and knee swelling was expected to peak 24 hours post-injection). 
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Observations, Measurements, and Specimens 
Knee Caliper Measurements 
Right and left knee caliper measurements were made using a Digitrix II micrometer 
(Fowler & NSK). Caliper measurements for Groups 1–2 were taken on Study Day (-8, Table 7-
1) as a baseline and at 4h and 8h post-injection and on Day (-7, Table 7-1) at 24h post-injection. 
The change in knee diameter from baseline was determined. Caliper measurements for Groups 
3–6 were taken on Study Day (-4, Table 7-1) as baseline, Day (0, Table 7-1) at 4h and 8h post-
injection, and Day (1, Table 7-1) at 24h post-injection. The change in knee diameter from 
baseline was determined. 
Von Frey (VF) Testing Methods 
Von Frey testing of Groups 3–6 was performed on Study Day (-4, baseline) and Day (1) 
(Table 7-1). The rats were habituated to the animal colonies for one week and handled four times 
for five minutes each after the week of habituation. The animals were habituated to the testing 
rack three times during this process. 
A Von Frey (VF) testing kit for our purposes consisted of a set of hairs that ranged from 
3.16 to 5.18 grams absolute threshold for rats. Each researcher used the same set of hairs to avoid 
variability between kits. Testing was done on the hind portions of the hind paw as the heel tends 
to give a more reliable and sensitive response. The purpose of testing was to determine which 
stiffness hair the rat would respond to 100% of the time. Data was entered into a spreadsheet and 
a separate program (psychofit) was used to translate the 100% response rate into a 50% 
threshold, which was used in reporting results. Testing began with three applications of the 4.31 
hair. A response was recorded if the animal had an obvious reaction to the pressure of the hair, 
typically manifested as lifting of the hind paw from the grate to relieve the pressure. Responses 
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were recorded on a template as either a 0 (no response) or a 1 (response). If the animal did not 
respond to the hair three times in a row, the next larger hair in the kit was applied, and the 
process was repeated until the animal responded three times in a row. Following the response, 
the previous filament was re-tested to confirm lack of response. If the animal did respond, the 
next smaller filament was applied and the process was repeated until the animal no longer 
responded. Once a lack of response was observed, the previous filament was re-tested to confirm 
the response. 
Incapacitance (IC) Testing Methods 
Incapacitance (IC) testing of Groups 3–6 was performed on Study Day (-4, baseline) and 
Day (1) (Table 7-1). The animals were trained for the process at least twice prior to the actual 
evaluation date. The animals were placed in the plexiglass housing of the incapacitance meter. 
The plexiglass housing consisted of a tube situated at a 45 degree angle, which allowed the 
animal to elevate its torso. Each animal was allowed to acclimate for approximately 5 minutes or 
until the animal appeared to be calmly standing with both feet on the force plates. The position of 
the animal was such that each hind paw rested on a separate force plate. The force exerted by 
each hind paw was averaged over a 1 second interval, and the mean of three readings constituted 
1 data point. The change in hind paw weight distribution was determined by the difference in the 
amount of weight between the right and left limbs [31]. 
Gait Evaluation Methods 
Gait testing of Groups 3–6 was performed on Study Day (-4, baseline) and Day (1) 
(Table 7-1). Gait was evaluated by applying ink to the ventral surface of the foot and 
documenting weight bearing during movement (footprints) across paper. The rear feet of each rat 
were placed in ink, then rats were placed on paper and allowed to walk the full length. This 
183 
 
process was repeated as necessary to generate 4 clear, evenly inked footprint pairs representing 
the overall pattern of gait. Gait was scored visually as described in Table 7-3 (descriptions refer 
to diseased leg). 
Necropsy Specimens 
The animals were euthanized for necropsy 24h post-injection on Study Day (-7, Groups 
1–2) and Day (1, Groups 3–6) (Table 7-1). Serum (≥200 µl/rat) was harvested and stored frozen 
(-80ºC for further analysis. Right and left knees were lavaged (50 µl of sterile saline per knee), 
and synovial fluid from each joint were collected, flash frozen in liquid nitrogen, and stored at (-
80ºC) for future analysis. Right and left knees were also collected from all animals in Groups 1–
2 and were flash frozen and stored (-80ºC)  for future analysis. Non-injected knees were 
collected from Group 4 rats and were flash frozen and stored (-80ºC) for future analysis. Injected 
knees were collected from Groups 3–6 and non-injected knees were collected from Group 3 and 
were placed in 10% neutral buffered formalin (NBF) before being transferred to 70% ethanol and 
processed for histopathology. 
Morphologic Pathology Methods 
Histopathology was performed on knees from Groups 3–6 only. Knees were cut in half in 
the frontal plane, and the two halves were embedded together. Sections were cut from each block 
and stained with toluidine blue. The inflammation, pannus, cartilage damage, and bone 
resorption were evaluated and scored according to the indicated criteria (Tables 7-4, 7-5, 7-6, 
and 7-7). 
Cytokine Measurements in Knee Lavage and Terminal Serum 
Knee lavage and terminal serum samples were assayed for IL-1β and TNF-α by 
immunology multiplex assay (RECYTMAG-65K; MILLIPLEX Rat Cytokine/Chemokine 
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Magnetic Bead Panel, Burlington, MA) in triplicate according to the manufacturer’s instructions. 
The cytokine concentrations were expressed as picograms per milliliter of either knee lavage or 
terminal serum. In addition, the pH of knee lavage samples was measured in triplicate using 
micro pH probe (Orion Star A211, Thermo Fisher, Waltham, MA) prior to cytokine 
measurements. 
Brightfield and Fluorescence Microscopy 
Microscopy was performed using a Nikon Eclipse Ti inverted microscope (Nikon 
Instruments, Melville, NY) as previously described [32, 33]. Briefly, brightfield images were 
captured using the Nikon DS-3 camera (Nikon Instruments), and fluorescence imaging in FITC 
channel (490/510 nm, green) and Cy5 channel (640/670 nm, far-red) was performed with the 
Photometrics CoolSnap MYO camera system (Photometrics, Tuscon, AZ) under the control of 
Nikon NIS-Elements AR software (Nikon Instruments). Illumination for fluorescence imaging 
was provided by the X-Cite 120Q Widefield Fluorescence Microscope Excitation Light Source 
(Excelitas Technology, Waltham, MA). 
Statistical Analysis 
Data were entered into Microsoft Excel, and arithmetic means and standard errors were 
calculated. Groups were compared to vehicle treated animals using a one-way analysis of 
variance (ANOVA) along with a Dunnett’s post-hoc analysis or a Student’s two-tailed t-test for 
measured data (parametric) or a Kruskal-Wallis (K-W) test along with a Dunn’s post-hoc 
analysis for scored data (non-parametric). Statistical analysis was performed using Prism 7.0d 
software (GraphPad). Unless indicated, Bolder BioPATH, Inc. performed statistical analysis on 
raw (untransformed) data only. Statistical tests make certain assumptions regarding normality 
and homogeneity of variance, and further analysis may be required if testing resulted in 
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violations of these assumptions. P values were rounded to three decimal places. Significance for 
all tests was set at p < 0.05. 
7.5 Results and Discussion 
The study was divided into two phases: Phase 1 and Phase 2. The goal of Phase 1 of the 
experiment was to determine if CFZ-HCl injection on its own (CFZ-HCl microcrystals or the 
formulation diluent) causes an inflammatory response. To eliminate the possibility of the 
inflammatory response due to endotoxins in the CFZ-HCl injectable formulation, prior to Phase 
1, both CFZ-HCl microcrystals and the formulation diluent were determined to be below the 
endotoxin limit by Charles River Labs (data not shown). Proceeding with the experiment, Phase 
1 revealed that CFZ injection still resulted in inflammation (swelling) when injected IA at 50 
µl/knee (equivalent to approximately 2.67 mg of CFZ-HCl per injection) (Figure 7-2A-B). In 
fact, CFZ injection resulted in significant increased knee caliper measurements 4-24 h post 
injection as compared to CFZ vehicle injection rat group (Figure 7-2A-B). 
While Phase 1 revealed that CFZ-HCl causes an inflammatory response, we decided to 
proceed with Phase 2, which specifically intended to explore whether CFZ-HCl microcrystal 
dissolution may ameliorate MSU crystal induced inflammation through a pH-dependent 
mechanism. Thus, in Phase 2 (main study), MSU microcrystals were mixed with the drug 
treatments, and 50 µl of the resulting mixture was injected into each knee (equivalent of 
approximately 2.67 mg and 1.34 mg of CFZ-HCl (Groups 4 and 5, respectively), 1.34 mg of DM 
(Groups 5 and 6); and/or 0.67 mg of MSU microcrystals per injection). Inflammation was 
monitored through various assays, including knee caliper differentials, Von Frey analysis, Gait 
analysis, and incapacitance testing, was performed 24 hours post injection. 
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The knee caliper measurements compared the size of the injected knee to the uninjected 
knee of an animal, making a knee caliper differential value. As the result, the knee caliper 
differentials were significantly increased from Day (-4) to Day (1) (Table 7-1) in rats treated 
with CFZ alone compared to vehicle control rats (Figure 7-3A). Interestingly, knee caliper 
differentials were significantly reduced on Day (1) (Table 7-1) in rats treated with CFZ + 
methylprednisolone or DepoMedrol alone compared to vehicle treated, control rats (Figure 7-
3A). In other words, CFZ on its own caused significant knee swelling compare to the vehicle 
treated group; methylprednisolone injection completely inhibited the CFZ-HCl effect on knee 
swelling. 
The Von Frey analysis uses a set of hair or fibers, which are small pieces of nylon rod 
that approximately 50 mm in length and of varying diameters, to test a rodent's sensitivity to a 
mechanical stimulus. In this test, the animal stands on an elevated mesh platform, and the Von 
Frey hairs are inserted through the mesh to poke the animal’s hind paw to evaluate the animal’s 
reactions. As a result, in rats treated with CFZ, Von Frey absolute thresholds were significantly 
decreased on Day (1) (Table 7-1) compared to vehicle treated rats, meaning that CFZ injection 
caused additional pain to the animals relative to the pain that was already caused by the MSU 
injection alone (Figure 7-3B). Nevertheless,  methylprednisolone alone significantly increased 
Von Frey absolute thresholds on Day (1) after both MSU and CFZ-HCl crystal injection 
compared to vehicle control rats, suggesting that methylprednisolone treatment was the most 
effective in eliminating the pain in the knee from the MSU induced gout (Figure 7-3B). 
Gait analysis is the systematic study of animal and human locomotion that is used to 
assess and treat the patients with conditions affecting their ability to walk. In this case, the gait 
(foot prints) score is used to determine how well the rat can walk 24 hour post the injection. As a 
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result, the gait scores were significantly increased in rats injected with CFZ-HCl microcrsytals 
alone compared to vehicle treated rats, meaning that CFZ-HCl microcrystal-induced 
inflammation interfered with the rat’s ability to walk properly (Figure 7-3C). Corresponding with 
the gait studies, incapacitence tests were performed, utilizing force plates to measure how much 
force is exerted by each hind paws in the plexiglass housing. The change in hind paw weight 
distribution was determined by the difference in the amount of weight between the right and left 
limbs (expressed as a percent of the combined total). As a result, the difference in weight bearing 
between left and right knees in vehicle treated rats increased from a mean of 5.54 g on Day (-4) 
to 24.46 g on Day (1) following injection of MSU crystals alone. Left-right weight bearing 
differentials were significantly increased on Day (1) in rats injected with MSU and CFZ-HCl 
crystals in combination and were significantly reduced on Day (1) in rats treated with 
methylprednisolone (Figure 7-3D). Again, these results indicated that CFZ-HCl and MSU 
combinations did not improve the inflammatory response relative to the MSU-injected joints. 
Again, methylprednisolone injection inhibited the effects of CFZ-HCl and MSU injections on the 
gait and incapacitance assays.  
On Day (1) (Table 7-1), the animals were necropsied, and the injected knees were 
subjected to histopathological analysis for inflammation, pannus, cartilage damage, and bone 
resorption. As the result, the vehicle treated rats had mild to moderate knee inflammation 
compared to control (uninjected) knees with no cartilage damage or bone resorption (Figure 7-
4A-C). One of 8 vehicle treated animals had very minimal pannus formation with the remaining 
animals in the group having none. Rats treated with CFZ had marked to severe knee 
inflammation with none to very minimal pannus formation and cartilage damage and no bone 
resorption. In fact, cartilage damage scores were significantly increased in rats treated with CFZ 
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compared to vehicle treated rats. Rats treated with methylprednisolone had none to very minimal 
inflammation with no pannus formation, cartilage damage, or bone resorption (Figure 7-4A-B). 
Knee inflammation and summed scores were significantly reduced in rats treated with 
methylprednisolone compared to vehicle treated animals (Figure 7-4A-C). Rats treated with CFZ 
+ methylprednisolone had knee histopathology that did not differ significantly from vehicle 
treated animals rats (Figure 7-4A-C). Overall, Phase 2 results further confirmed that CFZ 
injection alone caused more inflammation, pannus, and cartilage damage than the vehicle treated 
mice with MSU induced gout (Figure 7-4A-C). On the other hand, CFZ injection in combination 
with methylprednisolone showed very similar scores as methylprednisolone alone, further 
suggesting that Depomedrol inhibits the effects of CFZ-HCl and MSU injections. 
To study the molecular signaling mechanisms underlying the inflammatory response 
induced by CFZ-HCl and MSU injections alone or in combination, TNFα and IL-1β were 
measured in both terminal serum and knee lavage samples. It has been shown that MSU crystals 
activate resident tissue macrophages, which secrete inflammatory cytokines including TNFα and 
IL-1β locally and then make their way to the systemic circulation [34, 35]. Although blood 
cytokines were not significantly altered in  Phase 1 and 2 experiments regardless of the sample 
type (Figure 7-5A-D), TNFα and IL-1β concentrations were elevated in knee lavage samples 
from CFZ-HCl treated groups in Phase 1 and 2 (Figure 7-5C-D), paralleling the functional and 
histopathological results. 
Next, the pH was measured in the knee lavage samples (Figure 7-6A). At 80 mgs/ml, 
CFZ-HCl microcrystals did not lead to a decrease in the pH of the joints (Figure 7-6A), 
suggesting that there are proton transport mechanisms in the synovium that lead to fast pH 
equilibration with the blood. On the other hand, methylprednisolone treatment with and without 
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CFZ actually made synovium more alkaline by increasing the pH to around 8.2 (Figure 7-6A), 
which only would stabilize the MSU crystals within synovium.  
 Lastly, the knee lavage samples were subjected to the microscopic analysis. By visual 
inspection, no MSU crystals were present in the joints and that CFZ-HCl crystals could be 
clearly observed within macrophages, based on the fluorescence signal in Cy5 channel (Figure 7-
6B-C). Some of the CFZ-HCl crystals were destabilized in CFZ-HCl + methylprednisolone 
injections. 
7.6 Conclusion 
In conclusion, an intra-articular injection of CFZ-HCl microcrystals promoted 
inflammation in response to co-injection with MSU microcrystals, based on evaluation of animal 
knee swelling, behavioral testing, and joint histopathology. Glucocorticoid activation inhibited 
the inflammatory response resulting from both CFZ-HCl and MSU injections, alone and in 
combination, based on swelling, incapacitance, and pain analyses. These results were consistent 
with the pathological results as well as the measured cytokine changes in response to the various 
different treatments. Because there were no major changes in the pH of the joint induced by 
injection of CFZ-HCl, MSU or combination of the two, it was apparent that the inflammatory 
responses were not elicited by the acidity of microcrystalline or alkalinizing formulations on the 
local microenvironment. Instead, CFZ-HCl injected with MSU crystals led to increased 
macrophage recruitment, with phagocytosis of CFZ-HCl crystals and increased stabilization of 
phagocytosed CFZ-HCl crystals.  Nevertheless, methylprednisolone decreased the number of 
visible CFZ-HCl microcrystals associated with macrophages in the joint, suggesting that the 
stabilization of the injected microcrystals within macrophages may be primary factor driving the 
inflammatory response.  
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7.8 Figures and Tables 
 
 
 
 
Figure 7-1. Study hypothesis schematic.   
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Table 7-1. Study calendar. 
Mon Tue Wed Thu Fri Sat Sun 
5/14/2018 
Day (-15) 
5/15/2018 
Day (-14) 
5/16/2018 
Day (-13) 
5/17/2018 
Day (-12) 
5/18/2018 
Day (-11) 
5/19/2018 
Day (-10) 
5/20/2018 
Day (-9) 
Distribute 
animals on 
arrival into 
groups for 
acclimation 
 Acclimate to VF 
Rack & IC 
Training 
Grp 1-2: 
Inject CFZ / 
Vehicle 
Caliper 
  
Acclimate 
to VF Rack 
& IC 
Training 
Grp 1-2: 
Caliper 
 
Acclimate 
to VF Rack 
& IC 
Training 
  
5/21/2018 
Day (-8) 
5/22/2018 
Day (-7) 
5/23/2018 
Day (-6) 
5/24/2018 
Day (-5) 
5/25/2018 
Day (-4) 
5/26/2018 
Day (-3) 
5/27/2018 
Day (-2) 
Grp 1-2: 
Inject CFZ / 
Vehicle* 
Caliper 
 
*Adjusted Dose 
Grp 1-2: 
Caliper 
Necropsy 
  Grp 3-6: 
Randomize 
Baseline 
Caliper, VF, 
Gait, IC 
  
5/28/2018 
Day (-1) 
5/29/2018 
Day (0) 
5/30/2018 
Day (1) 
5/31/2018 
Day (2) 
6/1/2018 
Day (3) 
6/2/2018 
Day (4) 
6/3/2018 
Day (5) 
 Grp 3-6: 
Inject Test 
Article & 
MSU 
Caliper 
Grp 3-6: 
Caliper 
VF 
Gait 
IC 
Necropsy 
Grps 3-6: 
Inject MSU 
Caliper 
Grp 3-6: 
Caliper 
VF 
Gait 
IC 
Necropsy 
  
 
  
193 
 
 
 
 
Table 7-2. Groups and treatment information. 
Group N MSU Treatment Dose Route Dose Level 
(mg/mL) 
Dose Vol.* 
(mg/mL) 
Day 3 
Reactivation 
1 4 Vehicle CFZ Vehicle IA -- -- -- 
2 4 Vehicle CFZ IA 80 50 -- 
3 8 Yes CFZ Vehicle IA -- 50 MSU 
4 8 Yes CFZ IA 80 50 MSU 
5 8 Yes CFZ+DM IA 40+40 50 MSU 
6 8 Yes DM IA 40 50 MSU 
*25 µl of 40 mg/ml MSU was mixed with 50 µl of treatment and only 50 µl of the total mixture was injected 
IA into the knee 
CFZ = Clofazimine; DM = Depo-Medrol; MSU = Monosodium Urate; IA = Intra-Articular 
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Table 7-3. Gait evaluation scores. 
Score Meaning Details 
0 Normal Approximately equal ink staining to normal paw 
1 Slight limp/pain Reduced inking area relative to the normal paw, but no full regions or 
structures are missing 
2 Mild limp/pain Print extends to the end or near to the end of the “curlicue” structure. If 
normal paw has very little heel staining (rat walks mainly on toes/ball of 
foot), then slightly less staining 
3 Moderate limp/pain Toes and full ball of foot, extending to the top of the “curlicue” structure are 
present. If normal paw has very little heel staining (rat walks mainly on 
toes/ball of foot), then toes with small portion of ball of foot 
4 Marked limp/pain Toes and partial ball of foot, no heel or posterior foot. If normal paw has 
very little heel staining (rat walks mainly on toes/ball of foot), then toes only 
5 Severe limp/pain Toes only, no ball of foot, no heel. If normal paw has very little heel staining 
(rat walks mainly on toes/ball of foot), then partial toes or non-specific 
marks 
6 Hopping Carrying leg, no footprint is evident 
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Table 7-4. Inflammation scores. 
Score Meaning Details 
0 Normal -- 
0.5 Very Minimal Generally focal or multifocal, very minor inflammation 
1 Minimal Multifocal, minor infiltration of inflammatory cells in synovium/periarticular tissue, 
no obvious distension of joint capsule 
2 Mild Diffuse mild infiltration of entire synovium, minor if any distension of joint capsule 
3 Moderate Moderate infiltration with moderate edema, diffuse with moderate distension of joint 
capsule usually on both medial and lateral sides 
4 Marked Marked infiltration and marked edema, diffuse with marked distension of joint 
capsule on both medial and lateral sides or may have just one side severely 
distended and the other is milder 
5 Severe Severe infiltration with severe edema, diffuse with severe distension of joint capsule 
on both medial and lateral sides 
6 Very Severe Very severe infiltration with very severe edema, diffuse with very severe distension 
of the joint capsule on both medial and lateral sides 
 
The inflammatory infiltrate in rats with various types of arthritis consists of neutrophils and macrophages with 
smaller numbers of lymphocytes when the lesions are in the acute to subcute phase. Tissue edema and neutrophil 
exudates within the joint space are common in the acute to subacute phase. As the inflammation progresses to 
chronic, mononuclear inflammatory cells (monocytes, lymphocytes) predominate and fibroblast proliferation, often 
with deposition of metachromatic matrix, occurs in synovium and periarticular tissue. Exudate is less common in the 
joint space. Unless indicated in the comments area, the inflammation type is acute to subacute. 
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Table 7-5. Pannus scores.  
Score Meaning Details 
0 Normal -- 
0.5 Very Minimal Minimal infiltration of pannus in cartilage and subchondral bone, affects only 
marginal zones and affects only a few focal areas, less than 1% of area at risk 
affected 
1 Minimal Minimal infiltration of pannus in cartilage and subchondral bone, approximately 1–
10% of cartilage surface or subchondral bone affected 
2 Mild Mild infiltration (extends over up to 1/4 of surface or subchondral area of tibia or 
femur), approximately 11–25% of cartilage surface or subchondral bone affected 
3 Moderate Moderate infiltration (extends over >1/4 but < 1/2 of surface or subchondral area of 
tibia or femur) approximately 26–50% of cartilage surface or subchondral bone 
affected 
4 Marked Marked infiltration (extends over 1/2 to 3/4 of tibial or femoral surface) 
approximately 51–75% of cartilage surface or subchondral bone affected 
5 Severe Severe infiltration approximately 76–100% of cartilage surface or subchondral bone 
affected 
 
  
197 
 
 
 
 
Table 7-6. Cartilage damage scores. 
Score Meaning Details 
0 Normal -- 
0.5 Very Minimal Minimal decrease in toluidine blue staining, affects only marginal zones 
1 Minimal Minimal to mild loss of toluidine blue staining with less than 1% cartilage loss on all 
combined surfaces 
2 Mild Mild loss of toluidine blue staining with focal mild (superficial) chondrocyte loss 
and/or collagen disruption, may have few small areas of 50% depth of cartilage 
affected, 1–10% cartilage loss on all combined surfaces 
3 Moderate Moderate loss of toluidine blue staining with multifocal to diffuse moderate (depth 
to middle zone) chondrocyte loss and/or collagen disruption, may have several areas 
of full thickness loss, 11–25% cartilage loss on all combined surfaces 
4 Marked Marked loss of toluidine blue staining with multifocal to diffuse marked (depth to 
deep zone) chondrocyte loss and/or collagen disruption, total overall loss 26–50% of 
all combined surfaces 
5 Severe Severe diffuse loss of toluidine blue staining with multifocal severe (depth to tide 
mark), total overall loss greater than 50% of width of all surfaces combined 
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Table 7-7. Bone resorption scores. 
Score Meaning Details 
0 Normal -- 
0.5 Very Minimal Minimal resorption affects only marginal zones, less than 1% of area at risk affected 
1 Minimal Small areas of resorption, not readily apparent on low magnification, approximately 
1–10% of total joint width of subchondral bone affected 
2 Mild More numerous areas of resorption, definite loss of subchondral bone, 
approximately 11–25% of total joint width of subchondral bone affected 
3 Moderate Obvious resorption of subchondral bone approximately 26–50% of total joint width 
of subchondral bone affected 
4 Marked Obvious resorption of subchondral bone approximately 51–75% of total joint width 
of subchondral bone affected 
5 Severe Distortion of entire joint due to destruction approximately 76–100% of total joint 
width of subchondral bone affected 
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Figure 7-2. Phase 1 (Grp 1-2) – results. Knee caliper difference (A) and pictures (B) of the injected knees. 
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Figure 7-3. Phase 2 (Grp 3-6) – observational results. Knee caliper difference (A), Von Frey analysis (B), Gait 
analysis (C), and incapacitance scores (D). 
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Figure 7-4. Phase 2 (Grp 3-6) – histopathological results. Histopathology photomicrographs (A) and 
inflammation, pannus, cartilage damage and bone resorption individual (B) and summed (C) scores. 
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Figure 7-5. Phase 1 (Grp 1-2) and Phase 2 (Grp 3-6) cytokine measurements. Terminal serum (A,B) and knee 
lavage (C,D) IL-1β and TNF-α concentrations. 
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Figure 7-6. Phase 1 (Grp 1-2) and Phase 2 (Grp 3-6) pH and microscopic analysis of the knee lavage samples. 
The pH of knee lavage samples from Phase 1 and Phase 2 (A). Microscopic analysis of the knee lavage sample from 
Phase 1 (B) and Phase 2 (C). Scale bar = 10 µm. 
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Chapter 8 
Conclusions and Future Outlook 
8.1 CFZ-induced skin pigmentation is associated with CFZ free base, not CFZ-HCl salt. 
First, by using experimental and computational approaches, we probed the relationship 
between the biological mechanisms mediating lysosomal ion homeostasis and the self-assembly 
of a weakly basic small molecule building block (e.g. CFZ) into a functional, 
mechanopharmaceutical device (CFZ-HCl salt form) in macrophage lysosomes. 
Physicochemical considerations indicate that the intralysosomal stabilization of the self-
assembled mechanopharmaceutical device depends on the pHmax of the weakly basic building 
block and its affinity for chloride, both of which are consistent with the pH and chloride content 
of a physiological lysosomal microenvironment. Most importantly, in vitro and in silico studies 
revealed that high expression levels of the V-ATPase, irrespective of the expression levels of 
chloride channels, are necessary and sufficient to explain the cell-type dependent formation, 
stabilization, and biocompatibility of the self-assembled mechanopharmaceutical device within 
macrophages. Moreover, to accommodate increasingly massive loads of cargo, macrophages 
increase in numbers and adapt their intracellular membrane organization to expand the 
intracellular cargo space. 
To test whether CFZ-induced skin pigmentation is due to CFZ-HCl formation and 
accumulation, I identified a closely related CFZ analog that does not precipitate under 
physiological pH and chloride conditions that are required for CFZ-HCl accumulation and 
208 
 
stabilization. As a result, despite the absence of detectable Cy5(+) CFZ-HCl salt form in mice, 
administration of this analog still led to significant skin pigmentation. In CFZ treated mice, skin 
cryosections revealed no evidence of CFZ-HCl when analyzed with a microscopic imaging 
system specifically designed for detecting CFZ aggregates. Rather, the reflectance spectra of the 
skin revealed a signal corresponding to the soluble, free base form of the drug. Consistent with 
the low concentrations of CFZ in the skin, these results suggested that CFZ-induced skin 
pigmentation is not due to CFZ precipitation and CFZ-HCl formation and accumulation, but 
rather to the partitioning of the circulating, free base form of the drug into subcutaneous fat. 
8.2 Biomimetic formulation of micronized CFZ-HCl crystals are stable under lysosomal 
conditions in vitro and in vivo 
First, in order to distinguish between the potential adverse effects of insoluble drug 
biocrystals (e.g. Cy5(+) CFZ-HCl salt form) from those of the soluble molecules (CFZ free 
base), we designed an experimental strategy to compare how the accumulation of insoluble drug 
biocrystals might influence the immune signaling response of macrophages in live mice. 
Accordingly, we tested the specific hypothesis that CFZ biocrystals that accumulate in resident 
tissue macrophages can modulate (or activate) these cells’ inflammatory signaling pathways in 
vivo that lead to systemic changes in the inflammatory response. By assessing tumor necrosis 
factor alpha (TNF-α) and IL-1 receptor antagonist (IL-1RA) expression, as well as Casp 1 and 
IL-1β maturation, in the vital organs and blood of CFZ-treated mice, the results demonstrated 
that CFZ biocrystals in macrophages, but not the soluble form (e.g. CFZ free base), are 
specifically associated with an IL-1RA-mediated anti-inflammatory response. 
Knowing that CFZ drug biocrystals (e.g. Cy5(+) CFZ-HCl salt) are biocompatible, stable, 
long-lived, relatively non-toxic, and have anti-inflammatory properties, I developed a 
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biomimetic formulation of CFZ-HCl microcrystals. Based on the in vitro and in vivo data, 
micronized CFZ-HCl crystals were ingested by tissue macrophages and accumulated in liver and 
spleen, similar to CFZ biocrystals. In mice, IV injection of these biomimetic CFZ-HCl 
microcrystals led to visible drug accumulation in macrophages of the reticuloendothelial system 
with minimal skin accumulation or pigmentation. In fact, no skin pigmentation was observed 
when the total amount of CFZ-HCl administered was equivalent to the total oral dose leading to 
maximal skin pigmentation. Furthermore, IV administration did not result in overt toxicity and 
did not induce measurable changes in acute inflammatory response biomarkers. The anti-
inflammatory cytokine, IL-1RA, which was previously shown to be elevated following oral 
administration of CFZ, was not changed by the injected CFZ-HCl microparticles. My findings 
support additional studies into the possible use of parenteral (injected or inhaled) CFZ-HCl as 
means to circumvent the skin pigmentation side effect of the oral CFZ administration. For 
example, an inhalable, aerosolized formulation of CFZ-HCl may be a good strategy for treating 
MDR-TB.    
8.3 Local administration of biomimetic formulation of CFZ-HCl microcrystals in vivo 
leads to the recruitment of macrophages to the site of action, a pro-inflammatory response. 
 Since the biomimetic formulation of CFZ-HCl microcrystals proved suitable for 
parenteral administration without major toxicological consequences, I decided to determine its 
efficacy in one of possible indications – gout, most common inflammatory, crystal-induced 
arthropathy. Specifically, I studied whether the inflammatory response induced by MSU crystals 
directly injected into joints may be related to their alkalinizing effect on the local 
microenvironment or to their impact on macrophage recruitment. For this purpose, CFZ-HCl 
microcrystals were injected into the rat knee, alone or in combination with MSU crystals. As a 
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hypothesis, the micronized CFZ-HCl particles should lower the pH of the synovium upon 
dissolution, facilitating the dissolution and clearance of MSU crystals from the joint and 
reducing their alkalinizing effects. Contrary to my expectations, the results indicated that CFZ-
HCl injections significantly increased the severity of the inflammatory response induced by co-
injecting MSU microcrystals. This strong inflammatory response was attributed to increased 
macrophage recruitment from local CFZ-HCl treatment. Furthermore, treatment with 
methylprednisolone, reduced both CFZ- and MSU-induced inflammation, while destabilizing the 
CFZ-HCl microcrystals through increased alkalization. Because methylprednisolone is known to 
inhibit macrophage migration, I infer that macrophages exacerbate joint inflammation by 
stabilizing injected microcrystals; by reducing macrophage recruitment, methylprednisolone 
decreased injected microcrystal stability and lessened the inflammatory response.  
Overall, the results of this study suggest that my formulation is not suitable for gouty 
arthritis and increases the severity of the local inflammatory response by facilitating macrophage 
recruitment, which can be explained by liver granulomas with macrophage recruitment around 
Cy5(+) CFZ-HCl precipitates in Chapter 2. Even though CFZ-HCl is associated with the 
systemic anti-inflammatory activity in Chapter 2, I now know that CFZ-HCl also exerts local 
pro-inflammatory effects at the site of action. Even though the results of this study suggested that 
my formulation is not suitable for gouty arthritis, further investigation is required to determine 
efficacy and anti-inflammatory action of my formulation in MDR-TB and other potential new 
indications. 
8.4 Final Notes 
 The science and methodology portrayed in this dissertation can and should be applicable 
to the study of the accumulation, reformulation, and immunological side effects of other weakly 
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basic drugs. For example, amiodarone and nilotinib are also weak bases that accumulate and 
even precipitate out in macrophages. There are also at least a dozen of other drugs that lead to 
formation of granulomas in liver. One should investigate if these drugs are precipitating out due 
to stabilization of a specific ionized form by monitoring the protonation state of drugs using the 
novel methodology discussed in this thesis (e.g. Raman, 1H-NMR, etc) and not necessarily have 
to rely on fluorescence techniques to distinguish between ionized forms that may accumulate in 
cells or tissues. 
Overall, this dissertation augments the understanding of drug distribution and mechanism 
of action by effectively demonstrating how it is possible to distinguish the differential 
contribution of different ionization states of a drug (e.g. CFZ) to the drug’s efficacy and toxicity 
properties. Furthermore, this dissertation has advanced the rational design of formulations, in 
terms of being the first to develop a biomimetic form of a small molecule drug and 
demonstrating how the role of macrophages in determining the stability of biomimetic 
formulations can be probed. 
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Appendix A 
Supporting Information in Chapter 2 
A.1 Supplemental Materials and Methods 
Mouse bronchoalveolar lavage (BAL) harvest  
PBS/LPS-instilled and CFZ-treated or control mice were euthanized by exsanguination 
while deeply anesthetized with an intraperitoneal injection of ketamine/xylazine (100 mg/kg, 10 
mg/kg). The trachea was surgically exposed and cannulated with an 18G needle and the lungs 
were lavaged by instilling 1 ml DPBS (Life Technologies, Carlsbad, CA) containing 0.5 mM 
EDTA (Sigma, St. Louis, MO). The retrieved BAL was then centrifuged (10 min at 400 x g, 
4°C), and the supernatant was frozen (-80 °C), while the cell pellets were resuspended in 1 ml 
RPMI 1640 media (Life Technologies). To count total cells, the cells were stained with Trypan 
blue and counted using a hemocytometer. 
Immunohistochemistry and imaging 
After euthanasia with ketamine/xylazine and exsanguination, the liver, spleen and 
kidneys were removed en bloc and the lungs were inflated with 0.8 ml (50% OCT, 15% sucrose 
in PBS) and frozen in Tissue-Plus OCT compound (Fisher HealthCare, Houston, TX). Tissue 
blocks were sectioned at a thickness 6 µm, using Leica 3050S cryostat. For 
immunohistochemistry, sections were fixed in 4% paraformaldehyde for 10 min, blocked for 2 h 
and incubated with primary antibody at 1 ug/ml overnight (4°C) followed by HRP-conjugated 
secondary antibody for 1 h, DAB substrate incubation (intelliPATH FLX DAB chromogen kit, 
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Biocare Medical, Concord, CA) and hematoxylin counterstain. For fluorescence 
immunostaining, FITC-conjugated secondary antibody (Sigma) was incubated for 1 h, and 
Hoechst 33342 (Life Technologies) was used for nuclear detection. Non-fluorescence staining 
was performed by the Pathology Core for Animal Research (PCAR) in the Unit for Laboratory 
Animal Medicine (ULAM) at the University of Michigan. Sections were mounted on glass slides 
with ProlongGold (Life Technologies). Brightfield and fluorescence (DAPI, FITC and Cy5) 
images were acquired using the Nikon Eclipse Ti (Japan) inverted microscope equipped with a 
Nikon Digital Sight DS-Fi2 camera (Japan) for brightfield and Photometrics Coolsnap Myo 
camera (Tucson, AZ) for fluorescence. 
SDS-PAGE and Western Blot 
Harvested organs were washed in ice-cold DPBS and homogenized by sonication in 
radioimmunoprecipitation assay (RIPA) buffer (Sigma). Halt protease and phosphatase inhibitor 
cocktail and 0.5 M EDTA (Thermo Pierce) were added to the RIPA buffer (1:100 dilutions) 
before use. The protein concentration in homogenates was determined with a BCA assay 
(Thermo Pierce) and equal amounts of total protein were suspended in 4x sample buffer (Bio-
Rad, Hercules, CA) and heated (4 min at 94°C). Proteins were separated by SDS-PAGE in 4-
15% or 4-20% bis-acrylamide gels (Bio-Rad) and electroblotted onto PVDF membranes 
(Millipore, Billerica, MA) using the Criterion system (Bio-Rad). After blocking for 1 h in Tris-
buffered saline/Tween (TBST, pH 7.6; 20 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween20) 
containing 5% nonfat milk (Meijer), the blots were probed with primary antibodies diluted in 5% 
BSA or 5% nonfat milk overnight at 4°C. The membranes were washed with TBST and 
incubated with a 1:2000 dilution of HRP-conjugated anti-rabbit secondary antibodies (Millipore) 
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for 1 h at room temperature. Protein bands were visualized on X-ray film (Thermo) using 
chemiluminescence (Supersignal reagents; Pierce). 
Equation for Mouse Terminal Endpoint Assessment 𝐷abc=bdceeeeee = f(𝑜abc − ?̅?bdc)) + (𝑤abc − 𝑤jbdc)) + (𝑡abc − 𝑡b̅dc)) 𝐷abc=bdceeeeee: total distance between LPS-instilled mouse and mean of PBS-instilled mice ?̅?bdc: mean oxygen saturation change of PBS-instilled mice  𝑜abc: oxygen saturation change of LPS-instilled mouse 𝑤jbdc: mean weight change of PBS-instilled mice 𝑤abc: weight change of LPS-instilled mouse  𝑡b̅dc: mean temperature change of PBS-instilled mice 𝑡abc: temperature change of LPS-instilled mouse 
v All changes represent percent changes from day 0 baseline measurements 
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A.2 Supplemental Figures and Tables 
 
 
 
Figure S2-1. Clofazimine (CFZ) bioaccumulation and crystal formation in the lung occurs after 2 weeks in 
CD68 (+) macrophages. Representative brightfield and fluorescence (FITC for CD68 and Cy5 for CFZ) images of 
lung sections from control mice and mice treated with CFZ for 2 and 8 weeks. In the lung, CFZ can be seen 
accumulating inside macrophages after 2 week CFZ treatment with no crystallization (arrowhead). At 8 weeks, CFZ 
crystals can be seen located inside macrophages. Scale bar = 10 µm. 
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Figure S2-2. Clofazimine (CFZ) bioaccumulation does not affect IL-1β cleavage in the spleen, lung or kidney. 
Western blots of spleen, lung and kidney homogenates showing that IL-1β cleavage was not altered after 8 weeks of 
CFZ treatment. 
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Figure S2-3. 6 week CFZ-treated IL-1RA knockout mice displayed reduced body and liver weights compared 
to control diet wildtype mice. (A) 6 week CFZ-treated IL-1RA knockout (KO) mice show reduced body weight 
compared to control diet treated littermates and wildtype (WT) mice. (B) IL-1RA KO mice display reduced liver 
weight compared to WT, but spleen are comparable. (C) Representative brightfield and fluorescence (Cy5 for 
crystalline CFZ) images of liver sections from WT and IL-1RA KO mice treated with CFZ for 6 weeks. Scale bar = 
100 µm. (D) Cy5 fluorescence intensity values of liver sections from WT and IL-1RA KO and CFZ-treated mice. 
Data are the mean ± S.D. of 4 images. Scale bar = 100 µm. 
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Figure S2-4. Daily monitoring of changes in bodily functions in 8 week CFZ-treated and control mice after 
PBS or LPS-induced acute lung injury. Daily monitoring of changes in arterial oxygen saturation (A), body 
weight (B), temperature (C), heart rate (D), respiratory rate (E), and pulse distention (F) in 8 week CFZ-treated and 
control mice after PBS (white circle) or LPS (grey circle)-induced acute lung injury. Control mice lung function 
progressively deteriorated at a higher rate than CFZ-treated mice as CFZ-treated mice displayed higher arterial 
oxygen levels at day 5 and day 6 (A). Control mice injected with LPS lost weight more rapidly compared to CFZ-
treated mice (B). CFZ-treated mice were more resistant to hypothermia (C), drop in heart rate (D) and respiratory 
rate (E) after the second LPS injection compared to control-mice (day 4). Data is the compilation of two separate 
experiments and presented as mean ± S.D. (PBS n=4, LPS n=12). Black dots represent mice that reached terminal 
endpoint and were euthanized. One-way ANOVA was used to compare changes in parameters between control vs 
CFZ-treated mice with PBS or LPS injections per timepoint and p ≤ 0.05 was considered statistically significant. *p 
≤ 0.05, **p ≤ 0.01. 
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Table S2-1. Vital signs of control and clofazimine-treated mice (8 week treatment). 
Vital signs Control diet treated (n=16) 
CFZ treated 
 (n=16) P value 
Weight (g ± S.D.) 26.13 ± 1.49 24.39 ± 1.92 0.008 
Body Temperature (°C ± S.D.) 35.30 ± 0.54 35.52 ± 0.76 0.35 
Arterial O2 Saturation (% ± S.D.) 97.52 ± 0.76 99.01 ± 0.24 0.00000064 
Respiratory rate (brpm ± S.D.) 172.85 ± 18.25 154.29 ± 19.43 0.009 
Heart rate (bpm ± S.D.) 632.91 ± 89.55 573.94 ± 85.28 0.066 
Pulse distention (µm ± S.D) 512.22 ± 60.35 425.57 ± 52.32 0.00015 
P values were calculated using Student’s t-test (two-way, unpaired) 
 
 
  
221 
 
 
 
Appendix B 
Supporting Information in Chapter 3 
B.1 Supplementary methods 
HPLC analysis 
For the HPLC assay, the mobile phase was methanol:water (80:20) with 0.1% 
trifluoroacetic acid (1 ml/min flow rate). The stationary phase (column) was a C18 (unbonded 
silica particles) column (Atlantis® T3, 5 µm, 100Å), and the HPLC was equipped with a UV 
detector (Waters, Photodiode Array Detector 2996) @ 285 nm detection for CFZ. The retention 
time for CFZ was determined to be 4.75 min. 
Determination of solubility parameters 
We used a mathematical proof approach to determine [CFZH+]S as detailed below:  
First, we calculated [CFZH+] using the total solubility (ST) at each pH value and the 
constant intrinsic free base solubility, [CFZ]S, using the following equation, which was obtained 
by rearranging the terms in equation (14) (see main article): 
[CFZH+] = ST − [CFZ]S      (Supplementary Equation 1) 
Then, we chose a value, say “y”, from the list of the computed [CFZH+] values, and let 
“y” equal [CFZH+]S. By substituting “y’ in place of [CFZH+]S, we calculated for total solubility 
at the different pH values using equation (15) (see main article). Then, we compared this total 
solubility-pH dataset to that obtained using equation (13) (see main article). Then, we checked if 
there was the same total solubility value at a given pH in both datasets, which would represent 
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the intersection point of the two solubility-pH curves mentioned previously. This can be 
represented by the following equation: 
ST′ = [CFZ]S + [CFZH+]S       (Supplementary Equation 2) 
Where ST’ is the total solubility value at the intersection of the two solubility-pH curves, and 
both forms of the drug, CFZ and CFZH+, are present in equilibrium with their respective solid 
forms in the solid phase denoted by the subscript s. 
Moreover, to prove if our earlier assumption (“y” is equal to [CFZH+]S) was valid, we 
calculated the total solubility by plugging “y” in place of [CFZH+]S , supplementary equation (2), 
and checked if it was equal to ST’. Furthermore, by definition, the pH where both the intrinsic 
free base and salt forms of the drug are in the solid phase is known as pHmax. Thus, the pH 
associated with ST’ was deduced to be pHmax. 
Modeling proton influx 
V-ATPase is an electrogenic proton-pump, which inserts protons from the cytoplasm into 
the lysosome against an electrochemical gradient upon ATP hydrolysis [1, 2]. The rate at which 
a proton molecule is inserted per second (JHVATP) was obtained from published experimental 
studies [2] as a function of transmembrane pH gradient (Δ pH) in units of pH unit and membrane 
potential difference, which is also interchangeably known as membrane potential (ΔΨ), in units 
of mV. This rate was multiplied by the total number of active V-ATPase molecules per lysosome 
(NVATP) to obtain the total amount of proton molecules inserted into the lysosome in units of 
molecules per second, as follows: 
Hpump = NVATP × JHVATP (ΔpH ,ΔΨ)     (Supplementary Equation 3) 
Where lysosomal ΔΨ is dictated by the total net change in lysosomal ion content and is 
represented by the following relationship [3]: 
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ΔΨ= (F × VL) / (C′ × S) × [(Σi Zi [cations]i + Σi Zi [anions]i) − B]  (Supplementary Equation 4) 
Where VL is the lysosomal volume in units of L; Faraday’s constant (F) which equals 96485 
Coulomb/mol and is used to convert the lysosomal ion content in units of moles to units of 
Coulomb; C’ is the specific membrane capacitance per unit area of a biological membrane, 
which is experimentally approximated to be 1 µF/cm2 and is multiplied by the lysosomal surface 
area S represented in units of cm2 to obtain the total lysosomal membrane capacitance; Zi is 
valence for ion i; [cation] the concentration of cation i at a given time t in units of Molar; [anion] 
is the concentration of anion i at a given time t in units of Molar; B is the Donnan particles in 
units of Molar, which are impermeable lysosomal contents defined by initial lysosomal ion 
concentrations and net change in the intrinsic surface potentials, supplementary equation (5). In 
the model and simulations communicated herein, the initial lysosomal ions consist of proton, 
potassium, sodium, and chloride with their respective charge (+ or -1) represented as a 
coefficient of their respective concentration, which is denoted by the square brackets, 
supplementary equation (5). 
B = [H+]L,initial + [K+]L,initial + [Na+]L,initial − [Cl−]L,initial – (C × S) / (F ×VL) × {(Ψin − Ψout) +  
Ψinitial}        (Supplementary Equation 5) 
Where Ψin and Ψout are the intrinsic inner and outer surface potentials, respectively, in units of 
mV, which contribute to the change in ion concentration at membrane surface as described later, 
Ψinitial is the initial lysosomal membrane potential which is set to zero mV in order to maintain 
initial lysosomal membrane electroneutrality. 
Modeling chloride influx 
V-ATPase mediated proton influx into the lysosome is followed by lysosomal membrane 
potential increase which consequentially arrests further proton influx. Thus, to lower the 
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membrane potential for the continuation of V-ATPase proton-pumping activity, which is 
essential to lower lysosomal pH to physiological pH, the removal of lysosomal cation or the 
insertion of lysosomal anion is required. Accordingly, CLC7 is considered as the primary 
membrane potential dissipating protein which transports two chloride ions from the cytoplasm to 
the lysosome for every proton it transports from the lysosome to the cytoplasm [4]. The rate  
(JCl, HClC7) at which the ion transportations occur was empirically derived from a current-voltage 
experimental data [3] as a function of chemical (ΔpH, ΔCl) and electric potential gradients, 
(ΔΨ), as detailed in supplementary equations (6) and (7). This rate was multiplied by the total 
number of CLC7 molecules per lysosome (NClC7) in order to obtain the total amount of proton 
and chloride molecules transported across the lysosomal membrane through CLC7, as follows: 
HCLC7 = NCLC7 × JCl,HCLC7 (ΔpH,ΔCl,ΔΨ)    (Supplementary Equation 6) 
ClCLC7 = 2 × NCLC7 × JCl,HCLC7 (ΔpH,ΔCl,ΔΨ)    (Supplementary Equation 7) 
Where ΔCl is the chloride gradient comprised of the luminal chloride (ClL) and the cytoplasmic 
chloride (ClC). Moreover, the coefficient 2 in supplementary equation (7) defines the 2:1 
stoichiometric relationship between the chloride and proton ions transported by CLC7 across the 
lysosomal membrane. 
Modeling proton efflux 
In addition to CLC7, the passive diffusion of protons across the lysosomal membrane can 
also contribute to the dissipation of membrane potential in order to facilitate the proton pumping 
activity of V-ATPase. This passive proton leak is modeled by supplementary equation (8), which 
is derived from the Goldman-Hodgkin-Katz (GHK) ion flux equation that is commonly used to 
describe the passive diffusion of a given ion across a biological membrane, assuming a linear 
potential gradient across a lipid membrane [3]. 
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Hleak = [S × PH+ × Y × Z × [10−pHL − (10−pHC × e−Z×Y)] / ( 1 − e−Z×Y)] × Nav  
         (Supplementary Equation 8) 
Where S is the total lysosomal surface area in units of cm2 used to obtain the total amount of 
proton which passively diffuses across the lysosomal membrane; PH+ is the lysosomal membrane 
proton permeability in units of cm/s; Z is the valence of the ion (i.e. +1 for proton); pHL is the 
luminal pH used to calculate the total free lysosomal proton based on the logarithmic relationship 
of pH and free proton (pHL = -log[H+]); pHc is the cytoplasmic pH used to calculate the total free 
cytoplasmic proton based on the logarithmic relationship of pH and free proton (pHC = -log[H+]); 
Nav is Avogadro’s number used to convert the amount of transported protons in unit of moles to 
unit of molecules; Y is used to convert proton transportation in unit of charge per second to 
moles per second and is defined as: Y = (ΔΨ×F) / (R×T), where R is universal gas constant, F 
is Faraday’s constant, and T is absolute temperature. Moreover, for cells at room temperature (25 
°C), RT/F equals 25.69 mV, and is used for normalizing the lysosomal membrane potential 
communicated in this report. 
Modeling the effect of membrane leaflet potentials on ions 
In order to account for the effects of intrinsic external (Ψi,out) and internal (Ψi,in) leaflet 
potentials of the lysosomal membrane on cytoplasmic and lysosomal ion i concentrations, 
respectively, the individual cytoplasmic and lysosomal ion concentrations are computed using 
the following relationships, supplementary equations (9 and 10), derived from the GHK equation 
for a single ion concentration gradient, by setting net current flow equal to zero. 
ΔΨi,in = (−Z × R × T) / F x ln (Ci,in / Ci,L)     (Supplementary Equation 9) 
ΔΨi,out = (−Z × R × T) / F x ln (Ci,out / Ci,C)     (Supplementary Equation 10) 
226 
 
Where Ci,in is the internal concentration of a given ion (i) at the membrane surface facing the 
lysosomal compartment, Ci,L is the concentration of the ion (i) inside the lysosome, Ci,out is the 
external concentration of the ion (i) at the membrane surface facing the cytoplasmic 
compartment, Ci,C is the concentration of the ion (i) inside the cytoplasm. All units are molar. 
Governing equations 
Supplementary equations (3-10) were used in supplementary equations (11-13) to further 
define the ion movements as a function of time, in units of molecules per second. 
dH+/dt = Hpump − HCLC7 − Hleak − Hsequestered     (Supplementary Equation 11) 
dCl−/dt = 2 × NCLC7 × JCl,HCLC7 (ΔpH, ΔCl, ΔΨ) − Clsequestered  (Supplementary Equation 12) 
Moreover, extending supplementary equation (11), we can denote the change in 
lysosomal pH with respect to time by following the relationship between the lysosomal lumen 
buffering capacity (β) of the Donnan particles, which sequester non-free lysosomal protons, and 
free lysosomal protons which give rise to lysosomal pH as follows: 
dpH/dt = (−Hpump + HCLC7 + Hleak + Hsequestered) / (V × Nav ×β)  (Supplementary Equation 13) 
Where V is the lysosomal volume and is multiplied by Nav to convert the unit of molecules per 
second to molar per second, where the inverse of β is in units of pH units per molar. 
Numerical analysis 
Supplementary equations (11-13) were solved by numerical integration in Berkeley 
Madonna® using Rosenbrock stiff solver as a numerical integrator. 
Data visualization 
Multiple individual 2D datasets associated with the parametric simulations performed to 
generate simultaneous inhibitions of various lysosomal parameters were obtained. The datasets 
associated with each simultaneous inhibitions of lysosomal parameters were exported from 
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Berkeley Madonna and compiled into three separate matrices in a MS-Excel spreadsheet, such 
that the first rows and columns of the matrix correspond to the two parameters simultaneously 
varied in the model simulations to obtain the final lysosomal readout values (lysosomal pH, Cl-, 
and membrane potential), where each makes up the rest of the rows and columns of a single 
matrix. 
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B.2 Figures and Tables 
 
 
 
Figure S3-1. Fluorescence Microspectroscopy and (inset, i = brightfield, ii = green fluorescence, iii = far-red 
fluorescence) Epifluorescence Microscopy of CFZ-H+Cl- crystals indicating the lack of green fluorescence 
while being fluorescent in the far-red fluorescence range. The excitation wavelength (nm, Ex) and emission 
wavelength (nm, Em) are shown on the X-axis and Y-axis, respectively. The normalized fluorescence yield is shown 
by a contour plot that was normalized using a control slide first and then to the maximum measured fluorescence 
yield. The colors as shown represent contour levels from 0-1 in steps of 0.2. The green, red, and far-red fluorescence 
bandwidths are overlaid on top of the normalized fluorescence spectra. 
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Figure S3-2. Epifluorescence microscopy of RAW264.7 cells when incubated with CFZ (10 µM), 
Lysotracker® Blue (LB, 1 and 20 µM) at t = 1 hour. Scale bar, 10 µm. At 1 hour, green fluorescence spots 
indicative of CFZ are visible as mild diffuse staining rather than punctate staining observed at t = 24 hours. 
Vesicular staining pattern of LB, visible as blue punctate spots when incubated on its own, are absent when co-
incubated with CFZ at both LB = 1 and 20 µM. The control images were taken at t = 24 hours post initiation of 
experiments. 
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Figure S3-3. Pearson’s Colocalization Coefficient for multiple cell ROIs (n = 70) as obtained post 
epifluorescence microscopy of RAW264.7 cells incubated with CFZ (10 µM) at t = 24-72 hours. Fluorescence 
channel description is provided in Supplementary Table S3-2. The scatter distribution is further annotated with four 
horizontal lines denoting the Mean ± S.E. (same color lines as the distribution), Mean (green line) and the Median 
(black line) of the distribution. * -p < 0.005. 
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Figure S3-4. Viability of RAW264.7 cells treated with a) BafA1 and b) NPPB in the presence of CFZ (0-10 
µM). Data was collected at n = 6 with * - p < 0.05, ** - p < 0.01, *** - p < 0.001. Each point is compared in a pair-
wise independent Student t-test. 
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Figure S3-5. Model and simulation of the effects of V-ATPase and cytoplasmic chloride on the lysosomal 
accumulation of CFZ-H+Cl-. a) V-ATPase inhibition showed a more substantial effect than cytoplasmic chloride 
inhibition on the accumulation of CFZ-H+Cl- at the rate of 0.01 picomol/cell/day, as reflected by the changes in the 
lysosomal pH, Cl-, and membrane potential values of the CFZ-H+Cl- containing lysosome from that of the CFZ-
H+Cl- free lysosome. b) V-ATPase inhibition generally showed a more substantial effect than cytoplasmic chloride 
inhibition although the simultaneous inhibition of both parameters showed even more pronounced effect on the 
physiological accumulation of CFZ-H+Cl- at the rate of 0.01 picomol/cell/day, as reflected by the changes in the 
lysosomal pH, Cl-, and membrane potential values of the CFZ-H+Cl- containing lysosome from respective baseline 
physiological values. Arrow signs represent values outside of the axes plot range. 
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Figure S3-6. Model and simulation of the effects of V-ATPase and cytoplasmic chloride on the lysosomal 
accumulation of CFZ-H+Cl- at a higher dose. a) V-ATPase inhibition showed a more substantial effect than 
cytoplasmic chloride inhibition on the accumulation of CFZ-H+Cl- at the rate of 0.1 picomol/cell/day, as reflected by 
the changes in the lysosomal pH, Cl-, and membrane potential values of the CFZ-H+Cl- containing lysosome from 
that of the CFZ-H+Cl- free lysosome. b) V-ATPase inhibition generally showed a more substantial effect than 
cytoplasmic chloride inhibition although the simultaneous inhibition of both parameters showed even more 
pronounced effect on the physiological accumulation of CFZ-H+Cl- at the rate of 0.1 picomol/cell/day, as reflected 
by the changes in the lysosomal pH, Cl-, and membrane potential values of the CFZ-H+Cl- containing lysosome from 
respective baseline physiological values. Arrow signs represent values outside of the axes plot range. 
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Table S3-1. Model parameters. 
 
Symbol Description Baseline 
Input Value 
Range of Input Value Units 
pHC Cytosolic pH 7.2 Fixed pH Unit 
pHL Luminal pH 7.4 Fixed pH Unit 
[Cl-]C Cytosolic chloride concentration 10 1 x 10-5 - 10 mM 
[Cl-]L Luminal chloride concentration 110 Fixed mM 
[Na+]L Luminal sodium concentration 145 Fixed mM 
[K+]L Luminal potassium concentration 5 Fixed mM 
[H+]L Luminal proton concentration 0 Fixed mM 
PH+ Membrane proton permeability 6 x 10-5 Fixed cm/s 
V Lysosomal volume 1.65 x 10-16 Fixed L 
S Lysosomal surface area 1.45 x 10-8 Fixed cm2 
C' Specific bilayer capacitance 1 Fixed µFarad/cm2 
Β Buffering capacity 40 Fixed mM/pH unit 
NVATP V-ATPase number 300 1 x 10-4 - 300  
NCLC7 CLC7 number 5000 1 x 10-4 - 5000  
Ψout Outer surface potential -50b Fixed mV 
Ψin Inner surface potential 0b Fixed mV 
CLC_Cl CLC7 Cl- stoichiometry 2 Fixed  
CLC_H CLC7 H+ stoichiometry 1 Fixed  
R Gas constant 8.314 Fixed J.K-1.mol-1 
T Absolute temperature 0 Fixed Kelvin 
F Faraday's constant 96485 Fixed J/Volt 
Nav Avogardro's number 6.02 x 1023 Fixed molecules/mol 
a Rate of proton and chloride sequestration 
by CFZ to form CFZ-H+Cl- 
0 1.16 x 10-21 - 1.16 x 10-20 Moles/day 
 
a = Baseline input values are literature values [5-8] representing physiological lysosomes and are in agreement with 
previously published model [1, 3].  
b = Estimated intrinsic surface potentials for inner (Ψin) and outer (Ψout) leaflets of the lysosomal membrane 
accounted for when modeling membrane transporter mediated dynamic lysosomal and cytoplasmic ion 
concentrations at the membrane surface [1]. 
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Table S3-2. Fluorescence in RAW264.7 cells. (Channels (Ex/Em)) – Blue (350/405 nm), Green (490/510 nm), Red 
(590/610 nm), and Far-Red (640/670 nm). 
 
 Blue Green Red Far-Red 
CFZ - + + - 
CFZ-H+Cl- - - + + 
Lysotracker® Blue + - - - 
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Appendix C 
Supporting Information in Chapter 4 
C.1 Supplemental Materials and Methods 
Theoretical calculations of the concentration of neutral and protonated (charged) species of 
a weakly basic drug molecule in different subcellular compartments  
The total drug concentration output obtained after running the Virtual Cell model is 
comprised of the concentration of the neutral and ionized forms of the drug: CA = [B] + [BH&]          (1) 
Where CT is the total drug concentration, [B] is the concentration of the neutral drug, and [BH+] 
is the concentration of the ionized drug. 
Thus, using equation (1) and the Henderson-Hasselbalch equation (equation 2), we calculated the 
concentrations of the neutral and ionized forms of the weak base drug from the total drug 
concentration in the extracellular, cytoplasm, mitochondria, and lysosome: pH − p𝐾+ = log [.][./0]          (2) 
Determining the degree of supersaturation of the neutral and protonated drug species in 
the different subcellular compartments 
Drug concentration above thermodynamic drug solubility leads to supersaturation(3). 
Thus, using experimentally determined thermodynamic solubility value of the free base and 
protonated species of drug in aqueous media and octanol, we estimated the degree of 
supersaturation –DS(n)- of the free base as follows(3): 
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 DS(n) = 	 [.][.]m           (3) 
Where [B] is the steady state, free base drug concentration in aqueous compartment, and [B]s is 
the experimentally measured thermodynamic solubility of the free base drug in water.  
Similarly, we estimated the degree of supersaturation (DS+) of the charged protonated species in 
aqueous media as follows: DS(+) = 	 [./0]×[nYo]>mp            (4) 
Where Ksp is the solubility product of the salt form of the drug, [BH+] is the dissolved 
concentration of the ionized drug, and [Cl-] is the chloride concertation that interacts with the 
ionized drug through ion-ion interaction, producing the salt solubility product of the drug. 
Using pHmax and the intrinsic free base solubility of CFZ obtained from the literature(4), the Ksp 
was calculated assuming the counterion forms a 1:1 complex with the drug, using the following 
relationship: 𝐾J< = ( [.]mqrpstuvopwu))	          (5) 
Biochemical Analysis of Drug Concentrations in Plasma 
Mobile phase A was 5 mM ammonium acetate, adjusted to pH 9.9 with ammonium 
hydroxide, and mobile phase B was acetonitrile. The flow rate was 0.35 ml/min, with a linear 
gradient from 50 to 100% phase B over 1.5 min, followed by holding at 100% for 1.5 min, a 
return to 50% phase B, and then re-equilibration for 2.5 min. The mass spectrometer source 
conditions were set as follows: 325°C, gas flow at 10 liters/min, nebulizer at 40 lb/in2, capillary 
at 4,000 V, and positive ion mode. The MS acquisition parameters were as follows: MRM mode, 
transition 1 set at 473.1 to 1:431.1, a dwell time of 400 ms, fragmentor set at 180, a collision 
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energy of 40; transition 2 set at 473.1 to 429.1, a dwell time of 100 ms, fragmentor set at 180, 
and a collision energy of 40. 
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C.2 Supplemental Table 
Table S4-1: Cellular drug accumulation parameters for the Virtual Cell model (awillmer: Macrophage Cargo 
Capacity) 
Symbol Description Value Units 
init CT,E 
Initial total extracellular drug 
concentration 10 µM 
init CT,C 
Initial total cytoplasmic drug 
concentration 0 µM 
init CT,M 
Initial total mitochondrial drug 
concentration 0 µM 
init CT,L Initial total lysosomal drug concentration 0 µM 
init CT,CM 
Initial total cell membrane drug 
concentration 0 µM 
init CT,MM 
Initial total mitochondrial membrane drug 
concentration 0 µM 
init CT,LM 
Initial total lysosomal membrane drug 
concentration 0 µM 
[Cl-]L Lysosomal chloride concentration 110 mM 
pHE Extracellular pH 7.4  
pHC Cytoplasmic pH 7.2  
pHM Mitochondrial pH 8  
pHL Lysosomal pH 4.5  
LE Extracellular lipid fraction 0  
LC Cytoplasmic lipid fraction 0.05  
LM Mitochondrial lipid fraction 0.05  
LL Lysosomal lipid fraction 0.05  
WE Extracellular water fraction 1  
WC Cytoplasmic water fraction 0.95  
WM Mitochondrial water fraction 0.95  
WL Lysosomal water fraction 0.95  
γn* Activity coefficient of unionized drug 1  
γd* Activity coefficient of ionized drug 0.74  
ΨCM Cell membrane potential -70 mV 
ΨMM Mitochondrial membrane potential -160 mV 
ΨLM Lysosomal membrane potential 10 mV 
VE Extracellular volume 1x10-4  L 
DC Cytoplasmic diameter 12.4 µm 
DM Mitochondrial diameter 5.76 µm 
DL Lysosomal diameter 5.76 µm 
* activity coefficients of unionized and ionized molecules were obtained from the literature(1). The physicochemical 
properties were obtained from experimental data fitting (2) for CFZ free base and CFZ-HCl salt. The diameters of 
the cellular compartments were used to calculate volume and surface area, assuming spherical geometry. 
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